SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Bioxytran, Inc. – ‘10-K’ for 12/31/21 – ‘XML’

On:  Monday, 4/11/22, at 7:11am ET   ·   For:  12/31/21   ·   Accession #:  1539497-22-793   ·   File #:  1-35027

Previous ‘10-K’:  ‘10-K’ on 4/9/21 for 12/31/20   ·   Next:  ‘10-K’ on 3/31/23 for 12/31/22   ·   Latest:  ‘10-K’ on 3/22/24 for 12/31/23   ·   28 References:   

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 4/11/22  Bioxytran, Inc.                   10-K       12/31/21   65:5.8M                                   Nuvo Group, Inc./FA

Annual Report   —   Form 10-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   1.11M 
 7: R1          Cover                                               HTML     85K 
 8: R2          Consolidated Balance Sheets                         HTML    100K 
 9: R3          Consolidated Balance Sheets (Parenthetical)         HTML     37K 
10: R4          Consolidated Statements of Operations               HTML     75K 
11: R5          Consolidated Statement of Changes in Stockholders'  HTML     88K 
                Equity (Deficit)                                                 
12: R6          Consolidated Statement of Cash Flows                HTML     95K 
13: R7          Background and Organization                         HTML     36K 
14: R8          Summary of Significant Accounting Policies          HTML     44K 
15: R9          Going Concern and Management's Liquidity Plans      HTML     27K 
16: R10         Pre-Paid Expenses and Other Current Assets          HTML     22K 
17: R11         Intangibles                                         HTML     28K 
18: R12         Accounts Payables and Accrued Expenses and Other    HTML     31K 
                Current Liabilities                                              
19: R13         Convertible Notes Payable                           HTML     57K 
20: R14         Stockholders? Equity                                HTML    100K 
21: R15         Stock Option Plan and Stock-Based Compensation      HTML    242K 
22: R16         Provision for Income Taxes                          HTML     40K 
23: R17         Commitments and Contingencies                       HTML     26K 
24: R18         Subsequent Events                                   HTML     35K 
25: R19         Summary of Significant Accounting Policies          HTML     68K 
                (Policies)                                                       
26: R20         Intangibles (Tables)                                HTML     27K 
27: R21         Accounts Payables and Accrued Expenses and Other    HTML     30K 
                Current Liabilities (Tables)                                     
28: R22         Convertible Notes Payable (Tables)                  HTML     47K 
29: R23         Stockholders? Equity (Tables)                       HTML     80K 
30: R24         Stock Option Plan and Stock-Based Compensation      HTML    170K 
                (Tables)                                                         
31: R25         Provision for Income Taxes (Tables)                 HTML     31K 
32: R26         Subsequent Events (Tables)                          HTML     25K 
33: R27         Background and Organization (Details Narrative)     HTML     47K 
34: R28         Summary of Significant Accounting Policies          HTML     36K 
                (Details Narrative)                                              
35: R29         Going Concern and Management's Liquidity Plans      HTML     39K 
                (Details Narrative)                                              
36: R30         Pre-Paid Expenses and Other Current Assets          HTML     24K 
                (Details Narrative)                                              
37: R31         Schedule of intangible (Details)                    HTML     27K 
38: R32         Schedule of accounts payables and accrued expenses  HTML     39K 
                and other current liabilities (Details)                          
39: R33         Accounts Payables and Accrued Expenses and Other    HTML     22K 
                Current Liabilities (Details Narrative)                          
40: R34         The transactions set forth below were approved by   HTML     30K 
                the Company?s Board of Directors on June 4, 2021                 
                (Details)                                                        
41: R35         Convertible Notes Payable (Details)                 HTML     44K 
42: R36         Convertible notes payable consists of the           HTML     33K 
                following at December 31, 2021 and December 31,                  
                2020 (Details)                                                   
43: R37         Convertible Notes Payable (Details Narrative)       HTML     75K 
44: R38         Schedule of stock warrants granted (Details)        HTML     36K 
45: R39         Schedule of company's common stock warrants         HTML     34K 
                activity (Details)                                               
46: R40         Schedule of stock warrants (Details)                HTML     41K 
47: R41         Schedule of non-vested warrants (Details)           HTML     29K 
48: R42         Stockholders? Equity (Details Narrative)            HTML     98K 
49: R43         On December 3, 2021 the Company granted 322,580     HTML     39K 
                shares to an affiliate as compensation for                       
                Management Fee and Legal Expenses for a total                    
                value of $95,000, or 0.2945/share as per written                 
                agreement. (Details)                                             
50: R44         The fair value of stock options granted and         HTML     35K 
                revaluation of non-employee consultant options for               
                the year ended December 31, 2021 and 2020 was                    
                calculated with the following assumptions                        
                (Details)                                                        
51: R45         The following table summarizes the Company?s stock  HTML     43K 
                option activity during the year ended at December                
                31, 2021 (Details)                                               
52: R46         The following table summarizes information about    HTML    139K 
                stock options that are vested or expected to vest                
                at December 31, 2021 (Details)                                   
53: R47         The following table sets forth the status of the    HTML     39K 
                Company?s non-vested stock options as at December                
                31, 2021 and December 31, 2020 (Details)                         
54: R48         Stock Option Plan and Stock-Based Compensation      HTML    252K 
                (Details Narrative)                                              
55: R49         Schedule of deferred tax assets (Details)           HTML     27K 
56: R50         Schedule of effective tax rate (Details)            HTML     22K 
57: R51         Provision for Income Taxes (Details Narrative)      HTML     33K 
58: R52         Commitments and Contingencies (Details Narrative)   HTML     28K 
59: R53         A summary of the Notes issued under the PPM is as   HTML     28K 
                follows (Details)                                                
60: R54         Subsequent Events (Details Narrative)               HTML     43K 
63: XML         IDEA XML File -- Filing Summary                      XML    122K 
61: XML         XBRL Instance -- n2583-x37_10k_htm                   XML   1.33M 
62: EXCEL       IDEA Workbook of Financial Reports                  XLSX     83K 
 3: EX-101.CAL  XBRL Calculations -- bixt-20211231_cal               XML    121K 
 4: EX-101.DEF  XBRL Definitions -- bixt-20211231_def                XML    555K 
 5: EX-101.LAB  XBRL Labels -- bixt-20211231_lab                     XML    896K 
 6: EX-101.PRE  XBRL Presentations -- bixt-20211231_pre              XML    782K 
 2: EX-101.SCH  XBRL Schema -- bixt-20211231                         XSD    172K 
64: JSON        XBRL Instance as JSON Data -- MetaLinks              300±   429K 
65: ZIP         XBRL Zipped Folder -- 0001539497-22-000793-xbrl      Zip    195K

‘XML’   —   XBRL Instance — n2583-x37_10k_htm

This Document is an XBRL XML File.

                                                                                                                                                                                
<?xml version="1.0" encoding="windows-1252"?>
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:bixt="http://bioxytraninc.com/20211231" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xhtml="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<link:schemaRef xlink:href="bixt-20211231.xsd" xlink:type="simple"/>
<context id="From2021-01-01to2021-12-31">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="AsOf2021-06-30">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
</entity>
<period>
<instant> 2021-06-30 </instant>
</period>
</context>
<context id="AsOf2022-04-08">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
</entity>
<period>
<instant> 2022-04-08 </instant>
</period>
</context>
<context id="AsOf2021-12-31">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="AsOf2020-12-31">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="From2020-01-012020-12-31">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="AsOf2019-12-31_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2019-12-31 </instant>
</period>
</context>
<context id="AsOf2019-12-31_us-gaap_PreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2019-12-31 </instant>
</period>
</context>
<context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2019-12-31 </instant>
</period>
</context>
<context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2019-12-31 </instant>
</period>
</context>
<context id="AsOf2019-12-31_us-gaap_NoncontrollingInterestMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:NoncontrollingInterestMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2019-12-31 </instant>
</period>
</context>
<context id="AsOf2019-12-31">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
</entity>
<period>
<instant> 2019-12-31 </instant>
</period>
</context>
<context id="AsOf2020-12-31_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="AsOf2020-12-31_us-gaap_PreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="AsOf2020-12-31_us-gaap_NoncontrollingInterestMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:NoncontrollingInterestMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="From2020-01-012020-12-31_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="From2020-01-012020-12-31_us-gaap_PreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="From2020-01-012020-12-31_us-gaap_NoncontrollingInterestMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:NoncontrollingInterestMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="From2021-01-012021-12-31_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="From2021-01-012021-12-31_us-gaap_PreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="From2021-01-012021-12-31_us-gaap_NoncontrollingInterestMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:NoncontrollingInterestMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="AsOf2021-12-31_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="AsOf2021-12-31_us-gaap_PreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="AsOf2021-12-31_us-gaap_NoncontrollingInterestMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:NoncontrollingInterestMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="AsOf2017-10-05_custom_DelawareProvenanceMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> bixt:DelawareProvenanceMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2017-10-05 </instant>
</period>
</context>
<context id="AsOf2017-10-05">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
</entity>
<period>
<instant> 2017-10-05 </instant>
</period>
</context>
<context id="AsOf2018-09-21_custom_DelawareProvenanceMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> bixt:DelawareProvenanceMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2018-09-21 </instant>
</period>
</context>
<context id="AsOf2020-04-29_srt_SubsidiariesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis"> srt:SubsidiariesMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-04-29 </instant>
</period>
</context>
<context id="AsOf2020-04-29">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
</entity>
<period>
<instant> 2020-04-29 </instant>
</period>
</context>
<context id="AsOf2021-03-17">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
</entity>
<period>
<instant> 2021-03-17 </instant>
</period>
</context>
<context id="AsOf2021-12-31_srt_SubsidiariesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis"> srt:SubsidiariesMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="AsOf2020-12-31_srt_SubsidiariesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis"> srt:SubsidiariesMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="From2021-01-012021-12-31_srt_SubsidiariesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis"> srt:SubsidiariesMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="From2020-01-012020-12-31_srt_SubsidiariesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis"> srt:SubsidiariesMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="From2021-01-012021-12-31_us-gaap_ConvertibleDebtMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis"> us-gaap:ConvertibleDebtMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="AsOf2021-12-31_custom_ContractResearchOrganizationMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> bixt:ContractResearchOrganizationMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="AsOf2020-12-31_custom_ContractResearchOrganizationMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> bixt:ContractResearchOrganizationMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="AsOf2020-03-18_us-gaap_ConvertibleNotesPayableMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis"> us-gaap:ConvertibleNotesPayableMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-03-18 </instant>
</period>
</context>
<context id="From2019-10-232020-03-18_us-gaap_ConvertibleNotesPayableMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis"> us-gaap:ConvertibleNotesPayableMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2019-10-23 </startDate>
<endDate> 2020-03-18 </endDate>
</period>
</context>
<context id="From2019-10-232020-03-18_us-gaap_ConvertibleNotesPayableMember_srt_MinimumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MinimumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis"> us-gaap:ConvertibleNotesPayableMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2019-10-23 </startDate>
<endDate> 2020-03-18 </endDate>
</period>
</context>
<context id="From2019-10-232020-03-18_us-gaap_ConvertibleNotesPayableMember_srt_MaximumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis"> us-gaap:ConvertibleNotesPayableMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2019-10-23 </startDate>
<endDate> 2020-03-18 </endDate>
</period>
</context>
<context id="AsOf2020-03-18">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
</entity>
<period>
<instant> 2020-03-18 </instant>
</period>
</context>
<context id="From2020-04-152020-04-16">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
</entity>
<period>
<startDate> 2020-04-15 </startDate>
<endDate> 2020-04-16 </endDate>
</period>
</context>
<context id="From2021-01-012021-12-31_custom_TenOutstandingConvertibleNotesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis"> bixt:TenOutstandingConvertibleNotesMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="From2021-01-012021-09-30_custom_TenOutstandingConvertibleNotesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis"> bixt:TenOutstandingConvertibleNotesMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-09-30 </endDate>
</period>
</context>
<context id="From2021-05-022021-05-03_custom_NewNoteMember_custom_NineNoteAgreementsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis"> bixt:NewNoteMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis"> bixt:NineNoteAgreementsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-05-02 </startDate>
<endDate> 2021-05-03 </endDate>
</period>
</context>
<context id="AsOf2021-05-03_custom_NewNoteMember_custom_NineNoteAgreementsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis"> bixt:NewNoteMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis"> bixt:NineNoteAgreementsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-05-03 </instant>
</period>
</context>
<context id="From2021-11-192021-11-20">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
</entity>
<period>
<startDate> 2021-11-19 </startDate>
<endDate> 2021-11-20 </endDate>
</period>
</context>
<context id="AsOf2021-12-31_custom_NoteSoldInExchangeForCashMember_custom_WallachBethCapitalLLCMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis"> bixt:NoteSoldInExchangeForCashMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> bixt:WallachBethCapitalLLCMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="From2021-01-192021-01-20">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
</entity>
<period>
<startDate> 2021-01-19 </startDate>
<endDate> 2021-01-20 </endDate>
</period>
</context>
<context id="AsOf2021-06-04_custom_NoteSoldInExchangeForCashMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis"> bixt:NoteSoldInExchangeForCashMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-06-04 </instant>
</period>
</context>
<context id="AsOf2021-06-04_custom_NoteIssuedInExchangeForDefaultedNotesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis"> bixt:NoteIssuedInExchangeForDefaultedNotesMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-06-04 </instant>
</period>
</context>
<context id="From2021-01-012021-12-31_custom_OldNoteMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis"> bixt:OldNoteMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="AsOf2021-12-31_custom_OldNoteMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis"> bixt:OldNoteMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="From2021-01-012021-12-31_custom_OldNoteMember_us-gaap_WarrantMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis"> bixt:OldNoteMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="AsOf2021-12-31_custom_OldNoteMember_us-gaap_WarrantMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis"> bixt:OldNoteMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="AsOf2021-12-31_us-gaap_ConvertibleNotesPayableMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis"> us-gaap:ConvertibleNotesPayableMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="AsOf2020-12-31_us-gaap_ConvertibleNotesPayableMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis"> us-gaap:ConvertibleNotesPayableMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="From2019-12-262020-01-03_custom_AuctusNoteOneMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis"> bixt:AuctusNoteOneMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2019-12-26 </startDate>
<endDate> 2020-01-03 </endDate>
</period>
</context>
<context id="From2019-12-262020-01-03_custom_AuctusNoteTwoMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis"> bixt:AuctusNoteTwoMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2019-12-26 </startDate>
<endDate> 2020-01-03 </endDate>
</period>
</context>
<context id="From2020-02-152020-02-18_custom_AuctusNoteOneMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis"> bixt:AuctusNoteOneMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-02-15 </startDate>
<endDate> 2020-02-18 </endDate>
</period>
</context>
<context id="AsOf2020-03-12_custom_AuctusNoteOneAndTwoMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis"> bixt:AuctusNoteOneAndTwoMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-03-12 </instant>
</period>
</context>
<context id="From2020-03-102020-03-12_custom_AuctusNoteOneAndTwoMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis"> bixt:AuctusNoteOneAndTwoMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-03-10 </startDate>
<endDate> 2020-03-12 </endDate>
</period>
</context>
<context id="From2021-06-022021-06-04_custom_TwoConvertibleNotesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis"> bixt:TwoConvertibleNotesMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-06-02 </startDate>
<endDate> 2021-06-04 </endDate>
</period>
</context>
<context id="From2021-06-012021-06-04_custom_ThreeConvertibleNotesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis"> bixt:ThreeConvertibleNotesMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-06-01 </startDate>
<endDate> 2021-06-04 </endDate>
</period>
</context>
<context id="From2021-06-022021-06-04_custom_ThreeConvertibleNotesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis"> bixt:ThreeConvertibleNotesMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-06-02 </startDate>
<endDate> 2021-06-04 </endDate>
</period>
</context>
<context id="From2021-01-012021-12-31_custom_JointVentureAgreementMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis"> bixt:JointVentureAgreementMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="AsOf2021-12-31_custom_StockPlan2010Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> bixt:StockPlan2010Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="AsOf2020-12-31_custom_StockPlan2010Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> bixt:StockPlan2010Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="AsOf2021-12-31_us-gaap_WarrantMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="AsOf2020-12-31_us-gaap_WarrantMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="AsOf2021-12-31_us-gaap_WarrantMember_custom_ConvertibleNoteAgreementsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis"> bixt:ConvertibleNoteAgreementsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="From2021-01-012021-12-31_us-gaap_WarrantMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="From2021-01-012021-12-31_custom_StockPlan2021Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> bixt:StockPlan2021Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="From2020-01-012020-12-31_custom_StockPlan2010Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> bixt:StockPlan2010Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="AsOf2021-12-31_custom_MichaelSheikhOlaSoderquistAndDavidPlattMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> bixt:MichaelSheikhOlaSoderquistAndDavidPlattMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="From2021-01-012021-12-31_custom_CommonStockWarrantsMember_srt_MinimumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MinimumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> bixt:CommonStockWarrantsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="From2021-01-012021-12-31_custom_CommonStockWarrantsMember_srt_MaximumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> bixt:CommonStockWarrantsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="From2020-01-012020-12-31_custom_CommonStockWarrantsMember_srt_MinimumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MinimumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> bixt:CommonStockWarrantsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="From2020-01-012020-12-31_custom_CommonStockWarrantsMember_srt_MaximumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> bixt:CommonStockWarrantsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="From2021-01-012021-12-31_custom_CommonStockWarrantsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> bixt:CommonStockWarrantsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="From2020-01-012020-12-31_custom_CommonStockWarrantsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> bixt:CommonStockWarrantsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="From2019-01-012019-12-31">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
</entity>
<period>
<startDate> 2019-01-01 </startDate>
<endDate> 2019-12-31 </endDate>
</period>
</context>
<context id="AsOf2021-12-31_custom_CommonStockWarrantsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> bixt:CommonStockWarrantsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="From2021-01-012021-12-31_custom_StockPlan2010Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> bixt:StockPlan2010Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="AsOf2021-12-31_us-gaap_StockOptionMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> us-gaap:StockOptionMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="AsOf2020-12-31_us-gaap_StockOptionMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> us-gaap:StockOptionMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="From2019-12-302020-01-02_custom_ConsultantMember_custom_StockPlan2010Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> bixt:ConsultantMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> bixt:StockPlan2010Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2019-12-30 </startDate>
<endDate> 2020-01-02 </endDate>
</period>
</context>
<context id="From2020-01-012020-01-31_custom_SubcontractorsMember_custom_StockPlan2010Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> bixt:SubcontractorsMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> bixt:StockPlan2010Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-01-31 </endDate>
</period>
</context>
<context id="From2020-02-012020-02-21_custom_ThreeMemberOfTheAuditCommitteeMember_custom_StockPlan2010Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> bixt:ThreeMemberOfTheAuditCommitteeMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> bixt:StockPlan2010Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-02-01 </startDate>
<endDate> 2020-02-21 </endDate>
</period>
</context>
<context id="From2020-03-012020-03-18_custom_ConsultantMember_custom_StockPlan2010Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> bixt:ConsultantMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> bixt:StockPlan2010Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-03-01 </startDate>
<endDate> 2020-03-18 </endDate>
</period>
</context>
<context id="From2020-03-012020-03-25_custom_ThreeMembersOfTheCompanyBoardMember_custom_StockPlan2010Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> bixt:ThreeMembersOfTheCompanyBoardMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> bixt:StockPlan2010Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-03-01 </startDate>
<endDate> 2020-03-25 </endDate>
</period>
</context>
<context id="From2020-04-282020-05-01_custom_MikeSheikhMember_custom_StockPlan2010Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> bixt:MikeSheikhMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> bixt:StockPlan2010Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-04-28 </startDate>
<endDate> 2020-05-01 </endDate>
</period>
</context>
<context id="From2020-06-252020-07-01_custom_ThreeMembersOfTheCompanyBoardMember_custom_StockPlan2010Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> bixt:ThreeMembersOfTheCompanyBoardMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> bixt:StockPlan2010Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-06-25 </startDate>
<endDate> 2020-07-01 </endDate>
</period>
</context>
<context id="From2020-07-302020-08-03_custom_MedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember_custom_StockPlan2010Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> bixt:MedicalAdvisoryBoardMembersMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> bixt:StockPlan2010Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-07-30 </startDate>
<endDate> 2020-08-03 </endDate>
</period>
</context>
<context id="From2020-07-282020-08-03_custom_MedicalAdvisoryBoardMembersMember_custom_StockPlan2021Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> bixt:MedicalAdvisoryBoardMembersMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> bixt:StockPlan2021Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-07-28 </startDate>
<endDate> 2020-08-03 </endDate>
</period>
</context>
<context id="From2020-09-162020-09-17_custom_ConsultantMember_custom_StockPlan2021Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> bixt:ConsultantMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> bixt:StockPlan2021Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-09-16 </startDate>
<endDate> 2020-09-17 </endDate>
</period>
</context>
<context id="From2020-09-252020-10-01_custom_ThreeMembersOfTheCompanyBoardMember_custom_StockPlan2010Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> bixt:ThreeMembersOfTheCompanyBoardMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> bixt:StockPlan2010Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-09-25 </startDate>
<endDate> 2020-10-01 </endDate>
</period>
</context>
<context id="From2020-11-112020-11-13_custom_ThreeMembersOfTheCompanyBoardMember_custom_StockPlan2010Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> bixt:ThreeMembersOfTheCompanyBoardMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> bixt:StockPlan2010Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-11-11 </startDate>
<endDate> 2020-11-13 </endDate>
</period>
</context>
<context id="From2020-11-112020-11-13_custom_TwoMedicalConsultantsMember_custom_StockPlan2010Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> bixt:TwoMedicalConsultantsMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> bixt:StockPlan2010Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-11-11 </startDate>
<endDate> 2020-11-13 </endDate>
</period>
</context>
<context id="From2020-12-302021-01-02_custom_MedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember_custom_StockPlan2010Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> bixt:MedicalAdvisoryBoardMembersMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> bixt:StockPlan2010Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-12-30 </startDate>
<endDate> 2021-01-02 </endDate>
</period>
</context>
<context id="From2021-01-142021-01-15_custom_ManagersBoardAndMedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember_custom_StockPlan2010Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> bixt:ManagersBoardAndMedicalAdvisoryBoardMembersMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> bixt:StockPlan2010Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-14 </startDate>
<endDate> 2021-01-15 </endDate>
</period>
</context>
<context id="From2021-01-142021-01-15_custom_ManagersBoardAndMedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> bixt:ManagersBoardAndMedicalAdvisoryBoardMembersMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-14 </startDate>
<endDate> 2021-01-15 </endDate>
</period>
</context>
<context id="From2021-11-102021-11-20_custom_ManagersBoardAndMedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember_custom_StockPlan2010Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> bixt:ManagersBoardAndMedicalAdvisoryBoardMembersMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> bixt:StockPlan2010Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-11-10 </startDate>
<endDate> 2021-11-20 </endDate>
</period>
</context>
<context id="From2021-03-302021-04-02_custom_MedicalAdvisoryBoardMembersMember_custom_StockPlan2021Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> bixt:MedicalAdvisoryBoardMembersMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> bixt:StockPlan2021Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-03-30 </startDate>
<endDate> 2021-04-02 </endDate>
</period>
</context>
<context id="From2021-03-302021-04-02_custom_AuditCommitteeMember_custom_StockPlan2021Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> bixt:AuditCommitteeMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> bixt:StockPlan2021Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-03-30 </startDate>
<endDate> 2021-04-02 </endDate>
</period>
</context>
<context id="From2021-04-202021-04-22_custom_ConsultantMember_custom_StockPlan2021Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> bixt:ConsultantMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> bixt:StockPlan2021Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-04-20 </startDate>
<endDate> 2021-04-22 </endDate>
</period>
</context>
<context id="From2021-04-202021-04-22_custom_ConsultantOneMember_custom_StockPlan2021Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> bixt:ConsultantOneMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> bixt:StockPlan2021Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-04-20 </startDate>
<endDate> 2021-04-22 </endDate>
</period>
</context>
<context id="From2021-06-142021-06-15_custom_ConsultantMember_custom_StockPlan2021Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> bixt:ConsultantMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> bixt:StockPlan2021Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-06-14 </startDate>
<endDate> 2021-06-15 </endDate>
</period>
</context>
<context id="From2021-06-292021-07-02_custom_ConsultantThreeMember_custom_StockPlan2021Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> bixt:ConsultantThreeMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> bixt:StockPlan2021Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-06-29 </startDate>
<endDate> 2021-07-02 </endDate>
</period>
</context>
<context id="From2021-06-282021-07-02_custom_ConsultantMember_custom_StockPlan2021Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> bixt:ConsultantMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> bixt:StockPlan2021Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-06-28 </startDate>
<endDate> 2021-07-02 </endDate>
</period>
</context>
<context id="From2021-06-292021-07-02_custom_ConsultantMember_custom_StockPlan2021Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> bixt:ConsultantMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> bixt:StockPlan2021Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-06-29 </startDate>
<endDate> 2021-07-02 </endDate>
</period>
</context>
<context id="From2021-07-282021-08-02_custom_ConsultantMember_custom_StockPlan2021Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> bixt:ConsultantMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> bixt:StockPlan2021Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-07-28 </startDate>
<endDate> 2021-08-02 </endDate>
</period>
</context>
<context id="From2021-09-252021-10-01_custom_FourMembersOfTheCompanyBoardMember_custom_StockPlan2021Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> bixt:FourMembersOfTheCompanyBoardMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> bixt:StockPlan2021Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-09-25 </startDate>
<endDate> 2021-10-01 </endDate>
</period>
</context>
<context id="From2021-09-252021-10-01_custom_FourMembersOfTheCompanyBoardMember_custom_StockPlan2010Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> bixt:FourMembersOfTheCompanyBoardMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> bixt:StockPlan2010Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-09-25 </startDate>
<endDate> 2021-10-01 </endDate>
</period>
</context>
<context id="From2021-11-102021-11-20_custom_ConsultantMember_custom_StockPlan2021Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> bixt:ConsultantMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> bixt:StockPlan2021Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-11-10 </startDate>
<endDate> 2021-11-20 </endDate>
</period>
</context>
<context id="From2021-09-252021-10-01_custom_ConsultantMember_custom_StockPlan2010Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> bixt:ConsultantMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> bixt:StockPlan2010Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-09-25 </startDate>
<endDate> 2021-10-01 </endDate>
</period>
</context>
<context id="From2021-01-012021-12-31_custom_ShareBasedPaymentAwardsMember_custom_StockPlan2021Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> bixt:ShareBasedPaymentAwardsMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> bixt:StockPlan2021Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="From2020-01-012020-12-31_custom_ShareBasedPaymentAwardsMember_custom_StockPlan2021Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> bixt:ShareBasedPaymentAwardsMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> bixt:StockPlan2021Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="From2019-12-302020-01-02_custom_MedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember_custom_StockPlan2010Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> bixt:MedicalAdvisoryBoardMembersMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> bixt:StockPlan2010Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2019-12-30 </startDate>
<endDate> 2020-01-02 </endDate>
</period>
</context>
<context id="From2020-01-292020-02-02_custom_MedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember_custom_StockPlan2010Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> bixt:MedicalAdvisoryBoardMembersMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> bixt:StockPlan2010Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-29 </startDate>
<endDate> 2020-02-02 </endDate>
</period>
</context>
<context id="From2021-01-292021-02-01_custom_MedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember_custom_StockPlan2021Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> bixt:MedicalAdvisoryBoardMembersMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> bixt:StockPlan2021Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-29 </startDate>
<endDate> 2021-02-01 </endDate>
</period>
</context>
<context id="From2021-04-292021-05-01_custom_MedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember_custom_StockPlan2021Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> bixt:MedicalAdvisoryBoardMembersMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> bixt:StockPlan2021Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-04-29 </startDate>
<endDate> 2021-05-01 </endDate>
</period>
</context>
<context id="From2021-06-292021-07-01_custom_MedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember_custom_StockPlan2021Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> bixt:MedicalAdvisoryBoardMembersMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> bixt:StockPlan2021Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-06-29 </startDate>
<endDate> 2021-07-01 </endDate>
</period>
</context>
<context id="From2020-06-282020-07-01_custom_MedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember_custom_StockPlan2010Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> bixt:MedicalAdvisoryBoardMembersMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> bixt:StockPlan2010Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-06-28 </startDate>
<endDate> 2020-07-01 </endDate>
</period>
</context>
<context id="From2020-06-292020-07-01_custom_MedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember_custom_StockPlan2010Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> bixt:MedicalAdvisoryBoardMembersMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> bixt:StockPlan2010Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-06-29 </startDate>
<endDate> 2020-07-01 </endDate>
</period>
</context>
<context id="From2021-07-292021-08-01_custom_MedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember_custom_StockPlan2021Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> bixt:MedicalAdvisoryBoardMembersMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> bixt:StockPlan2021Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-07-29 </startDate>
<endDate> 2021-08-01 </endDate>
</period>
</context>
<context id="From2020-07-292020-08-01_custom_MedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember_custom_StockPlan2010Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> bixt:MedicalAdvisoryBoardMembersMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> bixt:StockPlan2010Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-07-29 </startDate>
<endDate> 2020-08-01 </endDate>
</period>
</context>
<context id="From2021-07-282021-08-01_custom_MedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember_custom_StockPlan2010Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> bixt:MedicalAdvisoryBoardMembersMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> bixt:StockPlan2010Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-07-28 </startDate>
<endDate> 2021-08-01 </endDate>
</period>
</context>
<context id="From2021-09-292021-10-01_custom_MedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember_custom_StockPlan2021Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> bixt:MedicalAdvisoryBoardMembersMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> bixt:StockPlan2021Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-09-29 </startDate>
<endDate> 2021-10-01 </endDate>
</period>
</context>
<context id="From2020-09-292020-10-01_custom_MedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember_custom_StockPlan2010Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> bixt:MedicalAdvisoryBoardMembersMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> bixt:StockPlan2010Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-09-29 </startDate>
<endDate> 2020-10-01 </endDate>
</period>
</context>
<context id="From2021-09-282021-10-01_custom_MedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember_custom_StockPlan2010Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> bixt:MedicalAdvisoryBoardMembersMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> bixt:StockPlan2010Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-09-28 </startDate>
<endDate> 2021-10-01 </endDate>
</period>
</context>
<context id="From2021-10-292021-11-01_custom_MedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember_custom_StockPlan2021Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> bixt:MedicalAdvisoryBoardMembersMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> bixt:StockPlan2021Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-10-29 </startDate>
<endDate> 2021-11-01 </endDate>
</period>
</context>
<context id="From2020-10-292020-11-01_custom_MedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember_custom_StockPlan2010Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> bixt:MedicalAdvisoryBoardMembersMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> bixt:StockPlan2010Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-10-29 </startDate>
<endDate> 2020-11-01 </endDate>
</period>
</context>
<context id="From2021-10-282021-11-01_custom_MedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember_custom_StockPlan2010Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> bixt:MedicalAdvisoryBoardMembersMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> bixt:StockPlan2010Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-10-28 </startDate>
<endDate> 2021-11-01 </endDate>
</period>
</context>
<context id="From2021-01-282021-02-01_custom_MedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember_custom_StockPlan2010Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> bixt:MedicalAdvisoryBoardMembersMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> bixt:StockPlan2010Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-28 </startDate>
<endDate> 2021-02-01 </endDate>
</period>
</context>
<context id="From2021-04-282021-05-01_custom_MedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember_custom_StockPlan2010Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> bixt:MedicalAdvisoryBoardMembersMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> bixt:StockPlan2010Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-04-28 </startDate>
<endDate> 2021-05-01 </endDate>
</period>
</context>
<context id="From2021-07-282021-08-01_custom_ConsultantMember_custom_StockPlan2021Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> bixt:ConsultantMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> bixt:StockPlan2021Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-07-28 </startDate>
<endDate> 2021-08-01 </endDate>
</period>
</context>
<context id="From2021-07-292021-08-01_custom_MedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember_custom_StockPlan2010Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> bixt:MedicalAdvisoryBoardMembersMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> bixt:StockPlan2010Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-07-29 </startDate>
<endDate> 2021-08-01 </endDate>
</period>
</context>
<context id="From2021-01-012021-12-31_custom_ThreeMembersOfTheCompanyBoardMember_custom_StockPlan2017Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> bixt:ThreeMembersOfTheCompanyBoardMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> bixt:StockPlan2017Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="From2020-01-012020-12-31_custom_ThreeMembersOfTheCompanyBoardMember_custom_StockPlan2017Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> bixt:ThreeMembersOfTheCompanyBoardMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> bixt:StockPlan2017Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="From2020-01-012020-12-31_us-gaap_StockCompensationPlanMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:StockCompensationPlanMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="AsOf2020-12-31_us-gaap_StockCompensationPlanMember_srt_MinimumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MinimumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:StockCompensationPlanMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="AsOf2020-12-31_us-gaap_StockCompensationPlanMember_srt_MaximumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:StockCompensationPlanMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="From2021-01-012021-12-31_us-gaap_StockCompensationPlanMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:StockCompensationPlanMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="AsOf2021-12-31_us-gaap_StockCompensationPlanMember_srt_MinimumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MinimumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:StockCompensationPlanMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="AsOf2021-12-31_us-gaap_StockCompensationPlanMember_srt_MaximumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:StockCompensationPlanMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="From2021-01-012021-12-31_srt_MinimumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MinimumMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="From2021-01-012021-12-31_srt_MaximumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="From2020-01-012020-12-31_srt_MinimumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MinimumMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="From2020-01-012020-12-31_srt_MaximumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2020-01-01 </startDate>
<endDate> 2020-12-31 </endDate>
</period>
</context>
<context id="AsOf2020-12-31_us-gaap_EmployeeStockOptionMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="AsOf2020-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MinimumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="AsOf2020-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MinimumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MinimumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="AsOf2021-12-31_custom_ExercisePriceSevenOneMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"> bixt:ExercisePriceSevenOneMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="From2021-01-012021-12-31_custom_ExercisePriceSevenOneMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"> bixt:ExercisePriceSevenOneMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="AsOf2021-12-31_custom_ExercisePriceSevenTwoMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"> bixt:ExercisePriceSevenTwoMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="From2021-01-012021-12-31_custom_ExercisePriceSevenTwoMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"> bixt:ExercisePriceSevenTwoMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="AsOf2021-12-31_custom_ExercisePriceSevenThreeMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"> bixt:ExercisePriceSevenThreeMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="From2021-01-012021-12-31_custom_ExercisePriceSevenThreeMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"> bixt:ExercisePriceSevenThreeMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="AsOf2021-12-31_custom_ExercisePriceSevenFourMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"> bixt:ExercisePriceSevenFourMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="From2021-01-012021-12-31_custom_ExercisePriceSevenFourMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"> bixt:ExercisePriceSevenFourMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="AsOf2021-12-31_custom_ExercisePriceFiveMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"> bixt:ExercisePriceFiveMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="From2021-01-012021-12-31_custom_ExercisePriceFiveMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"> bixt:ExercisePriceFiveMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="AsOf2021-12-31_custom_ExercisePriceSevenFiveMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"> bixt:ExercisePriceSevenFiveMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="From2021-01-012021-12-31_custom_ExercisePriceSevenFiveMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"> bixt:ExercisePriceSevenFiveMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="AsOf2021-12-31_custom_ExercisePriceSixMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"> bixt:ExercisePriceSixMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="From2021-01-012021-12-31_custom_ExercisePriceSixMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"> bixt:ExercisePriceSixMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="AsOf2021-12-31_custom_ExercisePriceSevenSixMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"> bixt:ExercisePriceSevenSixMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="From2021-01-012021-12-31_custom_ExercisePriceSevenSixMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"> bixt:ExercisePriceSevenSixMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="AsOf2021-12-31_custom_ExercisePriceSevenMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"> bixt:ExercisePriceSevenMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="From2021-01-012021-12-31_custom_ExercisePriceSevenMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"> bixt:ExercisePriceSevenMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="AsOf2021-12-31_custom_ExercisePriceSevenSevenMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"> bixt:ExercisePriceSevenSevenMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="From2021-01-012021-12-31_custom_ExercisePriceSevenSevenMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"> bixt:ExercisePriceSevenSevenMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="AsOf2021-12-31_custom_ExercisePriceEightOneMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"> bixt:ExercisePriceEightOneMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="From2021-01-012021-12-31_custom_ExercisePriceEightOneMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"> bixt:ExercisePriceEightOneMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="AsOf2021-12-31_custom_ExercisePriceSevenEightMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"> bixt:ExercisePriceSevenEightMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="From2021-01-012021-12-31_custom_ExercisePriceSevenEightMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"> bixt:ExercisePriceSevenEightMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="AsOf2021-12-31_custom_ExercisePriceNineMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"> bixt:ExercisePriceNineMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="From2021-01-012021-12-31_custom_ExercisePriceNineMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"> bixt:ExercisePriceNineMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="AsOf2021-12-31_custom_ExercisePriceSevenNineMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"> bixt:ExercisePriceSevenNineMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="From2021-01-012021-12-31_custom_ExercisePriceSevenNineMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"> bixt:ExercisePriceSevenNineMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="AsOf2021-12-31_custom_ExercisePriceTenMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"> bixt:ExercisePriceTenMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="From2021-01-012021-12-31_custom_ExercisePriceTenMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"> bixt:ExercisePriceTenMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="AsOf2021-12-31_custom_ExercisePriceSevenTenMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"> bixt:ExercisePriceSevenTenMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="From2021-01-012021-12-31_custom_ExercisePriceSevenTenMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"> bixt:ExercisePriceSevenTenMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="AsOf2021-12-31_custom_ExercisePriceElevenMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"> bixt:ExercisePriceElevenMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="From2021-01-012021-12-31_custom_ExercisePriceElevenMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"> bixt:ExercisePriceElevenMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="AsOf2021-12-31_custom_ExercisePriceSevenElevenMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"> bixt:ExercisePriceSevenElevenMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="From2021-01-012021-12-31_custom_ExercisePriceSevenElevenMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"> bixt:ExercisePriceSevenElevenMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="AsOf2021-12-31_custom_ExercisePriceTwelveMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"> bixt:ExercisePriceTwelveMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="From2021-01-012021-12-31_custom_ExercisePriceTwelveMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"> bixt:ExercisePriceTwelveMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="AsOf2021-12-31_custom_ExercisePriceSevenTwelveMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"> bixt:ExercisePriceSevenTwelveMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="From2021-01-012021-12-31_custom_ExercisePriceSevenTwelveMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"> bixt:ExercisePriceSevenTwelveMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="AsOf2021-12-31_custom_ExercisePriceThirteenMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"> bixt:ExercisePriceThirteenMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="From2021-01-012021-12-31_custom_ExercisePriceThirteenMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"> bixt:ExercisePriceThirteenMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="AsOf2021-12-31_custom_ExercisePriceSevenThirteenMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"> bixt:ExercisePriceSevenThirteenMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="From2021-01-012021-12-31_custom_ExercisePriceSevenThirteenMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"> bixt:ExercisePriceSevenThirteenMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="AsOf2021-12-31_custom_ExercisePriceFourteenMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"> bixt:ExercisePriceFourteenMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="From2021-01-012021-12-31_custom_ExercisePriceFourteenMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"> bixt:ExercisePriceFourteenMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="AsOf2021-12-31_custom_ExercisePriceSevenFourteenMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"> bixt:ExercisePriceSevenFourteenMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="From2021-01-012021-12-31_custom_ExercisePriceSevenFourteenMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"> bixt:ExercisePriceSevenFourteenMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-01-01 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="AsOf2020-12-31_custom_RestrictedStockOptionMember_custom_StockPlan2010Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> bixt:RestrictedStockOptionMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> bixt:StockPlan2010Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-12-31 </instant>
</period>
</context>
<context id="From2017-12-012017-12-22">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
</entity>
<period>
<startDate> 2017-12-01 </startDate>
<endDate> 2017-12-22 </endDate>
</period>
</context>
<context id="AsOf2021-12-31_custom_EmploymentAgreementsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis"> bixt:EmploymentAgreementsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="AsOf2020-06-05_custom_PowerUpMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis"> bixt:PowerUpMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2020-06-05 </instant>
</period>
</context>
<context id="AsOf2021-12-31_us-gaap_PrivatePlacementMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis"> us-gaap:PrivatePlacementMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="AsOf2022-01-12_us-gaap_ConvertibleDebtMember_us-gaap_SubsequentEventMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis"> us-gaap:ConvertibleDebtMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-01-12 </instant>
</period>
</context>
<context id="From2022-01-052022-01-12_us-gaap_ConvertibleDebtMember_us-gaap_SubsequentEventMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis"> us-gaap:ConvertibleDebtMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-05 </startDate>
<endDate> 2022-01-12 </endDate>
</period>
</context>
<context id="From2022-01-082022-01-10_us-gaap_SubsequentEventMember_srt_BoardOfDirectorsChairmanMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> srt:BoardOfDirectorsChairmanMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-08 </startDate>
<endDate> 2022-01-10 </endDate>
</period>
</context>
<context id="AsOf2022-01-10_us-gaap_SubsequentEventMember_srt_BoardOfDirectorsChairmanMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> srt:BoardOfDirectorsChairmanMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-01-10 </instant>
</period>
</context>
<context id="From2022-01-082022-01-10_us-gaap_SubsequentEventMember_custom_ConsultantsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> bixt:ConsultantsMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-08 </startDate>
<endDate> 2022-01-10 </endDate>
</period>
</context>
<context id="From2021-12-282021-12-31_us-gaap_ConvertibleDebtMember_us-gaap_PrivatePlacementMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis"> us-gaap:ConvertibleDebtMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis"> us-gaap:PrivatePlacementMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2021-12-28 </startDate>
<endDate> 2021-12-31 </endDate>
</period>
</context>
<context id="AsOf2021-12-31_us-gaap_ConvertibleDebtMember_us-gaap_PrivatePlacementMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001445815 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis"> us-gaap:ConvertibleDebtMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis"> us-gaap:PrivatePlacementMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<unit id="USD">
<measure> iso4217:USD </measure>
</unit>
<unit id="Shares">
<measure> shares </measure>
</unit>
<unit id="USDPShares">
<divide>
<unitNumerator>
<measure> iso4217:USD </measure>
</unitNumerator>
<unitDenominator>
<measure> shares </measure>
</unitDenominator>
</divide>
</unit>
<unit id="Pure">
<measure> pure </measure>
</unit>
<dei:EntityCentralIndexKey contextRef="From2021-01-01to2021-12-31"> 0001445815 </dei:EntityCentralIndexKey>
<dei:AmendmentFlag contextRef="From2021-01-01to2021-12-31"> false </dei:AmendmentFlag>
<dei:DocumentFiscalPeriodFocus contextRef="From2021-01-01to2021-12-31"> FY </dei:DocumentFiscalPeriodFocus>
<dei:DocumentFiscalYearFocus contextRef="From2021-01-01to2021-12-31"> 2021 </dei:DocumentFiscalYearFocus>
<dei:CurrentFiscalYearEndDate contextRef="From2021-01-01to2021-12-31"> --12-31 </dei:CurrentFiscalYearEndDate>
<us-gaap:PrepaidExpenseCurrent contextRef="AsOf2021-12-31" id="xdx2ixbrl0053" unitRef="USD" xsi:nil="true"/>
<us-gaap:CommitmentsAndContingencies contextRef="AsOf2021-12-31" id="xdx2ixbrl0086" unitRef="USD" xsi:nil="true"/>
<us-gaap:CommitmentsAndContingencies contextRef="AsOf2020-12-31" id="xdx2ixbrl0087" unitRef="USD" xsi:nil="true"/>
<us-gaap:PreferredStockValue contextRef="AsOf2021-12-31" id="xdx2ixbrl0092" unitRef="USD" xsi:nil="true"/>
<us-gaap:PreferredStockValue contextRef="AsOf2020-12-31" id="xdx2ixbrl0093" unitRef="USD" xsi:nil="true"/>
<us-gaap:PreferredStockSharesIssued contextRef="AsOf2020-12-31" decimals="INF" id="xdx2ixbrl0101" unitRef="Shares"> 0 </us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2020-12-31" decimals="INF" id="xdx2ixbrl0103" unitRef="Shares"> 0 </us-gaap:PreferredStockSharesOutstanding>
<us-gaap:PreferredStockSharesIssued contextRef="AsOf2021-12-31" decimals="INF" id="xdx2ixbrl0105" unitRef="Shares"> 0 </us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2021-12-31" decimals="INF" id="xdx2ixbrl0107" unitRef="Shares"> 0 </us-gaap:PreferredStockSharesOutstanding>
<us-gaap:IncomeTaxExpenseBenefit contextRef="From2021-01-01to2021-12-31" id="xdx2ixbrl0176" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncomeTaxExpenseBenefit contextRef="From2020-01-012020-12-31" id="xdx2ixbrl0177" unitRef="USD" xsi:nil="true"/>
<bixt:StockIssuedDuringPeriodValueConversionOfWarrants contextRef="From2020-01-012020-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0212" unitRef="USD" xsi:nil="true"/>
<bixt:ConversionOfSubsidiaryShares contextRef="From2021-01-01to2021-12-31" id="xdx2ixbrl0343" unitRef="USD" xsi:nil="true"/>
<bixt:DefaultFeeConvertibleNotes contextRef="From2021-01-01to2021-12-31" id="xdx2ixbrl0404" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncreaseDecreaseInOtherReceivables contextRef="From2021-01-01to2021-12-31" id="xdx2ixbrl0416" unitRef="USD" xsi:nil="true"/>
<us-gaap:RepaymentsOfNotesPayable contextRef="From2021-01-01to2021-12-31" id="xdx2ixbrl0446" unitRef="USD" xsi:nil="true"/>
<us-gaap:InterestPaidNet contextRef="From2021-01-01to2021-12-31" id="xdx2ixbrl0464" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncomeTaxesPaidNet contextRef="From2021-01-01to2021-12-31" id="xdx2ixbrl0467" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncomeTaxesPaidNet contextRef="From2020-01-012020-12-31" id="xdx2ixbrl0468" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2021-01-01to2021-12-31" id="xdx2ixbrl0473" unitRef="USD" xsi:nil="true"/>
<bixt:DebtDiscountOnConvertibleNote contextRef="From2020-01-012020-12-31" id="xdx2ixbrl0477" unitRef="USD" xsi:nil="true"/>
<bixt:DebtPremiumOnConvertibleNote contextRef="From2021-01-01to2021-12-31" id="xdx2ixbrl0479" unitRef="USD" xsi:nil="true"/>
<bixt:AccretionOfDebtPremiumToAdditionalPaidInCapital contextRef="From2021-01-01to2021-12-31" id="xdx2ixbrl0482" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssued1 contextRef="From2020-01-012020-12-31" id="xdx2ixbrl0486" unitRef="USD" xsi:nil="true"/>
<bixt:ForgivenessOfRelatedPartyDebtRecordedToAdditionalPaidinCapital contextRef="From2020-01-012020-12-31" id="xdx2ixbrl0492" unitRef="USD" xsi:nil="true"/>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-12-31" decimals="0" id="xdx2ixbrl0586" unitRef="USD"> -8753668 </us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2021-01-01to2021-12-31" id="xdx2ixbrl0608"> P19Y </us-gaap:FiniteLivedIntangibleAssetUsefulLife>
<us-gaap:TaxesPayableCurrentAndNoncurrent contextRef="AsOf2020-12-31" id="xdx2ixbrl0640" unitRef="USD" xsi:nil="true"/>
<bixt:Pension401k contextRef="AsOf2020-12-31" id="xdx2ixbrl0643" unitRef="USD" xsi:nil="true"/>
<us-gaap:AccountsPayableOtherCurrent contextRef="AsOf2021-12-31" id="xdx2ixbrl0645" unitRef="USD" xsi:nil="true"/>
<bixt:DefaultPenalty contextRef="AsOf2021-12-31" id="xdx2ixbrl0648" unitRef="USD" xsi:nil="true"/>
<us-gaap:DebtInstrumentTerm contextRef="From2021-05-022021-05-03_custom_NewNoteMember_custom_NineNoteAgreementsMember" id="xdx2ixbrl0685"> P1Y </us-gaap:DebtInstrumentTerm>
<us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2021-12-31_custom_OldNoteMember_us-gaap_WarrantMember" id="xdx2ixbrl0712"> P5Y </us-gaap:WarrantsAndRightsOutstandingTerm>
<bixt:DebtInstrumentFaceAmount2 contextRef="AsOf2020-12-31" id="xdx2ixbrl0725" unitRef="USD" xsi:nil="true"/>
<us-gaap:DebtDefaultLongtermDebtAmount contextRef="AsOf2021-12-31_us-gaap_ConvertibleNotesPayableMember" id="xdx2ixbrl0727" unitRef="USD" xsi:nil="true"/>
<us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2020-12-31_us-gaap_ConvertibleNotesPayableMember" id="xdx2ixbrl0731" unitRef="USD" xsi:nil="true"/>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2021-01-012021-12-31_custom_CommonStockWarrantsMember" id="xdx2ixbrl0786"> P5Y </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2020-01-012020-12-31_custom_CommonStockWarrantsMember" id="xdx2ixbrl0787"> P5Y </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<bixt:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm contextRef="From2019-01-012019-12-31" id="xdx2ixbrl0803"> P4Y9M18D </bixt:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm>
<bixt:SharebasedCompensationArrangementByPeriodWeightedAverageRemainingContractualTermGranted contextRef="From2020-01-012020-12-31" id="xdx2ixbrl0807"> P5Y </bixt:SharebasedCompensationArrangementByPeriodWeightedAverageRemainingContractualTermGranted>
<bixt:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm contextRef="From2020-01-012020-12-31" id="xdx2ixbrl0813"> P3Y10M25D </bixt:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm>
<bixt:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm contextRef="From2021-01-01to2021-12-31" id="xdx2ixbrl0819"> P2Y10M25D </bixt:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2021-01-012021-12-31_custom_CommonStockWarrantsMember" id="xdx2ixbrl0827"> P2Y10M25D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2021-01-012021-12-31_custom_CommonStockWarrantsMember" id="xdx2ixbrl0833"> P2Y10M25D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
<bixt:SharotebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2021-01-01to2021-12-31" id="xdx2ixbrl0836"> P2Y10M25D </bixt:SharotebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2021-01-01to2021-12-31" id="xdx2ixbrl0839"> P2Y10M25D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="AsOf2019-12-31" id="xdx2ixbrl0843" unitRef="Shares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="From2021-01-01to2021-12-31" id="xdx2ixbrl0850" unitRef="Shares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="From2021-01-01to2021-12-31" id="xdx2ixbrl0852" unitRef="Shares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="From2021-01-01to2021-12-31" id="xdx2ixbrl0853" unitRef="Shares" xsi:nil="true"/>
<bixt:WarrantsExercisableWeightedAverageRemainingContractualTerm contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember" id="xdx2ixbrl0857"> P2Y10M25D </bixt:WarrantsExercisableWeightedAverageRemainingContractualTerm>
<bixt:AggregateIntrinsicValueForFullyVestedExercisableWarrants contextRef="AsOf2021-12-31_us-gaap_WarrantMember" decimals="0" id="xdx2ixbrl0859" unitRef="USD"> 0 </bixt:AggregateIntrinsicValueForFullyVestedExercisableWarrants>
<bixt:AggregateIntrinsicValueForFullyVestedExercisableWarrants contextRef="AsOf2020-12-31_us-gaap_WarrantMember" decimals="0" id="xdx2ixbrl0860" unitRef="USD"> 0 </bixt:AggregateIntrinsicValueForFullyVestedExercisableWarrants>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2020-04-282020-05-01_custom_MikeSheikhMember_custom_StockPlan2010Member" id="xdx2ixbrl0911"> P3Y </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2021-01-01to2021-12-31" id="xdx2ixbrl1024"> P3Y </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2020-01-012020-12-31" id="xdx2ixbrl1025"> P3Y </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-012021-12-31_custom_ExercisePriceSevenOneMember" id="xdx2ixbrl1047"> P1Y11M12D </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-012021-12-31_custom_ExercisePriceSevenOneMember" id="xdx2ixbrl1051"> P1Y11M12D </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-012021-12-31_custom_ExercisePriceSevenTwoMember" id="xdx2ixbrl1055"> P1Y9M </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-012021-12-31_custom_ExercisePriceSevenTwoMember" id="xdx2ixbrl1059"> P1Y9M </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-012021-12-31_custom_ExercisePriceSevenThreeMember" id="xdx2ixbrl1063"> P1Y3M29D </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-012021-12-31_custom_ExercisePriceSevenThreeMember" id="xdx2ixbrl1067"> P1Y3M29D </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-012021-12-31_custom_ExercisePriceSevenFourMember" id="xdx2ixbrl1071"> P1Y9M29D </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-012021-12-31_custom_ExercisePriceSevenFourMember" id="xdx2ixbrl1075"> P1Y9M29D </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-012021-12-31_custom_ExercisePriceFiveMember" id="xdx2ixbrl1079"> P2Y3M29D </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-012021-12-31_custom_ExercisePriceSevenFiveMember" id="xdx2ixbrl1083"> P2Y3M29D </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-012021-12-31_custom_ExercisePriceSixMember" id="xdx2ixbrl1087"> P2Y0M15D </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-012021-12-31_custom_ExercisePriceSevenSixMember" id="xdx2ixbrl1091"> P2Y0M15D </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-012021-12-31_custom_ExercisePriceSevenMember" id="xdx2ixbrl1095"> P1Y </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-012021-12-31_custom_ExercisePriceSevenSevenMember" id="xdx2ixbrl1099"> P1Y </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-012021-12-31_custom_ExercisePriceEightOneMember" id="xdx2ixbrl1103"> P1Y2M30D </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-012021-12-31_custom_ExercisePriceSevenEightMember" id="xdx2ixbrl1107"> P1Y2M30D </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-012021-12-31_custom_ExercisePriceNineMember" id="xdx2ixbrl1111"> P9M29D </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-012021-12-31_custom_ExercisePriceSevenNineMember" id="xdx2ixbrl1115"> P9M29D </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-012021-12-31_custom_ExercisePriceTenMember" id="xdx2ixbrl1119"> P9M </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-012021-12-31_custom_ExercisePriceSevenTenMember" id="xdx2ixbrl1123"> P9M </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-012021-12-31_custom_ExercisePriceElevenMember" id="xdx2ixbrl1127"> P8M12D </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-012021-12-31_custom_ExercisePriceSevenElevenMember" id="xdx2ixbrl1131"> P8M12D </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-012021-12-31_custom_ExercisePriceTwelveMember" id="xdx2ixbrl1135"> P6M </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-012021-12-31_custom_ExercisePriceSevenTwelveMember" id="xdx2ixbrl1139"> P6M </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-012021-12-31_custom_ExercisePriceThirteenMember" id="xdx2ixbrl1143"> P6M29D </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-012021-12-31_custom_ExercisePriceSevenThirteenMember" id="xdx2ixbrl1147"> P6M29D </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-012021-12-31_custom_ExercisePriceFourteenMember" id="xdx2ixbrl1151"> P3M29D </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-012021-12-31_custom_ExercisePriceSevenFourteenMember" id="xdx2ixbrl1155"> P3M29D </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-01to2021-12-31" id="xdx2ixbrl1161"> P1Y2M19D </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-01to2021-12-31" id="xdx2ixbrl1165"> P1Y2M19D </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember" id="xdx2ixbrl1180" unitRef="USDPShares" xsi:nil="true"/>
<us-gaap:DeferredTaxAssetsNet contextRef="AsOf2021-12-31" id="xdx2ixbrl1211" unitRef="USD" xsi:nil="true"/>
<us-gaap:DeferredTaxAssetsNet contextRef="AsOf2020-12-31" id="xdx2ixbrl1212" unitRef="USD" xsi:nil="true"/>
<bixt:InvestmentsOptionsIssuanceDate contextRef="From2021-12-282021-12-31_us-gaap_ConvertibleDebtMember_us-gaap_PrivatePlacementMember" id="xdx2ixbrl1245"> 2022-01-12 </bixt:InvestmentsOptionsIssuanceDate>
<dei:DocumentType contextRef="From2021-01-01to2021-12-31"> 10-K </dei:DocumentType>
<dei:DocumentAnnualReport contextRef="From2021-01-01to2021-12-31"> true </dei:DocumentAnnualReport>
<dei:DocumentPeriodEndDate contextRef="From2021-01-01to2021-12-31"> 2021-12-31 </dei:DocumentPeriodEndDate>
<dei:DocumentTransitionReport contextRef="From2021-01-01to2021-12-31"> false </dei:DocumentTransitionReport>
<dei:EntityFileNumber contextRef="From2021-01-01to2021-12-31"> 001-35027 </dei:EntityFileNumber>
<dei:EntityRegistrantName contextRef="From2021-01-01to2021-12-31"> BIOXYTRAN, INC. </dei:EntityRegistrantName>
<dei:EntityIncorporationStateCountryCode contextRef="From2021-01-01to2021-12-31"> NV </dei:EntityIncorporationStateCountryCode>
<dei:EntityTaxIdentificationNumber contextRef="From2021-01-01to2021-12-31"> 26-2797630 </dei:EntityTaxIdentificationNumber>
<dei:EntityAddressAddressLine1 contextRef="From2021-01-01to2021-12-31"> 75 2nd Ave </dei:EntityAddressAddressLine1>
<dei:EntityAddressAddressLine2 contextRef="From2021-01-01to2021-12-31"> Ste 605 </dei:EntityAddressAddressLine2>
<dei:EntityAddressCityOrTown contextRef="From2021-01-01to2021-12-31"> Needham </dei:EntityAddressCityOrTown>
<dei:EntityAddressStateOrProvince contextRef="From2021-01-01to2021-12-31"> MA </dei:EntityAddressStateOrProvince>
<dei:EntityAddressPostalZipCode contextRef="From2021-01-01to2021-12-31"> 02494 </dei:EntityAddressPostalZipCode>
<dei:CityAreaCode contextRef="From2021-01-01to2021-12-31"> 617 </dei:CityAreaCode>
<dei:LocalPhoneNumber contextRef="From2021-01-01to2021-12-31"> 454-1199 </dei:LocalPhoneNumber>
<dei:EntityWellKnownSeasonedIssuer contextRef="From2021-01-01to2021-12-31"> No </dei:EntityWellKnownSeasonedIssuer>
<dei:EntityVoluntaryFilers contextRef="From2021-01-01to2021-12-31"> No </dei:EntityVoluntaryFilers>
<dei:EntityCurrentReportingStatus contextRef="From2021-01-01to2021-12-31"> Yes </dei:EntityCurrentReportingStatus>
<dei:EntityInteractiveDataCurrent contextRef="From2021-01-01to2021-12-31"> Yes </dei:EntityInteractiveDataCurrent>
<dei:EntityFilerCategory contextRef="From2021-01-01to2021-12-31"> Non-accelerated Filer </dei:EntityFilerCategory>
<dei:EntitySmallBusiness contextRef="From2021-01-01to2021-12-31"> true </dei:EntitySmallBusiness>
<dei:EntityEmergingGrowthCompany contextRef="From2021-01-01to2021-12-31"> false </dei:EntityEmergingGrowthCompany>
<dei:EntityShellCompany contextRef="From2021-01-01to2021-12-31"> false </dei:EntityShellCompany>
<dei:Security12bTitle contextRef="From2021-01-01to2021-12-31"> Common Stock, $0.001 par value per share </dei:Security12bTitle>
<dei:TradingSymbol contextRef="From2021-01-01to2021-12-31"> BIXT </dei:TradingSymbol>
<dei:EntityPublicFloat contextRef="AsOf2021-06-30" decimals="0" unitRef="USD"> 2215 </dei:EntityPublicFloat>
<dei:EntityCommonStockSharesOutstanding contextRef="AsOf2022-04-08" decimals="INF" unitRef="Shares"> 110840998 </dei:EntityCommonStockSharesOutstanding>
<dei:AuditorFirmId contextRef="From2021-01-01to2021-12-31"> 6117 </dei:AuditorFirmId>
<dei:AuditorName contextRef="From2021-01-01to2021-12-31"> Pinnacle Accountancy Group of Utah </dei:AuditorName>
<dei:AuditorLocation contextRef="From2021-01-01to2021-12-31"> Farmington, Utah </dei:AuditorLocation>
<us-gaap:Cash contextRef="AsOf2021-12-31" decimals="0" unitRef="USD"> 72358 </us-gaap:Cash>
<us-gaap:Cash contextRef="AsOf2020-12-31" decimals="0" unitRef="USD"> 41688 </us-gaap:Cash>
<us-gaap:PrepaidExpenseCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD"> 274715 </us-gaap:PrepaidExpenseCurrent>
<us-gaap:AssetsCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD"> 72358 </us-gaap:AssetsCurrent>
<us-gaap:AssetsCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD"> 316403 </us-gaap:AssetsCurrent>
<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2021-12-31" decimals="0" unitRef="USD"> 46932 </us-gaap:IntangibleAssetsNetExcludingGoodwill>
<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2020-12-31" decimals="0" unitRef="USD"> 10000 </us-gaap:IntangibleAssetsNetExcludingGoodwill>
<us-gaap:Assets contextRef="AsOf2021-12-31" decimals="0" unitRef="USD"> 119290 </us-gaap:Assets>
<us-gaap:Assets contextRef="AsOf2020-12-31" decimals="0" unitRef="USD"> 326403 </us-gaap:Assets>
<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD"> 624316 </us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD"> 348127 </us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
<us-gaap:AccountsPayableRelatedPartiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD"> 531000 </us-gaap:AccountsPayableRelatedPartiesCurrent>
<us-gaap:AccountsPayableRelatedPartiesCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD"> 307176 </us-gaap:AccountsPayableRelatedPartiesCurrent>
<us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD"> 2122181 </us-gaap:ConvertibleNotesPayableCurrent>
<us-gaap:ConvertibleNotesPayableCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD"> 1612356 </us-gaap:ConvertibleNotesPayableCurrent>
<us-gaap:LiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD"> 3277497 </us-gaap:LiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD"> 2267659 </us-gaap:LiabilitiesCurrent>
<us-gaap:Liabilities contextRef="AsOf2021-12-31" decimals="0" unitRef="USD"> 3277497 </us-gaap:Liabilities>
<us-gaap:Liabilities contextRef="AsOf2020-12-31" decimals="0" unitRef="USD"> 2267659 </us-gaap:Liabilities>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2020-12-31" decimals="INF" unitRef="USDPShares"> 0.001 </us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2021-12-31" decimals="INF" unitRef="USDPShares"> 0.001 </us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares"> 50000000 </us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares"> 50000000 </us-gaap:PreferredStockSharesAuthorized>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2020-12-31" decimals="INF" unitRef="USDPShares"> 0.001 </us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2021-12-31" decimals="INF" unitRef="USDPShares"> 0.001 </us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares"> 300000000 </us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares"> 300000000 </us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares"> 110840998 </us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesIssued contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares"> 110840998 </us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares"> 97450673 </us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesIssued contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares"> 97450673 </us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD"> 110841 </us-gaap:CommonStockValue>
<us-gaap:CommonStockValue contextRef="AsOf2020-12-31" decimals="0" unitRef="USD"> 97451 </us-gaap:CommonStockValue>
<us-gaap:AdditionalPaidInCapital contextRef="AsOf2021-12-31" decimals="0" unitRef="USD"> 5881876 </us-gaap:AdditionalPaidInCapital>
<us-gaap:AdditionalPaidInCapital contextRef="AsOf2020-12-31" decimals="0" unitRef="USD"> 1795125 </us-gaap:AdditionalPaidInCapital>
<us-gaap:MinorityInterest contextRef="AsOf2021-12-31" decimals="0" unitRef="USD"> -397256 </us-gaap:MinorityInterest>
<us-gaap:MinorityInterest contextRef="AsOf2020-12-31" decimals="0" unitRef="USD"> 888091 </us-gaap:MinorityInterest>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-12-31" decimals="0" unitRef="USD"> -8753668 </us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2020-12-31" decimals="0" unitRef="USD"> -4721923 </us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD"> -3158207 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" decimals="0" unitRef="USD"> -1941256 </us-gaap:StockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD"> 119290 </us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2020-12-31" decimals="0" unitRef="USD"> 326403 </us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:ResearchAndDevelopmentExpense contextRef="From2021-01-01to2021-12-31" decimals="0" unitRef="USD"> 2013762 </us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="From2020-01-012020-12-31" decimals="0" unitRef="USD"> 544519 </us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="From2021-01-01to2021-12-31" decimals="0" unitRef="USD"> 1617810 </us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="From2020-01-012020-12-31" decimals="0" unitRef="USD"> 476315 </us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense contextRef="From2021-01-01to2021-12-31" decimals="0" unitRef="USD"> 582862 </us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense>
<us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense contextRef="From2020-01-012020-12-31" decimals="0" unitRef="USD"> 247867 </us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense>
<us-gaap:OperatingExpenses contextRef="From2021-01-01to2021-12-31" decimals="0" unitRef="USD"> 4214434 </us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="From2020-01-012020-12-31" decimals="0" unitRef="USD"> 1268701 </us-gaap:OperatingExpenses>
<us-gaap:OperatingIncomeLoss contextRef="From2021-01-01to2021-12-31" decimals="0" unitRef="USD"> -4214434 </us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="From2020-01-012020-12-31" decimals="0" unitRef="USD"> -1268701 </us-gaap:OperatingIncomeLoss>
<us-gaap:InterestExpense contextRef="From2021-01-01to2021-12-31" decimals="0" unitRef="USD"> 236577 </us-gaap:InterestExpense>
<us-gaap:InterestExpense contextRef="From2020-01-012020-12-31" decimals="0" unitRef="USD"> 1014769 </us-gaap:InterestExpense>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2021-01-01to2021-12-31" decimals="0" unitRef="USD"> 77031 </us-gaap:AmortizationOfDebtDiscountPremium>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2020-01-012020-12-31" decimals="0" unitRef="USD"> 259057 </us-gaap:AmortizationOfDebtDiscountPremium>
<us-gaap:NonoperatingIncomeExpense contextRef="From2021-01-01to2021-12-31" decimals="0" unitRef="USD"> -313608 </us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="From2020-01-012020-12-31" decimals="0" unitRef="USD"> -1273826 </us-gaap:NonoperatingIncomeExpense>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="From2021-01-01to2021-12-31" decimals="0" unitRef="USD"> -4528042 </us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="From2020-01-012020-12-31" decimals="0" unitRef="USD"> -2542527 </us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
<us-gaap:NetIncomeLoss contextRef="From2021-01-01to2021-12-31" decimals="0" unitRef="USD"> -4528042 </us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="From2020-01-012020-12-31" decimals="0" unitRef="USD"> -2542527 </us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="From2021-01-01to2021-12-31" decimals="0" unitRef="USD"> -496297 </us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="From2020-01-012020-12-31" decimals="0" unitRef="USD"> -61909 </us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2021-01-01to2021-12-31" decimals="0" unitRef="USD"> -4031745 </us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2020-01-012020-12-31" decimals="0" unitRef="USD"> -2480618 </us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2021-01-01to2021-12-31" decimals="INF" unitRef="USDPShares"> -0.04 </us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2020-01-012020-12-31" decimals="INF" unitRef="USDPShares"> -0.03 </us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2021-01-01to2021-12-31" decimals="INF" unitRef="Shares"> 106252116 </us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2020-01-012020-12-31" decimals="INF" unitRef="Shares"> 93967677 </us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:SharesIssued contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 86475673 </us-gaap:SharesIssued>
<us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" decimals="0" unitRef="USD"> 86476 </us-gaap:StockholdersEquity>
<us-gaap:SharesIssued contextRef="AsOf2019-12-31_us-gaap_PreferredStockMember" decimals="INF" unitRef="Shares"> 0 </us-gaap:SharesIssued>
<us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_us-gaap_PreferredStockMember" decimals="0" unitRef="USD"> 0 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 1355542 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember" decimals="0" unitRef="USD"> -2241305 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_us-gaap_NoncontrollingInterestMember" decimals="0" unitRef="USD"> 0 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2019-12-31" decimals="0" unitRef="USD"> -799287 </us-gaap:StockholdersEquity>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 145438 </us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2020-01-012020-12-31" decimals="0" unitRef="USD"> 145438 </us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
<bixt:ClassExerciseOfWarrants contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 750000 </bixt:ClassExerciseOfWarrants>
<bixt:StockIssuedDuringPeriodValueConversionOfWarrants contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" decimals="0" unitRef="USD"> 750 </bixt:StockIssuedDuringPeriodValueConversionOfWarrants>
<bixt:StockIssuedDuringPeriodValueConversionOfWarrants contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> -750 </bixt:StockIssuedDuringPeriodValueConversionOfWarrants>
<bixt:IssuanceOptions2010Plan contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 18460 </bixt:IssuanceOptions2010Plan>
<bixt:IssuanceOptions2010Plan contextRef="From2020-01-012020-12-31" decimals="0" unitRef="USD"> 18460 </bixt:IssuanceOptions2010Plan>
<bixt:IssuanceShares2010PlanShares contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 8875000 </bixt:IssuanceShares2010PlanShares>
<bixt:IssuanceShares2010Plan contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" decimals="0" unitRef="USD"> 8875 </bixt:IssuanceShares2010Plan>
<bixt:IssuanceShares2010Plan contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 31982 </bixt:IssuanceShares2010Plan>
<bixt:IssuanceShares2010Plan contextRef="From2020-01-012020-12-31" decimals="0" unitRef="USD"> 40857 </bixt:IssuanceShares2010Plan>
<bixt:SharesIssuedToConsultants2010Plan contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 1000000 </bixt:SharesIssuedToConsultants2010Plan>
<bixt:AmountOfSharesIssuedToConsultants2010Plan contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" decimals="0" unitRef="USD"> 1000 </bixt:AmountOfSharesIssuedToConsultants2010Plan>
<bixt:AmountOfSharesIssuedToConsultants2010Plan contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 186550 </bixt:AmountOfSharesIssuedToConsultants2010Plan>
<bixt:AmountOfSharesIssuedToConsultants2010Plan contextRef="From2020-01-012020-12-31" decimals="0" unitRef="USD"> 187550 </bixt:AmountOfSharesIssuedToConsultants2010Plan>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> -937007 </us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt contextRef="From2020-01-012020-12-31" decimals="0" unitRef="USD"> -937007 </us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
<bixt:AdjustmentsToAdditionalPaidInCapitalDebtPremiumAccretion contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 961128 </bixt:AdjustmentsToAdditionalPaidInCapitalDebtPremiumAccretion>
<bixt:AdjustmentsToAdditionalPaidInCapitalDebtPremiumAccretion contextRef="From2020-01-012020-12-31" decimals="0" unitRef="USD"> 961128 </bixt:AdjustmentsToAdditionalPaidInCapitalDebtPremiumAccretion>
<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 350000 </us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" decimals="0" unitRef="USD"> 350 </us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 33782 </us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2020-01-012020-12-31" decimals="0" unitRef="USD"> 34132 </us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
<us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest contextRef="From2020-01-012020-12-31_us-gaap_NoncontrollingInterestMember" decimals="0" unitRef="USD"> 950000 </us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest>
<us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest contextRef="From2020-01-012020-12-31" decimals="0" unitRef="USD"> 950000 </us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest>
<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="From2020-01-012020-12-31_us-gaap_NoncontrollingInterestMember" decimals="0" unitRef="USD"> -61909 </us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="From2020-01-012020-12-31" decimals="0" unitRef="USD"> -61909 </us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
<us-gaap:ProfitLoss contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" decimals="0" unitRef="USD"> -2480618 </us-gaap:ProfitLoss>
<us-gaap:ProfitLoss contextRef="From2020-01-012020-12-31" decimals="0" unitRef="USD"> -2480618 </us-gaap:ProfitLoss>
<us-gaap:SharesIssued contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 97450673 </us-gaap:SharesIssued>
<us-gaap:StockholdersEquity contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" decimals="0" unitRef="USD"> 97451 </us-gaap:StockholdersEquity>
<us-gaap:SharesIssued contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember" decimals="INF" unitRef="Shares"> 0 </us-gaap:SharesIssued>
<us-gaap:StockholdersEquity contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember" decimals="0" unitRef="USD"> 0 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 1795125 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" decimals="0" unitRef="USD"> -4721923 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2020-12-31_us-gaap_NoncontrollingInterestMember" decimals="0" unitRef="USD"> 888091 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" decimals="0" unitRef="USD"> -1941256 </us-gaap:StockholdersEquity>
<bixt:IssuanceOptions2010Plan contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 14490 </bixt:IssuanceOptions2010Plan>
<bixt:IssuanceOptions2010Plan contextRef="From2021-01-01to2021-12-31" decimals="0" unitRef="USD"> 14490 </bixt:IssuanceOptions2010Plan>
<bixt:IssuanceShares2010PlanShares contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 4811309 </bixt:IssuanceShares2010PlanShares>
<bixt:IssuanceShares2010Plan contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" decimals="0" unitRef="USD"> 4811 </bixt:IssuanceShares2010Plan>
<bixt:IssuanceShares2010Plan contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 143259 </bixt:IssuanceShares2010Plan>
<bixt:IssuanceShares2010Plan contextRef="From2021-01-01to2021-12-31" decimals="0" unitRef="USD"> 148070 </bixt:IssuanceShares2010Plan>
<bixt:SharesIssuedToConsultants2010Plan contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 2893600 </bixt:SharesIssuedToConsultants2010Plan>
<bixt:AmountOfSharesIssuedToConsultants2010Plan contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" decimals="0" unitRef="USD"> 2893 </bixt:AmountOfSharesIssuedToConsultants2010Plan>
<bixt:AmountOfSharesIssuedToConsultants2010Plan contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 406459 </bixt:AmountOfSharesIssuedToConsultants2010Plan>
<bixt:AmountOfSharesIssuedToConsultants2010Plan contextRef="From2021-01-01to2021-12-31" decimals="0" unitRef="USD"> 409352 </bixt:AmountOfSharesIssuedToConsultants2010Plan>
<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 930864 </us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
<bixt:CommonStockIssuedForConversionOfConvertibleNotesAndAccruedInterest contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" decimals="0" unitRef="USD"> 931 </bixt:CommonStockIssuedForConversionOfConvertibleNotesAndAccruedInterest>
<bixt:CommonStockIssuedForConversionOfConvertibleNotesAndAccruedInterest contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 120111 </bixt:CommonStockIssuedForConversionOfConvertibleNotesAndAccruedInterest>
<bixt:CommonStockIssuedForConversionOfConvertibleNotesAndAccruedInterest contextRef="From2021-01-01to2021-12-31" decimals="0" unitRef="USD"> 121042 </bixt:CommonStockIssuedForConversionOfConvertibleNotesAndAccruedInterest>
<bixt:ForgivenessODebtfRelatedPartySubsidiarStockTransacion contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 2007187 </bixt:ForgivenessODebtfRelatedPartySubsidiarStockTransacion>
<bixt:ForgivenessODebtfRelatedPartySubsidiarStockTransacion contextRef="From2021-01-01to2021-12-31" decimals="0" unitRef="USD"> 2007187 </bixt:ForgivenessODebtfRelatedPartySubsidiarStockTransacion>
<us-gaap:ConversionOfStockSharesIssued1 contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 4754552 </us-gaap:ConversionOfStockSharesIssued1>
<bixt:ConversionOfSubsidiaryShares contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" decimals="0" unitRef="USD"> 4755 </bixt:ConversionOfSubsidiaryShares>
<bixt:ConversionOfSubsidiaryShares contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 1395245 </bixt:ConversionOfSubsidiaryShares>
<bixt:ConversionOfSubsidiaryShares contextRef="From2021-01-012021-12-31_us-gaap_NoncontrollingInterestMember" decimals="0" unitRef="USD"> -1400000 </bixt:ConversionOfSubsidiaryShares>
<bixt:SubsidiarySharesAcquiredByAffiliate contextRef="From2021-01-012021-12-31_us-gaap_NoncontrollingInterestMember" decimals="0" unitRef="USD"> 10500 </bixt:SubsidiarySharesAcquiredByAffiliate>
<bixt:SubsidiarySharesAcquiredByAffiliate contextRef="From2021-01-01to2021-12-31" decimals="0" unitRef="USD"> 10500 </bixt:SubsidiarySharesAcquiredByAffiliate>
<bixt:SubsidiaryStockOption contextRef="From2021-01-012021-12-31_us-gaap_NoncontrollingInterestMember" decimals="0" unitRef="USD"> 450 </bixt:SubsidiaryStockOption>
<bixt:SubsidiaryStockOption contextRef="From2021-01-01to2021-12-31" decimals="0" unitRef="USD"> 450 </bixt:SubsidiaryStockOption>
<bixt:SubsidiaryStockTransactions contextRef="From2021-01-012021-12-31_us-gaap_NoncontrollingInterestMember" decimals="0" unitRef="USD"> 600000 </bixt:SubsidiaryStockTransactions>
<bixt:SubsidiaryStockTransactions contextRef="From2021-01-01to2021-12-31" decimals="0" unitRef="USD"> 600000 </bixt:SubsidiaryStockTransactions>
<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="From2021-01-012021-12-31_us-gaap_NoncontrollingInterestMember" decimals="0" unitRef="USD"> -496297 </us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="From2021-01-01to2021-12-31" decimals="0" unitRef="USD"> -496297 </us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
<us-gaap:ProfitLoss contextRef="From2021-01-012021-12-31_us-gaap_PreferredStockMember" decimals="0" unitRef="USD"> 0 </us-gaap:ProfitLoss>
<us-gaap:ProfitLoss contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" decimals="0" unitRef="USD"> -4031745 </us-gaap:ProfitLoss>
<us-gaap:ProfitLoss contextRef="From2021-01-01to2021-12-31" decimals="0" unitRef="USD"> -4031745 </us-gaap:ProfitLoss>
<us-gaap:SharesIssued contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 110840998 </us-gaap:SharesIssued>
<us-gaap:StockholdersEquity contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" decimals="0" unitRef="USD"> 110841 </us-gaap:StockholdersEquity>
<us-gaap:SharesIssued contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember" decimals="INF" unitRef="Shares"> 0 </us-gaap:SharesIssued>
<us-gaap:StockholdersEquity contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember" decimals="0" unitRef="USD"> 0 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 5881876 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" decimals="0" unitRef="USD"> -8753668 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2021-12-31_us-gaap_NoncontrollingInterestMember" decimals="0" unitRef="USD"> -397256 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD"> -3158207 </us-gaap:StockholdersEquity>
<us-gaap:NetIncomeLoss contextRef="From2021-01-01to2021-12-31" decimals="0" unitRef="USD"> -4528042 </us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="From2020-01-012020-12-31" decimals="0" unitRef="USD"> -2542527 </us-gaap:NetIncomeLoss>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2021-01-01to2021-12-31" decimals="0" unitRef="USD"> 77031 </us-gaap:AmortizationOfDebtDiscountPremium>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2020-01-012020-12-31" decimals="0" unitRef="USD"> 259057 </us-gaap:AmortizationOfDebtDiscountPremium>
<bixt:DefaultFeeConvertibleNotes contextRef="From2020-01-012020-12-31" decimals="0" unitRef="USD"> -673956 </bixt:DefaultFeeConvertibleNotes>
<us-gaap:ShareBasedCompensation contextRef="From2021-01-01to2021-12-31" decimals="0" unitRef="USD"> 582862 </us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="From2020-01-012020-12-31" decimals="0" unitRef="USD"> 247867 </us-gaap:ShareBasedCompensation>
<us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="From2021-01-01to2021-12-31" decimals="0" unitRef="USD"> -274715 </us-gaap:IncreaseDecreaseInPrepaidExpense>
<us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="From2020-01-012020-12-31" decimals="0" unitRef="USD"> 274715 </us-gaap:IncreaseDecreaseInPrepaidExpense>
<us-gaap:IncreaseDecreaseInOtherReceivables contextRef="From2020-01-012020-12-31" decimals="0" unitRef="USD"> -50000 </us-gaap:IncreaseDecreaseInOtherReceivables>
<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2021-01-01to2021-12-31" decimals="0" unitRef="USD"> 1206088 </us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2020-01-012020-12-31" decimals="0" unitRef="USD"> 276194 </us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
<bixt:IncreaseDecreaseAccountsPayableAndAccruedExpensesRelatedParty contextRef="From2021-01-01to2021-12-31" decimals="0" unitRef="USD"> 689947 </bixt:IncreaseDecreaseAccountsPayableAndAccruedExpensesRelatedParty>
<bixt:IncreaseDecreaseAccountsPayableAndAccruedExpensesRelatedParty contextRef="From2020-01-012020-12-31" decimals="0" unitRef="USD"> 211176 </bixt:IncreaseDecreaseAccountsPayableAndAccruedExpensesRelatedParty>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2021-01-01to2021-12-31" decimals="0" unitRef="USD"> -1697399 </us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2020-01-012020-12-31" decimals="0" unitRef="USD"> -1098992 </us-gaap:NetCashProvidedByUsedInOperatingActivities>
<bixt:InvestmentInIntangibles contextRef="From2021-01-01to2021-12-31" decimals="0" unitRef="USD"> -36931 </bixt:InvestmentInIntangibles>
<bixt:InvestmentInIntangibles contextRef="From2020-01-012020-12-31" decimals="0" unitRef="USD"> -10000 </bixt:InvestmentInIntangibles>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2021-01-01to2021-12-31" decimals="0" unitRef="USD"> -36931 </us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2020-01-012020-12-31" decimals="0" unitRef="USD"> -10000 </us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:ProceedsFromStockPlans contextRef="From2021-01-01to2021-12-31" decimals="0" unitRef="USD"> 600000 </us-gaap:ProceedsFromStockPlans>
<us-gaap:ProceedsFromStockPlans contextRef="From2020-01-012020-12-31" decimals="0" unitRef="USD"> 950000 </us-gaap:ProceedsFromStockPlans>
<us-gaap:ProceedsFromNotesPayable contextRef="From2021-01-01to2021-12-31" decimals="0" unitRef="USD"> 1165000 </us-gaap:ProceedsFromNotesPayable>
<us-gaap:ProceedsFromNotesPayable contextRef="From2020-01-012020-12-31" decimals="0" unitRef="USD"> 264000 </us-gaap:ProceedsFromNotesPayable>
<us-gaap:RepaymentsOfNotesPayable contextRef="From2020-01-012020-12-31" decimals="0" unitRef="USD"> 232948 </us-gaap:RepaymentsOfNotesPayable>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2021-01-01to2021-12-31" decimals="0" unitRef="USD"> 1765000 </us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2020-01-012020-12-31" decimals="0" unitRef="USD"> 981052 </us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="From2021-01-01to2021-12-31" decimals="0" unitRef="USD"> 30670 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="From2020-01-012020-12-31" decimals="0" unitRef="USD"> -127940 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
<us-gaap:Cash contextRef="AsOf2020-12-31" decimals="0" unitRef="USD"> 41688 </us-gaap:Cash>
<us-gaap:Cash contextRef="AsOf2019-12-31" decimals="0" unitRef="USD"> 169628 </us-gaap:Cash>
<us-gaap:Cash contextRef="AsOf2021-12-31" decimals="0" unitRef="USD"> 72358 </us-gaap:Cash>
<us-gaap:Cash contextRef="AsOf2020-12-31" decimals="0" unitRef="USD"> 41688 </us-gaap:Cash>
<us-gaap:InterestPaidNet contextRef="From2020-01-012020-12-31" decimals="0" unitRef="USD"> 91362 </us-gaap:InterestPaidNet>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2020-01-012020-12-31" decimals="0" unitRef="USD"> 145438 </us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
<bixt:DebtDiscountOnConvertibleNote contextRef="From2021-01-01to2021-12-31" decimals="0" unitRef="USD"> 119850 </bixt:DebtDiscountOnConvertibleNote>
<bixt:DebtPremiumOnConvertibleNote contextRef="From2020-01-012020-12-31" decimals="0" unitRef="USD"> 937007 </bixt:DebtPremiumOnConvertibleNote>
<bixt:AccretionOfDebtPremiumToAdditionalPaidInCapital contextRef="From2020-01-012020-12-31" decimals="0" unitRef="USD"> 961128 </bixt:AccretionOfDebtPremiumToAdditionalPaidInCapital>
<us-gaap:StockIssued1 contextRef="From2021-01-01to2021-12-31" decimals="0" unitRef="USD"> 1400000 </us-gaap:StockIssued1>
<bixt:StockIssued1One contextRef="From2021-01-01to2021-12-31" decimals="0" unitRef="USD"> 121042 </bixt:StockIssued1One>
<bixt:StockIssued1One contextRef="From2020-01-012020-12-31" decimals="0" unitRef="USD"> 34132 </bixt:StockIssued1One>
<bixt:ForgivenessOfRelatedPartyDebtRecordedToAdditionalPaidinCapital contextRef="From2021-01-01to2021-12-31" decimals="0" unitRef="USD"> 2007187 </bixt:ForgivenessOfRelatedPartyDebtRecordedToAdditionalPaidinCapital>
<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2021-01-01to2021-12-31">
<p id="xdx_80C_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_z7ubRMGJdC9b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 1 – <span id="xdx_824_zigbnXQpKUc">BACKGROUND AND ORGANIZATION</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Business Operations</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Bioxytran, Inc. (the “Company”) is a clinical-stage pharmaceutical company focused on the development, manufacture and commercialization of therapeutic drugs designed to address hypoxia in humans, which is a lack of oxygen to tissues, in a safe and efficient manner. If it is not addressed, lack of oxygen to tissues, or hypoxia, results in necrosis, which is the death of cells comprising body tissue. Necrosis cannot be reversed. Our lead drug candidate, code named BXT-25, is an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer with intended applications to include treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. The Company’s initial focus is the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. The Company’s approach potentially will result in the creation of safe drug alternatives to existing therapies for effectively addressing hypoxic conditions in humans. Our drug development efforts are guided by specialists in co-polymer chemistry and other disciplines, and we intend to supplement our efforts with input from a scientific and medical advisory board whose members are leading physicians.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Subsidiary, Pharmalectin, Inc. (“Pharmalectin” or the “Subsidiary”) is pursuing their work with a candidate named, ProLectin, a complex polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin. Galectins are a member of a family of proteins in the body called lectins. These proteins interact with carbohydrate sugars located in, on the surface of, and in between cells. This interaction causes the cells to change behavior, including cell movement, multiplication, and other cellular functions. The interactions between lectins and their target carbohydrate sugars occur via a carbohydrate recognition domain, or CRD, within the lectin. Galectins are a subfamily of lectins that have a CRD that bind specifically to se. Galectins have a broad range of functions, including regulation of cell survival and adhesion, promotion of cell-to-cell interactions, growth of blood vessels, regulation of the immune response and inflammation. During viral infections galectins are upregulated and downregulated based on the type of virus.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Foreign Subsidiary, Pharmalectin (BVI), Inc. (“Pharmalectin BVI” or the “Foreign Subsidiary”) is the owner and custodian of the Company’s Copyrights, Trade Marks and Patents.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Organization</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Bioxytran, Inc. was organized on October 5, 2017 as a Delaware corporation, with a taxing structure for U.S. federal and state income tax as a C-Corporation with <span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_pid_uShares_c20171005__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DelawareProvenanceMember_z2D09NJW81a7" title="Common stock, shares authorized">95,000,000</span> authorized common shares with a par value of $<span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20171005_z20zAtR1MEsa" title="Common stock, par value">0.0001</span>, and <span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_pid_uShares_c20171005__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DelawareProvenanceMember_zRlf3Rzxhubk" title="Preferred stock, shares authorized">5,000,000</span> Preferred shares with a par value of $<span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20171005__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DelawareProvenanceMember_zva3sf7BJFVd" title="Preferred stock, par value">0.0001</span>. On September 21, 2018, the Company went under a reorganization in the form of a reverse merger and is currently registered as a Nevada corporation with a taxing structure for U.S. federal and state income tax as a C-Corporation with <span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_pid_uShares_c20180921__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DelawareProvenanceMember_zoQXB0FnIL9d" title="Common stock, shares authorized">300,000,000</span> authorized common shares with a par value of $<span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20180921__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DelawareProvenanceMember_zYFcV7tb6Zc6" title="Common stock, par value">0.001</span>, and <span id="xdx_90C_eus-gaap--PreferredStockSharesAuthorized_iI_pid_uShares_c20180921__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DelawareProvenanceMember_zODnosienPHb">50,000,000</span> Preferred shares with a par value of $<span id="xdx_905_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20180921__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DelawareProvenanceMember_zLaGe86lyGLb">0.001</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pharmalectin was organized on October 5, 2017 as a Delaware corporation, with a taxing structure for U.S. federal and state income tax as a C-Corporation with <span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_pid_uShares_c20171005__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DelawareProvenanceMember_zQQOp5TmZr88">95,000,000</span> authorized Common shares with a par value of $<span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20171005__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DelawareProvenanceMember_zQf062wa4mo3">0.0001</span>, and <span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_iI_pid_uShares_c20171005__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DelawareProvenanceMember_zh5gM3Eshmsd">5,000,000</span> Preferred shares with a par value of $<span id="xdx_90E_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20171005__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DelawareProvenanceMember_ztfgup8vqjPd">0.0001</span>. The Subsidiary was founded under the name of Bioxytran “Bioxytran (DE)”. On April 29, 2020, the name was changed to Pharmalectin, Inc. There are currently <span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_pid_uShares_c20200429__srt--ConsolidatedEntitiesAxis__srt--SubsidiariesMember_z6HMv5anjcS8" title="Common stock issue">30,000,000</span> issued and <span id="xdx_902_eus-gaap--CommonStockOtherSharesOutstanding_iI_pid_uShares_c20200429__srt--ConsolidatedEntitiesAxis__srt--SubsidiariesMember_z0yh3v6MtqK1" title="Common stock, outstanding">19,650,000</span> outstanding shares; <span id="xdx_90F_ecustom--EquityMethodInvestmentOwnership_iI_pid_uShares_c20200429_z2wjJLVFcHr" title="Common shares held">15,000,000</span> Common shares are held by Bioxytran and <span id="xdx_908_ecustom--EquityMethodInvestmentAdditional1_iI_pid_uShares_c20200429_zLHbaUCQYxh4" title="Equity method investment additional">4,650,000</span> Common shares are held by an affiliate. An additional <span id="xdx_90A_ecustom--EquityMethodInvestmentAdditional1_iI_pid_uShares_c20200429__srt--ConsolidatedEntitiesAxis__srt--SubsidiariesMember_zVfed1A8Ci07" title="Equity method investment additional">4,500,000</span> options are also held by an affiliate. The option agreement includes provisions for dilutive issuance and cash-less exercise. The beneficial ownership of the affiliate are Mike Sheikh, Ola Soderquist and David Platt.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pharmalectin BVI was organized on March 17, 2021 as a British Virgin Islands (BVI) Business Corporation with a BVI corporate taxing structure with <span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_iI_pid_uShares_c20210317_zmFDwkBNcTyc" title="Preferred stock, shares authorized">50,000</span> authorized shares with a par value of $<span id="xdx_908_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20210317_z4b8tL3Z75p8">1.00</span>. There are currently <span id="xdx_90D_eus-gaap--PreferredStockSharesOutstanding_iI_pid_uShares_c20210317_zw02njWV3qq4" title="Preferred stock share outstanding">50,000</span> outstanding shares held by the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Basis of Presentation</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The summary of significant accounting policies presented below is designed to assist in understanding the Company’s consolidated financial statements. Such financial statements and accompanying notes are the representations of the Company’s management, who are responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America (“U.S. GAAP”) in all material respects and have been consistently applied in preparing the accompanying consolidated financial statements. The Company has not earned any revenue from operations since inception. The Company chose December 31<sup>st</sup> as its fiscal year end.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Principles of Consolidation</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements include the accounts of Bioxytran, Inc. a Nevada Corporation, its majority owned subsidiary, Pharmalectin, Inc. of Delaware (collectively, the “Company”), as well as its wholly owned subsidiary, Pharmalectin (BVI), Inc of British Virgin Islands. All intercompany accounts have been eliminated upon consolidation.</p>
</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
<us-gaap:CommonStockSharesAuthorized contextRef="AsOf2017-10-05_custom_DelawareProvenanceMember" decimals="INF" unitRef="Shares"> 95000000 </us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2017-10-05" decimals="INF" unitRef="USDPShares"> 0.0001 </us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2017-10-05_custom_DelawareProvenanceMember" decimals="INF" unitRef="Shares"> 5000000 </us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2017-10-05_custom_DelawareProvenanceMember" decimals="INF" unitRef="USDPShares"> 0.0001 </us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized contextRef="AsOf2018-09-21_custom_DelawareProvenanceMember" decimals="INF" unitRef="Shares"> 300000000 </us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2018-09-21_custom_DelawareProvenanceMember" decimals="INF" unitRef="USDPShares"> 0.001 </us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2018-09-21_custom_DelawareProvenanceMember" decimals="INF" unitRef="Shares"> 50000000 </us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2018-09-21_custom_DelawareProvenanceMember" decimals="INF" unitRef="USDPShares"> 0.001 </us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized contextRef="AsOf2017-10-05_custom_DelawareProvenanceMember" decimals="INF" unitRef="Shares"> 95000000 </us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2017-10-05_custom_DelawareProvenanceMember" decimals="INF" unitRef="USDPShares"> 0.0001 </us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2017-10-05_custom_DelawareProvenanceMember" decimals="INF" unitRef="Shares"> 5000000 </us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2017-10-05_custom_DelawareProvenanceMember" decimals="INF" unitRef="USDPShares"> 0.0001 </us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesIssued contextRef="AsOf2020-04-29_srt_SubsidiariesMember" decimals="INF" unitRef="Shares"> 30000000 </us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockOtherSharesOutstanding contextRef="AsOf2020-04-29_srt_SubsidiariesMember" decimals="INF" unitRef="Shares"> 19650000 </us-gaap:CommonStockOtherSharesOutstanding>
<bixt:EquityMethodInvestmentOwnership contextRef="AsOf2020-04-29" decimals="INF" unitRef="Shares"> 15000000 </bixt:EquityMethodInvestmentOwnership>
<bixt:EquityMethodInvestmentAdditional1 contextRef="AsOf2020-04-29" decimals="INF" unitRef="Shares"> 4650000 </bixt:EquityMethodInvestmentAdditional1>
<bixt:EquityMethodInvestmentAdditional1 contextRef="AsOf2020-04-29_srt_SubsidiariesMember" decimals="INF" unitRef="Shares"> 4500000 </bixt:EquityMethodInvestmentAdditional1>
<us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2021-03-17" decimals="INF" unitRef="Shares"> 50000 </us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2021-03-17" decimals="INF" unitRef="USDPShares"> 1.00 </us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2021-03-17" decimals="INF" unitRef="Shares"> 50000 </us-gaap:PreferredStockSharesOutstanding>
<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2021-01-01to2021-12-31">
<p id="xdx_80E_eus-gaap--SignificantAccountingPoliciesTextBlock_z8MvvztxFeg3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 2 - <span id="xdx_82C_z5cEGfxa95li">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A summary of the significant accounting policies applied in the preparation of the accompanying financial statements follows.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zUhaq3AqqX66" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i><span id="xdx_86D_zkrZ7DOFmu54">Cash</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For purposes of the Statement of Cash Flows, the Company considers all highly liquid debt instruments purchased with a maturity date of three months or less to be cash equivalents.</p> <p id="xdx_852_zILojT9LViGc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_84F_eus-gaap--UseOfEstimates_zPiznIUSD9E4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i><span id="xdx_861_zNEMoHGPLOY1">Use of Estimates</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of expenses during the reporting period. Significant estimates include the fair value of the Company’s stock, stock-based compensation and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.</p> <p id="xdx_853_zZXk15J09YN9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_84A_eus-gaap--EarningsPerSharePolicyTextBlock_zs2YzRGCvbQ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i><span id="xdx_86C_zhUCv84Mipb8">Net Loss per Common Share, basic and diluted</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per common share is computed by dividing net loss by the weighted average number of shares of Common Stock outstanding during the year. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into Common Stock using the “treasury stock” and/or “if converted” methods as applicable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At December 31, 2021, we would, based on the market price of $<span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_uUSDPShares_c20211231_zKBmqFbwAaT7" title="Market price per share">0.40</span>/share, be obligated to issue approximately <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20211231_ztfeaRhqtzl8" title="Warrants outstanding">17,312,961</span> shares of Common Stock upon conversion of the currently outstanding convertible notes (the “New Notes”) and <span id="xdx_90E_eus-gaap--SharesIssued_iI_c20211231_zj7y7AxBrghl" title="Fair market value of shares issued">272,000</span> shares upon exercise of the warrants. For the New Notes, the shares total is based on $<span id="xdx_902_ecustom--SharesOutstandingValue_iI_c20211231_z1hVHypiKDZa" title="Outstanding shares value">2,250,685</span> of currently outstanding principal, default penalty and unpaid interest. At December 31, 2020, we would, based on market price of $<span id="xdx_905_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_uUSDPShares_c20201231_zAcJkYm1lHzc">0.24</span>/share, be obligated to issue approximately <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20201231_zWmKHqwx8cAb">11,974,301</span> shares of Common Stock upon conversion of the then outstanding convertible notes (the “Old Notes”) and <span id="xdx_90B_eus-gaap--SharesIssued_iI_c20201231_zvmDZPxoM892">272,000</span> shares upon exercise of the warrants. For the Old Notes, the shares total was based on $<span id="xdx_908_ecustom--SharesOutstandingValue_iI_c20201231_zMFVRUrTD8nb">1,867,991</span> of currently outstanding principal, default penalty and unpaid interest</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_906_eus-gaap--CommonStockConversionBasis_c20210101__20211231_zQDrGK9yTYA2" title="Convertible notes, description">The 2021 1-year notes (the “New Notes”), have an interest rate of 6% and are convertible at the lower of (i) a fixed price of $0.13, or (ii) 85% of the closing price of any Qualified Financing, which consist of any fundraising receiving gross proceeds of not less than $500,000. The New Notes are limited to converting no more than 4.99% of our issued an outstanding Common Stock.</span></p> <p id="xdx_85B_zsdd5emwobC7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_84F_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zUncoAP4kIKk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i><span id="xdx_86C_zq2lt0pcjAtf">Stock Based Compensation</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company measures the cost of services received from employees and non-employees in exchange for an award of equity instruments based on the fair value of the award on the grant date pursuant ASC 718. Stock-based compensation expense is recorded by the Company over the requisite service period, or vesting period, in the same expense classifications in the statements of operations, as if such amounts were paid in cash.</p> <p id="xdx_85F_z5l7pkvuMuv3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_84C_ecustom--AccountingForSubsidiaryStockTransactionsPolicyTextBlock_z0fJud5MbfAl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i><span id="xdx_860_zzCFW0xJN5mb">Accounting for subsidiary stock transactions</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">The Company accounts for subsidiary stock transactions in accordance with Opinions of the Accounting Principles Board 09 (APBO No. 9). In paragraph 28, this pronouncement excluded all adjustments form transactions in a company’s own stock “. . . from the determination of net income or the results of operations under all circumstances.” During the years ended December 31, 2021 and 2020, the Company sold <span id="xdx_90D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20211231__srt--ConsolidatedEntitiesAxis__srt--SubsidiariesMember_zaKL4n8e5av8" title="Ownership percentage">9</span>% and <span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20201231__srt--ConsolidatedEntitiesAxis__srt--SubsidiariesMember_zBfY3JkilzK3">15</span>%, respectively, of its subsidiary Pharmalectin for a total amount of $<span id="xdx_901_ecustom--EquityMethodInvestmentAmount_c20210101__20211231__srt--ConsolidatedEntitiesAxis__srt--SubsidiariesMember_zu3hqgkFEeTe" title="Equity method investment amount">600,000</span> and $<span id="xdx_909_ecustom--EquityMethodInvestmentAmount_c20200101__20201231__srt--ConsolidatedEntitiesAxis__srt--SubsidiariesMember_zR8myFtQOmW5">950,000</span>, respectively. During the years ended December 31, 2021 the Subsidiary also issued <span id="xdx_908_eus-gaap--SharesIssued_iI_uShares_c20211231__srt--ConsolidatedEntitiesAxis__srt--SubsidiariesMember_zCAjcL9t0cCg" title="Issue in stock option">4,500,000</span> stock options to its management. Accordingly, APIC has been adjusted with this amount for the year ended December 31, 2021 and 2020.</p> <p id="xdx_85C_zaMxLh5U5uR" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i> </i></b></p> <p id="xdx_84D_eus-gaap--IncomeTaxPolicyTextBlock_zn8alaOOg2e4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i><span id="xdx_868_zKBe2Hg0PFaa">Income Taxes</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or be settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is provided when it is more likely than not that some portion of the gross deferred tax asset will not be realized. The Company records interest and penalties related to income taxes as a component of provision for income taxes. The Company did not recognize any interest and penalty expense for the years ended December 31, 2021 and 2020.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 22, 2017, the Tax Cuts and Jobs Act (TCJA) was signed into law by the President of the United States. TCJA is a tax reform act that among other things, reduced corporate tax rates to 21 percent effective January 1, 2018. FASB ASC 740, Income Taxes, requires deferred tax assets and liabilities to be adjusted for the effect of a change in tax laws or rates in the year of enactment, which is the year in which the change was signed into law. Accordingly, the Company adjusted its deferred tax assets and liabilities at December 31, 2017, using the new corporate tax rate of 21 percent. See Note 10.</p> <p id="xdx_857_zT8SblQg1GP8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_84D_eus-gaap--ResearchAndDevelopmentExpensePolicy_zMD22iGWXMIf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i><span id="xdx_869_zlqqwdgkCW66">Research and Development</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for research and development costs in accordance with Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved as defined under the applicable agreement. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. During the year ended December 31, 2021 the Company incurred $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20211231_zEIzWZXYCFs9" title="Research and development expenses">2,013,762</span> in research and development expenses, while during the year ended December 31, 2020 the Company incurred $<span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_c20200101__20201231_zPX1DNtZMEd9">544,519</span>.</p> <p id="xdx_85F_zDHol8bwGOrf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_840_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zTVBo4hnLa05" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i><span id="xdx_863_zDziTPUf1bih">Intangibles – Goodwill and Other</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Valuation of intangibles are in accordance with ASC 350. Costs associated with the application and award of patents in the U.S. and various other countries are capitalized and amortized on a straight-line basis over the term of the patents as determined at award date, which varies depending on the pendency period of the application, generally approximating seventeen years. Capitalized patent costs, also referred to as patent prosecution costs, include internal legal labor, professional legal fees, government filing fees and translation fees related to expanding the Company’s patent portfolio. Costs associated with the maintenance and annuity fees of patents are accounted for as prepaid assets at the time of payment and amortized over the shorter of the maintenance period or remaining life of the related patent.</p> <p id="xdx_85C_zA4xtbqjRJgd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_847_ecustom--AccruedExpensesPolicyTextBlock_zF449DBPBvw8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i><span id="xdx_86F_z0Pv5h1pnno3">Accrued Expenses</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As part of the process of preparing our consolidated financial statements, we are required to estimate accrued expenses. This process involves identifying services that third parties have performed on our behalf and estimating the level of service performed and the associated cost incurred on these services as at each balance sheet date in our consolidated financial statements. Examples of estimated accrued expenses include professional service fees, such as those arising from the services of attorneys and accountants and accrued payroll expenses. In connection with these service fees, our estimates are most affected by our understanding of the status and timing of services provided relative to the actual services incurred by the service providers. In the event that we do not identify certain costs that have been incurred or we under- or over-estimate the level of services or costs of such services, our reported expenses for a reporting period could be understated or overstated. The date on which certain services commence, the level of services performed on or before a given date, and the cost of services are often subject to our judgment. We make these judgments based upon the facts and circumstances known to us in accordance with accounting principles generally accepted in the U.S.</p> <p id="xdx_856_znJ94zghhf1a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_84E_ecustom--WarrantsPolicyTextBlock_zUQdn8a3m9i7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i><span id="xdx_864_zgt87Ihw9NY9">Warrants</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has issued Common Stock warrants in connection with the execution of certain equity and debt financings. The fair value of warrants is determined using the Black-Scholes option-pricing model using assumptions regarding volatility of our common share price, remaining life of the warrant, and risk-free interest rates at each period end.</p> <p id="xdx_850_zP0VgtKvh9lk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i> </i></b></p> <p id="xdx_842_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zpO46MsnFdm8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i><span id="xdx_861_zRozSZwwhSKi">Fair Value</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities, and short-term borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value.</p> <p id="xdx_85D_z28qiFMtDcW4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_849_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zhESI7XX5GAc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i><span id="xdx_86C_zw91DBdQ8Juj">Recent Accounting Pronouncements</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s financial position, results of operations or cash flows.</p> <p id="xdx_858_z12yqcEWZ7Pk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
</us-gaap:SignificantAccountingPoliciesTextBlock>
<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2021-01-01to2021-12-31">
<p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zUhaq3AqqX66" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i><span id="xdx_86D_zkrZ7DOFmu54">Cash</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For purposes of the Statement of Cash Flows, the Company considers all highly liquid debt instruments purchased with a maturity date of three months or less to be cash equivalents.</p>
</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
<us-gaap:UseOfEstimates contextRef="From2021-01-01to2021-12-31">
<p id="xdx_84F_eus-gaap--UseOfEstimates_zPiznIUSD9E4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i><span id="xdx_861_zNEMoHGPLOY1">Use of Estimates</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of expenses during the reporting period. Significant estimates include the fair value of the Company’s stock, stock-based compensation and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.</p>
</us-gaap:UseOfEstimates>
<us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2021-01-01to2021-12-31">
<p id="xdx_84A_eus-gaap--EarningsPerSharePolicyTextBlock_zs2YzRGCvbQ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i><span id="xdx_86C_zhUCv84Mipb8">Net Loss per Common Share, basic and diluted</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per common share is computed by dividing net loss by the weighted average number of shares of Common Stock outstanding during the year. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into Common Stock using the “treasury stock” and/or “if converted” methods as applicable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At December 31, 2021, we would, based on the market price of $<span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_uUSDPShares_c20211231_zKBmqFbwAaT7" title="Market price per share">0.40</span>/share, be obligated to issue approximately <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20211231_ztfeaRhqtzl8" title="Warrants outstanding">17,312,961</span> shares of Common Stock upon conversion of the currently outstanding convertible notes (the “New Notes”) and <span id="xdx_90E_eus-gaap--SharesIssued_iI_c20211231_zj7y7AxBrghl" title="Fair market value of shares issued">272,000</span> shares upon exercise of the warrants. For the New Notes, the shares total is based on $<span id="xdx_902_ecustom--SharesOutstandingValue_iI_c20211231_z1hVHypiKDZa" title="Outstanding shares value">2,250,685</span> of currently outstanding principal, default penalty and unpaid interest. At December 31, 2020, we would, based on market price of $<span id="xdx_905_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_uUSDPShares_c20201231_zAcJkYm1lHzc">0.24</span>/share, be obligated to issue approximately <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20201231_zWmKHqwx8cAb">11,974,301</span> shares of Common Stock upon conversion of the then outstanding convertible notes (the “Old Notes”) and <span id="xdx_90B_eus-gaap--SharesIssued_iI_c20201231_zvmDZPxoM892">272,000</span> shares upon exercise of the warrants. For the Old Notes, the shares total was based on $<span id="xdx_908_ecustom--SharesOutstandingValue_iI_c20201231_zMFVRUrTD8nb">1,867,991</span> of currently outstanding principal, default penalty and unpaid interest</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_906_eus-gaap--CommonStockConversionBasis_c20210101__20211231_zQDrGK9yTYA2" title="Convertible notes, description">The 2021 1-year notes (the “New Notes”), have an interest rate of 6% and are convertible at the lower of (i) a fixed price of $0.13, or (ii) 85% of the closing price of any Qualified Financing, which consist of any fundraising receiving gross proceeds of not less than $500,000. The New Notes are limited to converting no more than 4.99% of our issued an outstanding Common Stock.</span></p>
</us-gaap:EarningsPerSharePolicyTextBlock>
<us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="AsOf2021-12-31" decimals="INF" unitRef="USDPShares"> 0.40 </us-gaap:DebtInstrumentConvertibleConversionPrice1>
<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares"> 17312961 </us-gaap:ClassOfWarrantOrRightOutstanding>
<us-gaap:SharesIssued contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares"> 272000 </us-gaap:SharesIssued>
<bixt:SharesOutstandingValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD"> 2250685 </bixt:SharesOutstandingValue>
<us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="AsOf2020-12-31" decimals="INF" unitRef="USDPShares"> 0.24 </us-gaap:DebtInstrumentConvertibleConversionPrice1>
<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares"> 11974301 </us-gaap:ClassOfWarrantOrRightOutstanding>
<us-gaap:SharesIssued contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares"> 272000 </us-gaap:SharesIssued>
<bixt:SharesOutstandingValue contextRef="AsOf2020-12-31" decimals="0" unitRef="USD"> 1867991 </bixt:SharesOutstandingValue>
<us-gaap:CommonStockConversionBasis contextRef="From2021-01-01to2021-12-31"> The 2021 1-year notes (the “New Notes”), have an interest rate of 6% and are convertible at the lower of (i) a fixed price of $0.13, or (ii) 85% of the closing price of any Qualified Financing, which consist of any fundraising receiving gross proceeds of not less than $500,000. The New Notes are limited to converting no more than 4.99% of our issued an outstanding Common Stock. </us-gaap:CommonStockConversionBasis>
<us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2021-01-01to2021-12-31">
<p id="xdx_84F_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zUncoAP4kIKk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i><span id="xdx_86C_zq2lt0pcjAtf">Stock Based Compensation</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company measures the cost of services received from employees and non-employees in exchange for an award of equity instruments based on the fair value of the award on the grant date pursuant ASC 718. Stock-based compensation expense is recorded by the Company over the requisite service period, or vesting period, in the same expense classifications in the statements of operations, as if such amounts were paid in cash.</p>
</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
<bixt:AccountingForSubsidiaryStockTransactionsPolicyTextBlock contextRef="From2021-01-01to2021-12-31">
<p id="xdx_84C_ecustom--AccountingForSubsidiaryStockTransactionsPolicyTextBlock_z0fJud5MbfAl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i><span id="xdx_860_zzCFW0xJN5mb">Accounting for subsidiary stock transactions</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">The Company accounts for subsidiary stock transactions in accordance with Opinions of the Accounting Principles Board 09 (APBO No. 9). In paragraph 28, this pronouncement excluded all adjustments form transactions in a company’s own stock “. . . from the determination of net income or the results of operations under all circumstances.” During the years ended December 31, 2021 and 2020, the Company sold <span id="xdx_90D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20211231__srt--ConsolidatedEntitiesAxis__srt--SubsidiariesMember_zaKL4n8e5av8" title="Ownership percentage">9</span>% and <span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20201231__srt--ConsolidatedEntitiesAxis__srt--SubsidiariesMember_zBfY3JkilzK3">15</span>%, respectively, of its subsidiary Pharmalectin for a total amount of $<span id="xdx_901_ecustom--EquityMethodInvestmentAmount_c20210101__20211231__srt--ConsolidatedEntitiesAxis__srt--SubsidiariesMember_zu3hqgkFEeTe" title="Equity method investment amount">600,000</span> and $<span id="xdx_909_ecustom--EquityMethodInvestmentAmount_c20200101__20201231__srt--ConsolidatedEntitiesAxis__srt--SubsidiariesMember_zR8myFtQOmW5">950,000</span>, respectively. During the years ended December 31, 2021 the Subsidiary also issued <span id="xdx_908_eus-gaap--SharesIssued_iI_uShares_c20211231__srt--ConsolidatedEntitiesAxis__srt--SubsidiariesMember_zCAjcL9t0cCg" title="Issue in stock option">4,500,000</span> stock options to its management. Accordingly, APIC has been adjusted with this amount for the year ended December 31, 2021 and 2020.</p>
</bixt:AccountingForSubsidiaryStockTransactionsPolicyTextBlock>
<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="AsOf2021-12-31_srt_SubsidiariesMember" decimals="INF" unitRef="Pure"> 0.09 </us-gaap:EquityMethodInvestmentOwnershipPercentage>
<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="AsOf2020-12-31_srt_SubsidiariesMember" decimals="INF" unitRef="Pure"> 0.15 </us-gaap:EquityMethodInvestmentOwnershipPercentage>
<bixt:EquityMethodInvestmentAmount contextRef="From2021-01-012021-12-31_srt_SubsidiariesMember" decimals="0" unitRef="USD"> 600000 </bixt:EquityMethodInvestmentAmount>
<bixt:EquityMethodInvestmentAmount contextRef="From2020-01-012020-12-31_srt_SubsidiariesMember" decimals="0" unitRef="USD"> 950000 </bixt:EquityMethodInvestmentAmount>
<us-gaap:SharesIssued contextRef="AsOf2021-12-31_srt_SubsidiariesMember" decimals="INF" unitRef="Shares"> 4500000 </us-gaap:SharesIssued>
<us-gaap:IncomeTaxPolicyTextBlock contextRef="From2021-01-01to2021-12-31">
<p id="xdx_84D_eus-gaap--IncomeTaxPolicyTextBlock_zn8alaOOg2e4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i><span id="xdx_868_zKBe2Hg0PFaa">Income Taxes</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or be settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is provided when it is more likely than not that some portion of the gross deferred tax asset will not be realized. The Company records interest and penalties related to income taxes as a component of provision for income taxes. The Company did not recognize any interest and penalty expense for the years ended December 31, 2021 and 2020.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 22, 2017, the Tax Cuts and Jobs Act (TCJA) was signed into law by the President of the United States. TCJA is a tax reform act that among other things, reduced corporate tax rates to 21 percent effective January 1, 2018. FASB ASC 740, Income Taxes, requires deferred tax assets and liabilities to be adjusted for the effect of a change in tax laws or rates in the year of enactment, which is the year in which the change was signed into law. Accordingly, the Company adjusted its deferred tax assets and liabilities at December 31, 2017, using the new corporate tax rate of 21 percent. See Note 10.</p>
</us-gaap:IncomeTaxPolicyTextBlock>
<us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2021-01-01to2021-12-31">
<p id="xdx_84D_eus-gaap--ResearchAndDevelopmentExpensePolicy_zMD22iGWXMIf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i><span id="xdx_869_zlqqwdgkCW66">Research and Development</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for research and development costs in accordance with Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved as defined under the applicable agreement. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. During the year ended December 31, 2021 the Company incurred $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20211231_zEIzWZXYCFs9" title="Research and development expenses">2,013,762</span> in research and development expenses, while during the year ended December 31, 2020 the Company incurred $<span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_c20200101__20201231_zPX1DNtZMEd9">544,519</span>.</p>
</us-gaap:ResearchAndDevelopmentExpensePolicy>
<us-gaap:ResearchAndDevelopmentExpense contextRef="From2021-01-01to2021-12-31" decimals="0" unitRef="USD"> 2013762 </us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="From2020-01-012020-12-31" decimals="0" unitRef="USD"> 544519 </us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="From2021-01-01to2021-12-31">
<p id="xdx_840_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zTVBo4hnLa05" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i><span id="xdx_863_zDziTPUf1bih">Intangibles – Goodwill and Other</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Valuation of intangibles are in accordance with ASC 350. Costs associated with the application and award of patents in the U.S. and various other countries are capitalized and amortized on a straight-line basis over the term of the patents as determined at award date, which varies depending on the pendency period of the application, generally approximating seventeen years. Capitalized patent costs, also referred to as patent prosecution costs, include internal legal labor, professional legal fees, government filing fees and translation fees related to expanding the Company’s patent portfolio. Costs associated with the maintenance and annuity fees of patents are accounted for as prepaid assets at the time of payment and amortized over the shorter of the maintenance period or remaining life of the related patent.</p>
</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
<bixt:AccruedExpensesPolicyTextBlock contextRef="From2021-01-01to2021-12-31">
<p id="xdx_847_ecustom--AccruedExpensesPolicyTextBlock_zF449DBPBvw8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i><span id="xdx_86F_z0Pv5h1pnno3">Accrued Expenses</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As part of the process of preparing our consolidated financial statements, we are required to estimate accrued expenses. This process involves identifying services that third parties have performed on our behalf and estimating the level of service performed and the associated cost incurred on these services as at each balance sheet date in our consolidated financial statements. Examples of estimated accrued expenses include professional service fees, such as those arising from the services of attorneys and accountants and accrued payroll expenses. In connection with these service fees, our estimates are most affected by our understanding of the status and timing of services provided relative to the actual services incurred by the service providers. In the event that we do not identify certain costs that have been incurred or we under- or over-estimate the level of services or costs of such services, our reported expenses for a reporting period could be understated or overstated. The date on which certain services commence, the level of services performed on or before a given date, and the cost of services are often subject to our judgment. We make these judgments based upon the facts and circumstances known to us in accordance with accounting principles generally accepted in the U.S.</p>
</bixt:AccruedExpensesPolicyTextBlock>
<bixt:WarrantsPolicyTextBlock contextRef="From2021-01-01to2021-12-31">
<p id="xdx_84E_ecustom--WarrantsPolicyTextBlock_zUQdn8a3m9i7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i><span id="xdx_864_zgt87Ihw9NY9">Warrants</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has issued Common Stock warrants in connection with the execution of certain equity and debt financings. The fair value of warrants is determined using the Black-Scholes option-pricing model using assumptions regarding volatility of our common share price, remaining life of the warrant, and risk-free interest rates at each period end.</p>
</bixt:WarrantsPolicyTextBlock>
<us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2021-01-01to2021-12-31">
<p id="xdx_842_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zpO46MsnFdm8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i><span id="xdx_861_zRozSZwwhSKi">Fair Value</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities, and short-term borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value.</p>
</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2021-01-01to2021-12-31">
<p id="xdx_849_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zhESI7XX5GAc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i><span id="xdx_86C_zw91DBdQ8Juj">Recent Accounting Pronouncements</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s financial position, results of operations or cash flows.</p>
</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
<us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="From2021-01-01to2021-12-31">
<p id="xdx_805_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_z76M9zjo4y0f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 3 – <span id="xdx_825_zY9OrjigCdQk">GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">As at December 31, 2021, the Company had cash of $<span id="xdx_908_eus-gaap--Cash_iI_c20211231_zg4iXdGzCB39" title="Cash">72,358</span> and a negative working capital of $<span id="xdx_908_ecustom--NegativeWorkingCapital_iN_di_c20210101__20211231_zqLPMkFofWO2" title="Negative working capital">3,205,139</span>. As at December 31, 2021, the Company has not yet generated any revenues, and has incurred cumulative net losses of $<span id="xdx_90F_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_dxL_c20211231_zZnSaEr6I4bf" title="Cumulative net loss::XDX::-8%2C753%2C668"><span style="-sec-ix-hidden: xdx2ixbrl0586">8,753,668</span></span>. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">During the year ended December 31, 2021, the Company raised $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfDebt_c20210101__20211231_zjlYVAY0YLe2">1,165,000</span> from issuance of convertible notes, and exchanged an additional note of $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfDebt_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zlf5VPeBkNkj">1,000,000</span> against the defaulted convertible loans and accrued interest that mounted to $<span id="xdx_901_eus-gaap--InterestExpense_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zBNjpbGx5Q1h" title="Accrued interest">2,020,323</span>. Another 1. The Company also raised $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20200101__20201231_zz7Zy5Qrqkqj" title="Proceeds from the issuance of common stock">600,000</span> in cash proceeds from the issuance of Common Stock in our Subsidiary. During the year ended December 31, 2020, the Company raised $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfDebt_c20200101__20201231_zlELE11Yc9Lh" title="Proceeds from issuance of debt">264,000</span> from issuance of convertible notes, and paid back $<span id="xdx_906_ecustom--PaidBackIssuanceOfConvertibleDebt_c20200101__20201231_zXdrrp3Nm8Sb" title="Proceeds from issuance of debt">232,948</span>. The Company also raised $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20210101__20211231_zQQ2tubQlM0f">950,000</span> in cash proceeds from the issuance of Common Stock in our Subsidiary. The Company is aware that its current cash on hand will not be sufficient to fund its projected operating requirements through the month of May 2022 and is pursuing alternative opportunities to funding.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company intends to raise additional capital through private placements of debt and equity securities, but there can be no assurance that these funds will be available on terms acceptable to the Company, or will be sufficient to enable the Company to fully complete its development activities or sustain operations. If the Company is unable to raise sufficient additional funds, it will have to develop and implement a plan to further extend payables, reduce overhead, or scale back its current business plan until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan will be successful.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Accordingly, the accompanying consolidated financial statements have been prepared in conformity with U.S. GAAP, which contemplates continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The consolidated financial statements do not include any adjustment that might result from the outcome of this uncertainty.</p>
</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
<us-gaap:Cash contextRef="AsOf2021-12-31" decimals="0" unitRef="USD"> 72358 </us-gaap:Cash>
<bixt:NegativeWorkingCapital contextRef="From2021-01-01to2021-12-31" decimals="0" unitRef="USD"> -3205139 </bixt:NegativeWorkingCapital>
<us-gaap:ProceedsFromIssuanceOfDebt contextRef="From2021-01-01to2021-12-31" decimals="0" unitRef="USD"> 1165000 </us-gaap:ProceedsFromIssuanceOfDebt>
<us-gaap:ProceedsFromIssuanceOfDebt contextRef="From2021-01-012021-12-31_us-gaap_ConvertibleDebtMember" decimals="0" unitRef="USD"> 1000000 </us-gaap:ProceedsFromIssuanceOfDebt>
<us-gaap:InterestExpense contextRef="From2021-01-012021-12-31_us-gaap_ConvertibleDebtMember" decimals="0" unitRef="USD"> 2020323 </us-gaap:InterestExpense>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2020-01-012020-12-31" decimals="0" unitRef="USD"> 600000 </us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfDebt contextRef="From2020-01-012020-12-31" decimals="0" unitRef="USD"> 264000 </us-gaap:ProceedsFromIssuanceOfDebt>
<bixt:PaidBackIssuanceOfConvertibleDebt contextRef="From2020-01-012020-12-31" decimals="0" unitRef="USD"> 232948 </bixt:PaidBackIssuanceOfConvertibleDebt>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2021-01-01to2021-12-31" decimals="0" unitRef="USD"> 950000 </us-gaap:ProceedsFromIssuanceOfCommonStock>
<bixt:PrepaidExpensesAndOtherCurrentAssetsTextBlock contextRef="From2021-01-01to2021-12-31">
<p id="xdx_807_ecustom--PrepaidExpensesAndOtherCurrentAssetsTextBlock_zEr9pqQwjHie" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 4 – <span id="xdx_82A_zpiyZyysWhIe">PRE-PAID EXPENSES AND OTHER CURRENT ASSETS</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">On December 31, 2021, there were <span id="xdx_905_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_do_c20211231__srt--TitleOfIndividualAxis__custom--ContractResearchOrganizationMember_z2ygi2yna54k" title="Prepaid expense and other assets current">no</span> Pre-paid Expenses. At December 31, 2020 there were $<span id="xdx_901_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iI_do_c20201231__srt--TitleOfIndividualAxis__custom--ContractResearchOrganizationMember_zwI8R9TbKzj1">274,715</span> in Pre-paid Expenses.</p>
</bixt:PrepaidExpensesAndOtherCurrentAssetsTextBlock>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2021-12-31_custom_ContractResearchOrganizationMember" decimals="0" unitRef="USD"> 0 </us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2020-12-31_custom_ContractResearchOrganizationMember" decimals="0" unitRef="USD"> 274715 </us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="From2021-01-01to2021-12-31">
<p id="xdx_80C_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_zgGPjXuMg5Wd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 5 - <span id="xdx_829_z6GznVzgkSK1">INTANGIBLES</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. No impairment charges were recorded for the years ended December 31, 2021 and 2020.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_894_eus-gaap--ScheduleOfImpairedIntangibleAssetsTextBlock_z3G4DHykNSNa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Amortization of capitalized patent costs associated with the application and award of patents in the U.S. and various other countries are capitalized and amortized on a straight-line basis over the term of the patents as determined at the award date, which varies depending on the pendency period of the application, generally approximating seventeen years. The current patent application is still in process, and is therefore not yet amortized.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span id="xdx_8B3_zLYYk79sEse9" style="display: none; visibility: hidden">Schedule of intangible</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Estimated Remaining</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Life (years)</b></p></td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 61%; text-align: left">Capitalized patent costs</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dxL_c20210101__20211231_ze8bIJEbXq4l" style="width: 10%; text-align: center" title="Estimated life (years)::XDX::P19Y"><span style="-sec-ix-hidden: xdx2ixbrl0608">19</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--CapitalizedPatentCosts_iI_c20211231_z6e7vl2Ejpv4" style="width: 10%; text-align: right" title="Capitalized patent costs">46,932</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--CapitalizedPatentCosts_iI_c20201231_z6BsbbBOjXGb" style="width: 10%; text-align: right" title="Capitalized patent costs">10,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Accumulated amortization</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_d0_c20211231_zFe7ErCjhU8e" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated amortization">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_d0_c20201231_zT3DPBG28sA7" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated amortization">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Intangible assets, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20211231_zBGSz9M4X2xj" style="text-align: right" title="Intangible assets, net">46,932</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20201231_zZJvlmiE7TGj" style="text-align: right" title="Intangible assets, net">10,000</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A0_zAdD8je5Jdj9" style="margin-top: 0; margin-bottom: 0"> </p>
</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
<us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock contextRef="From2021-01-01to2021-12-31">
<p id="xdx_894_eus-gaap--ScheduleOfImpairedIntangibleAssetsTextBlock_z3G4DHykNSNa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Amortization of capitalized patent costs associated with the application and award of patents in the U.S. and various other countries are capitalized and amortized on a straight-line basis over the term of the patents as determined at the award date, which varies depending on the pendency period of the application, generally approximating seventeen years. The current patent application is still in process, and is therefore not yet amortized.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span id="xdx_8B3_zLYYk79sEse9" style="display: none; visibility: hidden">Schedule of intangible</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Estimated Remaining</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Life (years)</b></p></td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 61%; text-align: left">Capitalized patent costs</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dxL_c20210101__20211231_ze8bIJEbXq4l" style="width: 10%; text-align: center" title="Estimated life (years)::XDX::P19Y"><span style="-sec-ix-hidden: xdx2ixbrl0608">19</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--CapitalizedPatentCosts_iI_c20211231_z6e7vl2Ejpv4" style="width: 10%; text-align: right" title="Capitalized patent costs">46,932</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--CapitalizedPatentCosts_iI_c20201231_z6BsbbBOjXGb" style="width: 10%; text-align: right" title="Capitalized patent costs">10,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Accumulated amortization</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_d0_c20211231_zFe7ErCjhU8e" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated amortization">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_d0_c20201231_zT3DPBG28sA7" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated amortization">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Intangible assets, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20211231_zBGSz9M4X2xj" style="text-align: right" title="Intangible assets, net">46,932</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20201231_zZJvlmiE7TGj" style="text-align: right" title="Intangible assets, net">10,000</td><td style="text-align: left"> </td></tr> </table>
</us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock>
<bixt:CapitalizedPatentCosts contextRef="AsOf2021-12-31" decimals="0" unitRef="USD"> 46932 </bixt:CapitalizedPatentCosts>
<bixt:CapitalizedPatentCosts contextRef="AsOf2020-12-31" decimals="0" unitRef="USD"> 10000 </bixt:CapitalizedPatentCosts>
<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2021-12-31" decimals="0" unitRef="USD"> 0 </us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2020-12-31" decimals="0" unitRef="USD"> 0 </us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2021-12-31" decimals="0" unitRef="USD"> 46932 </us-gaap:FiniteLivedIntangibleAssetsNet>
<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2020-12-31" decimals="0" unitRef="USD"> 10000 </us-gaap:FiniteLivedIntangibleAssetsNet>
<us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="From2021-01-01to2021-12-31">
<p id="xdx_803_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_z2yKuxWpmgQd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 6 – <span id="xdx_82C_zsRcOWui9CF8">ACCOUNTS PAYABLES AND ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 31, 2021, there was $<span id="xdx_902_eus-gaap--AccountsPayableRelatedPartiesCurrentAndNoncurrent_iI_c20211231_zNDf3lPQqyth" title="Accrued expenses in accounts payables to related parties">531,000</span> in Accounts Payables to related parties in form of payroll and advanced expenses. On December 31, 2020 there was $<span id="xdx_90B_eus-gaap--AccountsPayableRelatedPartiesCurrentAndNoncurrent_iI_c20201231_zE5bcPCRZY11" title="Accrued expenses in accounts payables to related parties">307,176</span> in Accounts Payables to related parties.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_89A_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zVvwqhArQSpc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table represents the major components of accounts payables and accrued expenses and other current liabilities at December 31, 2021 and December 31, 2020:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8B9_zVfzUZJaWi54" style="display: none; visibility: hidden">Schedule of accounts payables and accrued expenses and other current liabilities</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20211231_zQcbRFn1u3Y5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20201231_zr6YUXekIQAk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_ecustom--AccountsPayablesRelatedParty_iI_ztIgGpa6mfmi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left; text-indent: -12pt; padding-left: 12pt">Accounts payable related party <sup id="xdx_F4B_zs44SnFe37E">(1)</sup></td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">531,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">307,176</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AccruedProfessionalFeesCurrent_iI_maAPAAEzBWX_maAPAAEzNgS_zXr3Q1DwQjU3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -12pt; padding-left: 12pt">Professional fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">375,371</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">84,325</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_maAPAAEzBWX_maAPAAEzNgS_zC92zM6LvoEd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -12pt; padding-left: 12pt">Interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">85,685</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">263,135</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--TaxesPayableCurrentAndNoncurrent_iI_zqPfRPKNXGf1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -12pt; padding-left: 12pt">Payroll taxes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">32,010</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0640">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--Pension401k_iI_zDwFktYGSN88" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -12pt; padding-left: 12pt">Pension/401K</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">131,250</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0643">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AccountsPayableOtherCurrent_iI_maAPAAEzBWX_maAPAAEzNgS_zgTyiUDY6yE8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -12pt; padding-left: 12pt">Other accounts payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0645">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">667</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--DefaultPenalty_iI_maAPAAEzBWX_maAPAAEzNgS_zVV1HChD9vN7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -12pt; padding-left: 12pt">Default penalty</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0648">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">673,956</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--NotesPayableRelatedPartiesCurrentAndNoncurrent_iI_maAPAAEzNgS_zcrE5gOsisSg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -12pt; padding-left: 12pt">Convertible note payable</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,122,181</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">938,400</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_ecustom--AccountsPayablesAndAccruedExpensesAndOtherCurrentLiabilities_iI_mtAPAAEzNgS_zLlyGZJILZ42" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-indent: -12pt; padding-left: 12pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,277,497</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,267,659</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span id="xdx_F06_zt0T2zZfZX7e" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span id="xdx_F14_zQLQcZPWF0Xb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$210,000 to each the CFO and the CEO for 6 months of salary for the period July through December 2021, and $111,000 to the VP for salary and expenses for the same period, while there was $120,000 to each the CFO and the CEO at and $67,176 for the VP at December 31, 2020.</span></td> </tr></table> <p id="xdx_8A7_zgCZ1cJOAona" style="margin-top: 0; margin-bottom: 0"> </p>
</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
<us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD"> 531000 </us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent>
<us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD"> 307176 </us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent>
<us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="From2021-01-01to2021-12-31">
<p id="xdx_89A_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zVvwqhArQSpc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table represents the major components of accounts payables and accrued expenses and other current liabilities at December 31, 2021 and December 31, 2020:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8B9_zVfzUZJaWi54" style="display: none; visibility: hidden">Schedule of accounts payables and accrued expenses and other current liabilities</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20211231_zQcbRFn1u3Y5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20201231_zr6YUXekIQAk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_ecustom--AccountsPayablesRelatedParty_iI_ztIgGpa6mfmi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left; text-indent: -12pt; padding-left: 12pt">Accounts payable related party <sup id="xdx_F4B_zs44SnFe37E">(1)</sup></td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">531,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">307,176</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AccruedProfessionalFeesCurrent_iI_maAPAAEzBWX_maAPAAEzNgS_zXr3Q1DwQjU3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -12pt; padding-left: 12pt">Professional fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">375,371</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">84,325</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_maAPAAEzBWX_maAPAAEzNgS_zC92zM6LvoEd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -12pt; padding-left: 12pt">Interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">85,685</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">263,135</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--TaxesPayableCurrentAndNoncurrent_iI_zqPfRPKNXGf1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -12pt; padding-left: 12pt">Payroll taxes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">32,010</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0640">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--Pension401k_iI_zDwFktYGSN88" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -12pt; padding-left: 12pt">Pension/401K</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">131,250</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0643">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AccountsPayableOtherCurrent_iI_maAPAAEzBWX_maAPAAEzNgS_zgTyiUDY6yE8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -12pt; padding-left: 12pt">Other accounts payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0645">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">667</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--DefaultPenalty_iI_maAPAAEzBWX_maAPAAEzNgS_zVV1HChD9vN7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -12pt; padding-left: 12pt">Default penalty</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0648">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">673,956</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--NotesPayableRelatedPartiesCurrentAndNoncurrent_iI_maAPAAEzNgS_zcrE5gOsisSg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -12pt; padding-left: 12pt">Convertible note payable</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,122,181</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">938,400</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_ecustom--AccountsPayablesAndAccruedExpensesAndOtherCurrentLiabilities_iI_mtAPAAEzNgS_zLlyGZJILZ42" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-indent: -12pt; padding-left: 12pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,277,497</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,267,659</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span id="xdx_F06_zt0T2zZfZX7e" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span id="xdx_F14_zQLQcZPWF0Xb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$210,000 to each the CFO and the CEO for 6 months of salary for the period July through December 2021, and $111,000 to the VP for salary and expenses for the same period, while there was $120,000 to each the CFO and the CEO at and $67,176 for the VP at December 31, 2020.</span></td> </tr></table>
</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
<bixt:AccountsPayablesRelatedParty contextRef="AsOf2021-12-31" decimals="0" id="Fact000630" unitRef="USD"> 531000 </bixt:AccountsPayablesRelatedParty>
<bixt:AccountsPayablesRelatedParty contextRef="AsOf2020-12-31" decimals="0" id="Fact000631" unitRef="USD"> 307176 </bixt:AccountsPayablesRelatedParty>
<us-gaap:AccruedProfessionalFeesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD"> 375371 </us-gaap:AccruedProfessionalFeesCurrent>
<us-gaap:AccruedProfessionalFeesCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD"> 84325 </us-gaap:AccruedProfessionalFeesCurrent>
<us-gaap:InterestPayableCurrentAndNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD"> 85685 </us-gaap:InterestPayableCurrentAndNoncurrent>
<us-gaap:InterestPayableCurrentAndNoncurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD"> 263135 </us-gaap:InterestPayableCurrentAndNoncurrent>
<us-gaap:TaxesPayableCurrentAndNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD"> 32010 </us-gaap:TaxesPayableCurrentAndNoncurrent>
<bixt:Pension401k contextRef="AsOf2021-12-31" decimals="0" unitRef="USD"> 131250 </bixt:Pension401k>
<us-gaap:AccountsPayableOtherCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD"> 667 </us-gaap:AccountsPayableOtherCurrent>
<bixt:DefaultPenalty contextRef="AsOf2020-12-31" decimals="0" unitRef="USD"> 673956 </bixt:DefaultPenalty>
<us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD"> 2122181 </us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent>
<us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD"> 938400 </us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent>
<bixt:AccountsPayablesAndAccruedExpensesAndOtherCurrentLiabilities contextRef="AsOf2021-12-31" decimals="0" unitRef="USD"> 3277497 </bixt:AccountsPayablesAndAccruedExpensesAndOtherCurrentLiabilities>
<bixt:AccountsPayablesAndAccruedExpensesAndOtherCurrentLiabilities contextRef="AsOf2020-12-31" decimals="0" unitRef="USD"> 2267659 </bixt:AccountsPayablesAndAccruedExpensesAndOtherCurrentLiabilities>
<us-gaap:ShortTermDebtTextBlock contextRef="From2021-01-01to2021-12-31">
<p id="xdx_80C_eus-gaap--ShortTermDebtTextBlock_zvjeVKg22LYj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 7 – <span id="xdx_82F_zb1FUtEZd1Wg">CONVERTIBLE NOTES PAYABLE</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Between October 23, 2019 and March 18, 2020, the Company issued senior convertible debentures for an aggregate of $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20200318__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zrPjC2Jo9Xfl" title="Aggregate amount">938,400</span> (the “Convertible Debentures”) in exchange for an aggregate net cash proceeds of $<span id="xdx_906_ecustom--NetCashProceed_c20191023__20200318__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zU68u3AW9Zo3" title="Net cash proceed">836,000</span>, net of financing costs. The Convertible Debentures have a stated interest rate of <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_pid_dp_uPure_c20191023__20200318__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember__srt--RangeAxis__srt--MinimumMember_zjCQmvAxHqmf" title="Interest rate">4</span>-<span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_pid_dp_uPure_c20191023__20200318__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember__srt--RangeAxis__srt--MaximumMember_zTu4XOu0ouC" title="Interest rate">8</span>% per annum payable quarterly beginning October 23, 2020 and were due one year from the date of issuance, the latest due March 18, 2021 and were convertible into shares of the Company’s Common Stock at the option of the holder at a conversion price to the lesser of: (i) <span id="xdx_907_ecustom--ConvertibleNoteDescribtion_c20191023__20200318__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_z44eg8bGvkwa" title="Convertible note description">the lowest trading price for the twenty-day period prior to the date of the Convertible Debentures or (ii) 65% of the average of the three lowest trading prices during the twenty days prior to a conversion notice on the applicable trading market or the closing bid price on the applicable trading market</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, the variable conversion rate component requires that the Convertible Debentures be valued at its stock redemption value (i.e., “if-converted” value) pursuant to ASC 480, Distinguishing Liabilities from Equity, with the excess over the undiscounted face value being deemed a premium to be added to the principal balance and accreted to additional paid-in capital over the life of the Convertible Debentures.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Along with the issuance of the Convertible Debentures, the Company issued an aggregate of 272,000 warrants to purchase the Company’s Common Stock at $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20200318_zW5XvUpIPZgg" title="Warrant per share">2.00</span> per share, expiring five years from the date of issuance, the latest being March 18, 2020. These warrants contain a cashless exercise and certain anti-dilutive (reset) provisions. The Company determined that the Warrants were exempt from derivative accounting and were valued at $97,279 on the Date of Inception using the Black Scholes Options Pricing Model. As the warrants were exercisable immediately, this debt discount was amortized in its entirety to interest expense on the date of issuance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In connection with the Debt Restructuring, described here below, the outstanding warrants were transferred to the Company’s management (issued in the name of NDPD, Inc.) in lieu of interest on amounts due as at May 31, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Debt Restructuring</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 16, 2020, SEC ordered, pursuant to Section 12(k) of the Securities Exchange Act of 1934, that trading of BIXT be suspended for the period <span id="xdx_90B_ecustom--DescriptionOfSuspendedPeriod_c20200415__20200416_zpe0ODnJRF86" title="Description of suspended period">April 16 through April 29, 2020</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the SEC ordered suspension the Company defaulted on the outstanding Convertible Debentures; resulting in an increase of the interest to <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_pid_dp_uPure_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--TenOutstandingConvertibleNotesMember_zn6eY34JGcf1">21</span>% and the principal to increase to <span id="xdx_90C_ecustom--DebtInstrumentPrincipalRateIncreaseDecrease_pid_dp_uPure_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--TenOutstandingConvertibleNotesMember_zOsniKiTYi2" title="Debt interest rate">168</span>% of principal loan amount. The convertible debt increased by $<span id="xdx_901_ecustom--DebtInstrumentIncreaseForPeriodNet_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--TenOutstandingConvertibleNotesMember_zaYtKXftYqo3" title="Increase in debt amount">666,456</span> to $<span id="xdx_90D_eus-gaap--DebtInstrumentIncreaseDecreaseForPeriodNet_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--TenOutstandingConvertibleNotesMember_zHmObvcn8U2a" title="Amoun of debt">1,604,856</span> while the interest accrual increased to approximately $28,563/month. At the default date, April 16, 2020, remaining debt discount of $<span id="xdx_908_eus-gaap--AmortizationOfDebtDiscountPremium_c20210101__20210930__us-gaap--DebtInstrumentAxis__custom--TenOutstandingConvertibleNotesMember_z8FrYG9LIct9" title="Amortized debt discount">76,265</span> was amortized to interest expense and the remaining debt premium of $<span id="xdx_900_ecustom--RemainingDebtPremiumAccretedToAdditionalPaidinCapital_c20210101__20210930__us-gaap--DebtInstrumentAxis__custom--TenOutstandingConvertibleNotesMember_ztqUL8jNq0x9" title="Remaining debt premium accreted to additional paid in capital">856,560</span> was accreted to additional paid-in capital.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 2 and 3, 2021, Bioxytran, Inc. (the “Company”) entered into nine note agreements for a total amount of $3,266,846 in <span id="xdx_900_eus-gaap--DebtInstrumentTerm_dxL_c20210502__20210503__us-gaap--DebtInstrumentAxis__custom--NewNoteMember__us-gaap--TypeOfArrangementAxis__custom--NineNoteAgreementsMember_zmUrY2IrJLik" title="Debt term::XDX::P1Y"><span style="-sec-ix-hidden: xdx2ixbrl0685">1</span></span>-year notes (the “New Notes”), with an interest rate of <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210503__us-gaap--DebtInstrumentAxis__custom--NewNoteMember__us-gaap--TypeOfArrangementAxis__custom--NineNoteAgreementsMember_zBIorZhaYq3a" title="Debt rate">6</span>% convertible at the lower of (i) a fixed price of $0.13, or (ii) 85% of the closing price of any Qualified Financing, which consist of any fundraising receiving gross proceeds of not less than $500,000. The New Notes required the Company to prepare and file a Registration Statement on Form S-1 within a period of 60 days from issuance of the New Notes. A Form S-1 was filed with the SEC on June 24, 2021 and was declared effective by SEC on July 23, 2021, wherein the New Notes have a 180-day lock-up period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 20, 2021, management forgave the Company their part of the loan for an amount of $<span title="Accrued salaries"><span id="xdx_90C_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20211119__20211120_zoR2knZoVVaf" title="Loan forgive amount">986,864</span></span> originating from accrued salaries recorded as additional paid-in capital. See details under Note 8.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_89F_eus-gaap--SummaryOfTroubledDebtRestructuringNoteDebtorTextBlock_zzeT9dENwyl7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BD_zC0wREedVx7f">The transactions set forth below were approved by the Company’s Board of Directors on June 4, 2021</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center">Name</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_483_ecustom--PrincipalDue_iI_zxUKVHnwNaec" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Principal due</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31, 2021</b></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_48F_eus-gaap--InterestReceivable_iI_zj8Z8J0onLk5" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Accrued interest</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31, 2021</b></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_482_ecustom--Total_iI_zEe0xQQ6qPg" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Total amount due</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31, 2021</b></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_412_20210604__us-gaap--DebtInstrumentAxis__custom--NoteSoldInExchangeForCashMember_zcLECFSvw342" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 59%; text-align: left; padding-left: 1.45pt">Notes sold in exchange for cash</td><td style="width: 1%"> </td> <td id="xdx_F41_zNfFBcE84DLg" style="width: 1%; text-align: right">(1</td><td style="width: 1%; text-align: left">)</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">1,165,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">46,108</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">1,211,108</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_41D_20210604__us-gaap--DebtInstrumentAxis__custom--NoteIssuedInExchangeForDefaultedNotesMember_zIrh2x15pVDi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 1.45pt">Note issued in exchange for defaulted notes</td><td style="padding-bottom: 1pt"> </td> <td id="xdx_F47_zsECFsAOG7r7" style="text-align: right">(2</td><td style="padding-bottom: 1pt; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,000,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">39,577</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,039,577</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; padding-left: 1.45pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">2,165,000</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">85,685</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">2,250,685</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> </table> <p id="xdx_8A1_zeqmNsZJ2eB1" style="margin-top: 0; margin-bottom: 0"> </p> <p style="margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span id="xdx_F0A_zKEcIGfcRs4j" style="font: 10pt Times New Roman, Times, Serif">(1)</span></td><td style="text-align: justify"><span id="xdx_F18_zkcqwTLKHOl5" style="font: 10pt Times New Roman, Times, Serif">Net cash received for these notes were $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--NoteSoldInExchangeForCashMember__dei--LegalEntityAxis__custom--WallachBethCapitalLLCMember_z8R6IdTrwiBj">1,045,150</span>, after a Debt Discount of $<span id="xdx_90B_ecustom--DebtDiscount_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--NoteSoldInExchangeForCashMember__dei--LegalEntityAxis__custom--WallachBethCapitalLLCMember_z2dxgPvsVc07" title="Debt discount">119,850</span> was paid to the sole Placement Agent: WallachBeth Capital, LLC (Member FINRA / SIPC).</span></td> </tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span id="xdx_F06_zxQXMdgt7lp6" style="font: 10pt Times New Roman, Times, Serif">(2)</span></td><td style="text-align: justify"><span id="xdx_F1C_zUewFkTCgMD7" style="font: 10pt Times New Roman, Times, Serif">The “Old Notes” were paid off and assumed by a different entity/company. Portions of the balance was forgiven and a new note of $<span id="xdx_90D_ecustom--ConvertibleNotesPayableNetOfPremiumAndDiscountRelatedParty_iI_c20211231_zIN3Yo5YYj88" title="Note issue amount">1,000,000</span> was issued.</span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The defaulted notes were returned to the Company on May 26, 2021. The debt forgiveness of $1,020,323 was recorded as additional paid-in capital.</p> <p id="xdx_897_eus-gaap--ScheduleOfExtinguishmentOfDebtTextBlock_zIsyGrflrUxg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BD_zld0BKETf3i9" style="display: none; visibility: hidden">CONVERTIBLE NOTES PAYABLE</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Due at</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>May 26, 2019</b></p></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal</b></span><br/> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amount</b></span></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Default Penalty</b></span></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants Issued</b></span></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Term</b></span></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span><br/> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amortization</b></span><br/> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of Warrants</b></span></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accrued Interest</b></span></td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td id="xdx_984_eus-gaap--DebtInstrumentDescription_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--OldNoteMember_zNrczyR4aF7d" style="vertical-align: bottom; width: 8%; padding-left: 12pt; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> Old Notes</span></td> <td style="width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td id="xdx_981_ecustom--DebtInstrumentDefaulted_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--OldNoteMember_zPmgosliU3Cj" style="vertical-align: bottom; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Defaulted </span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_986_eus-gaap--DebtInstrumentFaceAmount_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--OldNoteMember_zd2iOKVUTxu9" style="border-bottom: black 2.25pt double; vertical-align: bottom; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">938,400</span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="width: 1%"> </td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_989_eus-gaap--DebtDefaultLongtermDebtAmount_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--OldNoteMember_zXB67l8gMDrd" style="border-bottom: black 2.25pt double; vertical-align: bottom; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">673,956</span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="width: 1%"> </td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; width: 1%"> </td> <td id="xdx_989_ecustom--StockIssuedDuringPeriodSharesWarrantsIssues_pii_uShares_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--OldNoteMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0Y5xr0u7og8" style="border-bottom: black 2.25pt double; vertical-align: bottom; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">272,000</span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20211231__us-gaap--DebtInstrumentAxis__custom--OldNoteMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRLJJSjFR4l4" style="vertical-align: bottom; width: 4%; text-align: right" title="::XDX::P5Y"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0712">5 </span></span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_uUSDPShares_c20211231__us-gaap--DebtInstrumentAxis__custom--OldNoteMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zeF9HyNc7bbg" style="vertical-align: bottom; width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.00 </span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="width: 1%"> </td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98F_ecustom--AmortizationOfWarrants_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--OldNoteMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvAjjPxczxMa" style="border-bottom: black 2.25pt double; vertical-align: bottom; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97,279</span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="width: 1%"> </td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_984_eus-gaap--InterestReceivable_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--OldNoteMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQSi7Ybcqm1h" style="border-bottom: black 2.25pt double; vertical-align: bottom; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">407,967</span></td> <td style="vertical-align: bottom; width: 1%"> </td></tr> </table> <p style="margin-top: 0; margin-bottom: 0"> </p> <p id="xdx_8A4_z7e5SqLejty6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">As part of the pay-off, the debt originating from a January 20, 2021 summary judgement by the Supreme Court of the State of New York, County of Nassau, awarding Power Up damages in the amount of $<span id="xdx_902_eus-gaap--LossContingencyDamagesAwardedValue_c20210119__20210120_zfK5AacSak71" title="Damage mount">420,750</span> for Breach of Contact was agreed to be dismissed by prejudice. As a result, the damages recorded in the first quarter of 2021 was reversed in the Statement of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">As described in the above, the outstanding warrants were transferred to the Company’s management (issued in the name of NDPD, Inc.) in lieu of interest on amounts due as at May 31, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_896_eus-gaap--ScheduleOfShortTermDebtTextBlock_zG23jUBNUUj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span id="xdx_8B1_zPl3J0ANodq8">Convertible notes payable consists of the following at December 31, 2021 and December 31, 2020</span>:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20211231_z654mN7OFsxb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20201231_zp0zP3XEmdPh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_400_ecustom--DebtInstrumentFaceAmount1_iI_z0pCtHaD1IJ4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left; text-indent: -12pt; padding-left: 12pt">Principal balance</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">1,165,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">938,400</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_ecustom--DebtInstrumentFaceAmount2_iI_zhxwCOWpvBnk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -12pt; padding-left: 12pt">Principal balance, related party</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0725">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DebtDefaultLongtermDebtAmount_iI_hus-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zQG6jo0N8tQk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -12pt; padding-left: 12pt">Default penalty</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0727">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">673,956</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di_hus-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_ztfn2dyzaL8d" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -12pt; padding-left: 12pt">Unamortized debt discount</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(42,819</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0731">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LongTermDebt_iI_hus-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zXpRJVMcJSJa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -12pt; padding-left: 12pt">Outstanding, net of debt discount and premium</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,122,181</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,612,356</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AA_zBjwyAZu6V5h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p>
</us-gaap:ShortTermDebtTextBlock>
<us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2020-03-18_us-gaap_ConvertibleNotesPayableMember" decimals="0" unitRef="USD"> 938400 </us-gaap:DebtInstrumentFaceAmount>
<bixt:NetCashProceed contextRef="From2019-10-232020-03-18_us-gaap_ConvertibleNotesPayableMember" decimals="0" unitRef="USD"> 836000 </bixt:NetCashProceed>
<us-gaap:DebtInstrumentInterestRateIncreaseDecrease contextRef="From2019-10-232020-03-18_us-gaap_ConvertibleNotesPayableMember_srt_MinimumMember" decimals="INF" unitRef="Pure"> 0.04 </us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
<us-gaap:DebtInstrumentInterestRateIncreaseDecrease contextRef="From2019-10-232020-03-18_us-gaap_ConvertibleNotesPayableMember_srt_MaximumMember" decimals="INF" unitRef="Pure"> 0.08 </us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
<bixt:ConvertibleNoteDescribtion contextRef="From2019-10-232020-03-18_us-gaap_ConvertibleNotesPayableMember"> the lowest trading price for the twenty-day period prior to the date of the Convertible Debentures or (ii) 65% of the average of the three lowest trading prices during the twenty days prior to a conversion notice on the applicable trading market or the closing bid price on the applicable trading market </bixt:ConvertibleNoteDescribtion>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2020-03-18" decimals="INF" unitRef="USDPShares"> 2.00 </us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<bixt:DescriptionOfSuspendedPeriod contextRef="From2020-04-152020-04-16"> April 16 through April 29, 2020 </bixt:DescriptionOfSuspendedPeriod>
<us-gaap:DebtInstrumentInterestRateIncreaseDecrease contextRef="From2021-01-012021-12-31_custom_TenOutstandingConvertibleNotesMember" decimals="INF" unitRef="Pure"> 0.21 </us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
<bixt:DebtInstrumentPrincipalRateIncreaseDecrease contextRef="From2021-01-012021-12-31_custom_TenOutstandingConvertibleNotesMember" decimals="INF" unitRef="Pure"> 1.68 </bixt:DebtInstrumentPrincipalRateIncreaseDecrease>
<bixt:DebtInstrumentIncreaseForPeriodNet contextRef="From2021-01-012021-12-31_custom_TenOutstandingConvertibleNotesMember" decimals="0" unitRef="USD"> 666456 </bixt:DebtInstrumentIncreaseForPeriodNet>
<us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet contextRef="From2021-01-012021-12-31_custom_TenOutstandingConvertibleNotesMember" decimals="0" unitRef="USD"> 1604856 </us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2021-01-012021-09-30_custom_TenOutstandingConvertibleNotesMember" decimals="0" unitRef="USD"> 76265 </us-gaap:AmortizationOfDebtDiscountPremium>
<bixt:RemainingDebtPremiumAccretedToAdditionalPaidinCapital contextRef="From2021-01-012021-09-30_custom_TenOutstandingConvertibleNotesMember" decimals="0" unitRef="USD"> 856560 </bixt:RemainingDebtPremiumAccretedToAdditionalPaidinCapital>
<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="AsOf2021-05-03_custom_NewNoteMember_custom_NineNoteAgreementsMember" decimals="INF" unitRef="Pure"> 0.06 </us-gaap:DebtInstrumentInterestRateStatedPercentage>
<us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2021-11-192021-11-20" decimals="0" unitRef="USD"> 986864 </us-gaap:DebtConversionConvertedInstrumentAmount1>
<us-gaap:SummaryOfTroubledDebtRestructuringNoteDebtorTextBlock contextRef="From2021-01-01to2021-12-31">
<p id="xdx_89F_eus-gaap--SummaryOfTroubledDebtRestructuringNoteDebtorTextBlock_zzeT9dENwyl7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BD_zC0wREedVx7f">The transactions set forth below were approved by the Company’s Board of Directors on June 4, 2021</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center">Name</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_483_ecustom--PrincipalDue_iI_zxUKVHnwNaec" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Principal due</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31, 2021</b></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_48F_eus-gaap--InterestReceivable_iI_zj8Z8J0onLk5" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Accrued interest</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31, 2021</b></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_482_ecustom--Total_iI_zEe0xQQ6qPg" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Total amount due</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31, 2021</b></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_412_20210604__us-gaap--DebtInstrumentAxis__custom--NoteSoldInExchangeForCashMember_zcLECFSvw342" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 59%; text-align: left; padding-left: 1.45pt">Notes sold in exchange for cash</td><td style="width: 1%"> </td> <td id="xdx_F41_zNfFBcE84DLg" style="width: 1%; text-align: right">(1</td><td style="width: 1%; text-align: left">)</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">1,165,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">46,108</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">1,211,108</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_41D_20210604__us-gaap--DebtInstrumentAxis__custom--NoteIssuedInExchangeForDefaultedNotesMember_zIrh2x15pVDi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 1.45pt">Note issued in exchange for defaulted notes</td><td style="padding-bottom: 1pt"> </td> <td id="xdx_F47_zsECFsAOG7r7" style="text-align: right">(2</td><td style="padding-bottom: 1pt; text-align: left">)</td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,000,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">39,577</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,039,577</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; padding-left: 1.45pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">2,165,000</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">85,685</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">2,250,685</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> </table>
</us-gaap:SummaryOfTroubledDebtRestructuringNoteDebtorTextBlock>
<bixt:PrincipalDue contextRef="AsOf2021-06-04_custom_NoteSoldInExchangeForCashMember" decimals="0" id="Fact000692" unitRef="USD"> 1165000 </bixt:PrincipalDue>
<us-gaap:InterestReceivable contextRef="AsOf2021-06-04_custom_NoteSoldInExchangeForCashMember" decimals="0" id="Fact000693" unitRef="USD"> 46108 </us-gaap:InterestReceivable>
<bixt:Total contextRef="AsOf2021-06-04_custom_NoteSoldInExchangeForCashMember" decimals="0" id="Fact000694" unitRef="USD"> 1211108 </bixt:Total>
<bixt:PrincipalDue contextRef="AsOf2021-06-04_custom_NoteIssuedInExchangeForDefaultedNotesMember" decimals="0" id="Fact000695" unitRef="USD"> 1000000 </bixt:PrincipalDue>
<us-gaap:InterestReceivable contextRef="AsOf2021-06-04_custom_NoteIssuedInExchangeForDefaultedNotesMember" decimals="0" id="Fact000696" unitRef="USD"> 39577 </us-gaap:InterestReceivable>
<bixt:Total contextRef="AsOf2021-06-04_custom_NoteIssuedInExchangeForDefaultedNotesMember" decimals="0" id="Fact000697" unitRef="USD"> 1039577 </bixt:Total>
<us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2021-12-31_custom_NoteSoldInExchangeForCashMember_custom_WallachBethCapitalLLCMember" decimals="0" unitRef="USD"> 1045150 </us-gaap:DebtInstrumentFaceAmount>
<bixt:DebtDiscount contextRef="AsOf2021-12-31_custom_NoteSoldInExchangeForCashMember_custom_WallachBethCapitalLLCMember" decimals="0" unitRef="USD"> 119850 </bixt:DebtDiscount>
<bixt:ConvertibleNotesPayableNetOfPremiumAndDiscountRelatedParty contextRef="AsOf2021-12-31" decimals="0" unitRef="USD"> 1000000 </bixt:ConvertibleNotesPayableNetOfPremiumAndDiscountRelatedParty>
<us-gaap:ScheduleOfExtinguishmentOfDebtTextBlock contextRef="From2021-01-01to2021-12-31">
<p id="xdx_897_eus-gaap--ScheduleOfExtinguishmentOfDebtTextBlock_zIsyGrflrUxg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BD_zld0BKETf3i9" style="display: none; visibility: hidden">CONVERTIBLE NOTES PAYABLE</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Due at</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>May 26, 2019</b></p></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal</b></span><br/> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amount</b></span></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Default Penalty</b></span></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants Issued</b></span></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Term</b></span></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span><br/> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amortization</b></span><br/> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of Warrants</b></span></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accrued Interest</b></span></td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td id="xdx_984_eus-gaap--DebtInstrumentDescription_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--OldNoteMember_zNrczyR4aF7d" style="vertical-align: bottom; width: 8%; padding-left: 12pt; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> Old Notes</span></td> <td style="width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td id="xdx_981_ecustom--DebtInstrumentDefaulted_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--OldNoteMember_zPmgosliU3Cj" style="vertical-align: bottom; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Defaulted </span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_986_eus-gaap--DebtInstrumentFaceAmount_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--OldNoteMember_zd2iOKVUTxu9" style="border-bottom: black 2.25pt double; vertical-align: bottom; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">938,400</span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="width: 1%"> </td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_989_eus-gaap--DebtDefaultLongtermDebtAmount_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--OldNoteMember_zXB67l8gMDrd" style="border-bottom: black 2.25pt double; vertical-align: bottom; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">673,956</span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="width: 1%"> </td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; width: 1%"> </td> <td id="xdx_989_ecustom--StockIssuedDuringPeriodSharesWarrantsIssues_pii_uShares_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--OldNoteMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0Y5xr0u7og8" style="border-bottom: black 2.25pt double; vertical-align: bottom; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">272,000</span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20211231__us-gaap--DebtInstrumentAxis__custom--OldNoteMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRLJJSjFR4l4" style="vertical-align: bottom; width: 4%; text-align: right" title="::XDX::P5Y"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0712">5 </span></span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pii_uUSDPShares_c20211231__us-gaap--DebtInstrumentAxis__custom--OldNoteMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zeF9HyNc7bbg" style="vertical-align: bottom; width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.00 </span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="width: 1%"> </td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98F_ecustom--AmortizationOfWarrants_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--OldNoteMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvAjjPxczxMa" style="border-bottom: black 2.25pt double; vertical-align: bottom; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97,279</span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="width: 1%"> </td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_984_eus-gaap--InterestReceivable_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--OldNoteMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQSi7Ybcqm1h" style="border-bottom: black 2.25pt double; vertical-align: bottom; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">407,967</span></td> <td style="vertical-align: bottom; width: 1%"> </td></tr> </table> <p style="margin-top: 0; margin-bottom: 0"> </p>
</us-gaap:ScheduleOfExtinguishmentOfDebtTextBlock>
<us-gaap:DebtInstrumentDescription contextRef="From2021-01-012021-12-31_custom_OldNoteMember">  Old Notes </us-gaap:DebtInstrumentDescription>
<bixt:DebtInstrumentDefaulted contextRef="From2021-01-012021-12-31_custom_OldNoteMember"> Defaulted  </bixt:DebtInstrumentDefaulted>
<us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2021-12-31_custom_OldNoteMember" decimals="0" unitRef="USD"> 938400 </us-gaap:DebtInstrumentFaceAmount>
<us-gaap:DebtDefaultLongtermDebtAmount contextRef="AsOf2021-12-31_custom_OldNoteMember" decimals="0" unitRef="USD"> 673956 </us-gaap:DebtDefaultLongtermDebtAmount>
<bixt:StockIssuedDuringPeriodSharesWarrantsIssues contextRef="From2021-01-012021-12-31_custom_OldNoteMember_us-gaap_WarrantMember" decimals="INF" unitRef="Shares"> 272000 </bixt:StockIssuedDuringPeriodSharesWarrantsIssues>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2021-12-31_custom_OldNoteMember_us-gaap_WarrantMember" decimals="INF" unitRef="USDPShares"> 2.00 </us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<bixt:AmortizationOfWarrants contextRef="AsOf2021-12-31_custom_OldNoteMember_us-gaap_WarrantMember" decimals="0" unitRef="USD"> 97279 </bixt:AmortizationOfWarrants>
<us-gaap:InterestReceivable contextRef="AsOf2021-12-31_custom_OldNoteMember_us-gaap_WarrantMember" decimals="0" unitRef="USD"> 407967 </us-gaap:InterestReceivable>
<us-gaap:LossContingencyDamagesAwardedValue contextRef="From2021-01-192021-01-20" decimals="0" unitRef="USD"> 420750 </us-gaap:LossContingencyDamagesAwardedValue>
<us-gaap:ScheduleOfShortTermDebtTextBlock contextRef="From2021-01-01to2021-12-31">
<p id="xdx_896_eus-gaap--ScheduleOfShortTermDebtTextBlock_zG23jUBNUUj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span id="xdx_8B1_zPl3J0ANodq8">Convertible notes payable consists of the following at December 31, 2021 and December 31, 2020</span>:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20211231_z654mN7OFsxb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20201231_zp0zP3XEmdPh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_400_ecustom--DebtInstrumentFaceAmount1_iI_z0pCtHaD1IJ4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left; text-indent: -12pt; padding-left: 12pt">Principal balance</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">1,165,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">938,400</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_ecustom--DebtInstrumentFaceAmount2_iI_zhxwCOWpvBnk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -12pt; padding-left: 12pt">Principal balance, related party</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0725">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DebtDefaultLongtermDebtAmount_iI_hus-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zQG6jo0N8tQk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -12pt; padding-left: 12pt">Default penalty</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0727">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">673,956</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di_hus-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_ztfn2dyzaL8d" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -12pt; padding-left: 12pt">Unamortized debt discount</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(42,819</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0731">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LongTermDebt_iI_hus-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zXpRJVMcJSJa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -12pt; padding-left: 12pt">Outstanding, net of debt discount and premium</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,122,181</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,612,356</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
</us-gaap:ScheduleOfShortTermDebtTextBlock>
<bixt:DebtInstrumentFaceAmount1 contextRef="AsOf2021-12-31" decimals="0" unitRef="USD"> 1165000 </bixt:DebtInstrumentFaceAmount1>
<bixt:DebtInstrumentFaceAmount1 contextRef="AsOf2020-12-31" decimals="0" unitRef="USD"> 938400 </bixt:DebtInstrumentFaceAmount1>
<bixt:DebtInstrumentFaceAmount2 contextRef="AsOf2021-12-31" decimals="0" unitRef="USD"> 1000000 </bixt:DebtInstrumentFaceAmount2>
<us-gaap:DebtDefaultLongtermDebtAmount contextRef="AsOf2020-12-31_us-gaap_ConvertibleNotesPayableMember" decimals="0" unitRef="USD"> 673956 </us-gaap:DebtDefaultLongtermDebtAmount>
<us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2021-12-31_us-gaap_ConvertibleNotesPayableMember" decimals="0" unitRef="USD"> 42819 </us-gaap:DebtInstrumentUnamortizedDiscount>
<us-gaap:LongTermDebt contextRef="AsOf2021-12-31_us-gaap_ConvertibleNotesPayableMember" decimals="0" unitRef="USD"> 2122181 </us-gaap:LongTermDebt>
<us-gaap:LongTermDebt contextRef="AsOf2020-12-31_us-gaap_ConvertibleNotesPayableMember" decimals="0" unitRef="USD"> 1612356 </us-gaap:LongTermDebt>
<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2021-01-01to2021-12-31">
<p id="xdx_80D_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z8HXsrzq1Gba" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 8 – <span id="xdx_828_zO2kXegyS3U7">STOCKHOLDERS’ EQUITY</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Preferred stock</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As at December 31, 2021 and 2020, no preferred shares have been designated or issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Common stock</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 3, 2020, <span id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_uShares_c20191226__20200103__us-gaap--DebtInstrumentAxis__custom--AuctusNoteOneMember_zyIPFhlhZSu" title="Shares issued for conversion of accrued interest, shares">100,000</span> shares of Common Stock were issued as a result of conversion of accrued interest and principal on the Auctus Note #2 for a total of $<span id="xdx_905_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20191226__20200103__us-gaap--DebtInstrumentAxis__custom--AuctusNoteTwoMember_zOKAy7mDhHxa" title="Conversion of accrued interest">12,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 18, 2020, <span id="xdx_901_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_uShares_c20200215__20200218__us-gaap--DebtInstrumentAxis__custom--AuctusNoteOneMember_zBfxOC3o9XF7">250,000</span> shares of Common Stock were issued as a result of conversion of accrued interest and principal on the Auctus Note #2 for a total of $<span id="xdx_908_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20200215__20200218__us-gaap--DebtInstrumentAxis__custom--AuctusNoteOneMember_zB9TqJ1OGzki" title="Conversion of accrued interest">22,132</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 12, 2020, <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_uShares_c20200312__us-gaap--DebtInstrumentAxis__custom--AuctusNoteOneAndTwoMember_zW0sAJnuZTec" title="Warrants converted cashless exercise">750,000</span> of Common Stock were issued in exchange for <span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_pid_uShares_c20200310__20200312__us-gaap--DebtInstrumentAxis__custom--AuctusNoteOneAndTwoMember_z3y5Fnnpxlqg" title="Warrants as part of a convertible note agreement">416,666</span> warrants with cashless exercise, originating from Auctus Notes #1 and #2.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 4, 2021,<span id="xdx_90E_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pii_uShares_c20210602__20210604__us-gaap--DebtInstrumentAxis__custom--TwoConvertibleNotesMember_zomx3Zsv4iv" title="Shares issued for conversion of accrued interest, shares"> 930,864</span> shares of Common Stock were issued to two consultants as a result of conversion of accrued interest and principal for two convertible notes for a total of $<span id="xdx_906_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20210602__20210604__us-gaap--DebtInstrumentAxis__custom--TwoConvertibleNotesMember_zlcupKsrZqS5" title="Conversion of accrued interest">121,042</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 4, 2021, <span id="xdx_90D_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pii_uShares_c20210601__20210604__us-gaap--DebtInstrumentAxis__custom--ThreeConvertibleNotesMember_z9aUFd87V944" title="Shares issued for conversion of accrued interest, shares">7,591,261</span> shares of Common Stock were issued to management as a result of conversion of accrued interest and principal for three convertible notes for a total of $<span id="xdx_90F_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20210602__20210604__us-gaap--DebtInstrumentAxis__custom--ThreeConvertibleNotesMember_zcBZtSohKNWk">986,864</span>. To avoid dilution of the Company stock, the shares were returned to treasury and cancelled on November 20, 2021, and the original debt consisting of accrued salary was forgiven.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 3, 2021 a company affiliate converted their holdings in the Subsidiary into <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--JointVentureAgreementMember_zTmGv3Q0yyNd" title="Number of shares issued">4,754,552</span> shares, or 0.2945/share in accordance with a joint venture agreement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended December 31, 2021, a net of <span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_pid_uShares_c20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_zDjzehIY4ST1">7,704,909</span> shares of Common Stock were awarded at an average cost per share of $<span id="xdx_909_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_zC1cNCYK5q42" title="Common stock, par value">0.07</span>, under the 2010 and the 2016 Stock Plans for a total value of $557,422. For the year ended December 31, 2020, <span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_pid_uShares_c20201231__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_zoq1F47mrRQ5">9,875,000</span> shares of Common Stock were awarded at an average cost per share of $<span id="xdx_90D_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20201231__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_zAd0BHIONPy">0.01</span>, under the 2010 Stock Plan for a total value of $228,407. For details, see Shares Awarded and Issued under Note 9.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As at December 31, 2021, the Company has <span id="xdx_900_eus-gaap--CommonStockSharesIssued_iI_pii_uShares_c20211231_zvATgEBREvg2" title="Common stock, shares issued"><span id="xdx_906_eus-gaap--CommonStockSharesOutstanding_iI_pii_uShares_c20211231_zSrtdaBLG2d9" title="Common stock, shares, outstanding">110,840,998</span></span> shares of Common Stock issued and outstanding. At December 31, 2020 there were <span id="xdx_905_eus-gaap--CommonStockSharesOutstanding_iI_pii_uShares_c20201231_ziZsBCj0vbvf"><span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_pii_uShares_c20201231_zJVWjQrrAMWj" title="Common stock, shares issued">97,450,673</span></span> shares of Common Stock issued and outstanding.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Common Stock Warrants</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_89E_ecustom--ScheduleOfStockWarrantsGrantedTableTextBlock_zah1x98Tgd34" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of stock warrants granted for the year ended December 31, 2021 was calculated with the following assumptions:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8B7_zWVgMjvCa0r9" style="display: none; visibility: hidden">Schedule of stock warrants granted</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></td> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020</b></span></td> <td style="text-align: center"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; width: 74%; padding-left: 12pt; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rate</span></td> <td style="width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MinimumMember_zvLFLpnZSn9l" title="Risk-free interest rate, Minimum">0.16</span> - <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MaximumMember_zc6NJNbbltAd" title="Risk-free interest rate, Maximum">1.00</span></span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td style="width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MinimumMember_zi634hm9znYj" title="Risk-free interest rate, Minimum">0.46</span> - <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MaximumMember_z3NUXil9zXW6">1.67</span></span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr> <td style="vertical-align: bottom; padding-left: 12pt; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected dividend yield</span></td> <td> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zwsmUSDb4rXf" title="Expected dividend yield">0</span></span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zPqRGkJRzZ69">0</span></span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; padding-left: 12pt; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Volatility factor (monthly)</span></td> <td> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zouViYmkGbJj" title="Volatility factor (monthly)">175.34</span></span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zsAjukJiVkU3" title="Volatility factor (monthly)">158.22</span></span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr> <td style="vertical-align: bottom; padding-left: 12pt; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected life of warrant</span></td> <td> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zhXEHvDCufR4" title="Expected life of warrant::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0786">5</span></span> years</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zQuq3tM10sCi" title="::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0787">5</span></span> years</span></td> <td style="vertical-align: bottom"> </td></tr> </table> <p id="xdx_8A9_zUB22OCI2837" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended December 31, 2021 the Company awarded <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_uShares_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z9otHGAKQsga" title="Warrant">405,334</span> warrants, valued at $<span id="xdx_905_eus-gaap--WarrantsAndRightsOutstanding_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTlh63j9X3e9" title="Warrant value">145,438</span>, and <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_uShares_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1gKE3M6VVfb" title="Warrants converted cashless exercise">750,000</span> shares of Common Stock were issued in a cashless exercise. For the year ended December 31, 2020 the Company issued <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_uShares_c20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTP6Kk64EKrg">408,333</span> warrants to purchase Common Stock as part of a convertible note agreements. The warrants total value allocated to debt discount was $<span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstanding_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNoteAgreementsMember_zp3pdGBA82Oa" title="Warrant value">129,929</span>. For details, see Convertible Note Payable under Note 7.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_894_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z4IOVrZOUre7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table summarizes the Company’s Common Stock warrant activity for the year ended December 31, 2021 and 2020:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8B3_zhQfgAW2guR5" style="display: none; visibility: hidden">Schedule of company's common stock warrants activity</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 95%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of Warrants</b></span></td> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average Exercise Price</b></span></td> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted- Average Remaining Expected Term</b></span></td> <td style="text-align: center"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; width: 60%; padding-left: 12pt; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding as at January 1, 2020</span></td> <td style="width: 2%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_uShares_c20200101__20201231_zrEZ7b37BCk4" style="vertical-align: bottom; width: 9%; text-align: right" title="Number of shares, Outstanding, Beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">616,666</span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="width: 2%"> </td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20200101__20201231_z3syUzJ0y2Ob" style="vertical-align: bottom; width: 9%; text-align: right" title="Weighted Average Exercise Price, Outstanding as of beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.60</span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="width: 2%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td id="xdx_982_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm_dxL_c20190101__20191231_zBrc6wLSYiLb" style="vertical-align: bottom; width: 10%; text-align: right" title="::XDX::P4Y9M18D"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0803">4.8</span></span></td> <td style="vertical-align: bottom; width: 1%"> </td></tr> <tr> <td style="vertical-align: bottom; padding-left: 12pt; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td> <td> </td> <td style="vertical-align: bottom"> </td> <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_uShares_c20200101__20201231_zKUpuupwCwt2" style="vertical-align: bottom; text-align: right" title="Number of shares, Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">405,334</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.29</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="vertical-align: bottom"> </td> <td id="xdx_987_ecustom--SharebasedCompensationArrangementByPeriodWeightedAverageRemainingContractualTermGranted_dxL_c20200101__20201231_z5XlCB1nrzD" style="vertical-align: bottom; text-align: right" title="Weighted-Average Remaining Expected Term, Options granted::XDX::P5Y"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0807">5.0</span></span></td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; padding-left: 12pt; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td> <td> </td> <td style="vertical-align: bottom"> </td> <td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_uShares_c20200101__20201231_z8vM8oKQqApj" style="vertical-align: bottom; text-align: right" title="Number of shares, Exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(750,000</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">) </span></td> <td> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: bottom; padding-left: 12pt; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited/Canceled</span></td> <td> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; padding-left: 12pt; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding as at December 31, 2020</span></td> <td> </td> <td style="vertical-align: bottom"> </td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231_z7LhlgWcFTFb" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">272,000</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20210101__20211231_zGqrXRmFx8v7" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.00</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="vertical-align: bottom"> </td> <td id="xdx_98C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm_dxL_c20200101__20201231_zd9hAxa0sFqi" style="vertical-align: bottom; text-align: right" title="Weighted-Average Remaining Expected Term, Beginning balance::XDX::P3Y10M25D"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0813">3.9</span></span></td> <td style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: bottom; padding-left: 12pt; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td> <td> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; padding-left: 12pt; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td> <td> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: bottom; padding-left: 12pt; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited/Canceled</span></td> <td> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; padding-left: 12pt; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding as at December 31, 2021</span></td> <td> </td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"> </td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210101__20211231_znyxxX6uCIDe" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="Number of shares, Outstanding, Ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">272,000</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20210101__20211231_z4gmM4dpZpw1" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="Weighted-Average Exercise Price, Outstanding, Ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.00</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"> </td> <td id="xdx_981_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm_dxL_c20210101__20211231_zFkVKm7AiOA" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="Weighted-Average Remaining Expected Term, Ending balance::XDX::P2Y10M25D"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0819">2.9</span></span></td> <td style="vertical-align: bottom"> </td></tr> </table> <p id="xdx_8AF_zCtPCP9zkDYc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_89A_ecustom--ScheduleOfStockWarrantsTableTextBlock_z0NSgl7TjXhk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes information about stock warrants that are vested or expected to vest at December 31, 2021:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8BF_ztoOeGoqs151" style="display: none; visibility: hidden">Schedule of stock warrants</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 98%; margin-right: auto"> <tr style="vertical-align: bottom"> <td colspan="4" style="text-align: center"> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td style="text-align: center"> </td> <td> </td> <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants Outstanding</b></span></td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td style="text-align: center"> </td> <td style="border-bottom: black 1pt solid"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercisable Warrants</b></span></td> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of Warrants</b></span></td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span><br/> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span><br/> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span><br/> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span><br/> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Per Share</b></span></td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average Remaining Contractual Life (Years)</b></span></td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate Intrinsic Value</b></span></td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of Warrants</b></span></td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average Exercise Price Per Share</b></span></td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average Remaining Contractual Life (Years)</b></span></td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate Intrinsic</b></span><br/> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></td> <td style="text-align: center"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; width: 2%; padding-left: 12pt; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="vertical-align: bottom; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.00</span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pid_uShares_c20211231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zK0pulKBznEl" style="vertical-align: bottom; width: 8%; text-align: right" title="Number of Warrants"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">272,000</span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20211231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zqljdamjmRy5" style="vertical-align: bottom; width: 7%; text-align: right" title="Weighted Average Exercise Price Per Share"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.00</span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_pid_dxL_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zMJwy3cCR8o3" style="vertical-align: bottom; width: 12%; text-align: right" title="Weighted Average Remaining Contractual Life (Years)::XDX::P2Y10M25D"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0827">2.90</span></span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="vertical-align: bottom; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_pid_uShares_c20211231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zWLMZt99kI06" style="vertical-align: bottom; width: 8%; text-align: right" title="Number of Warrants"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">272,000</span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20211231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zrge8VyrCCi9" style="vertical-align: bottom; width: 7%; text-align: right" title="Weighted Average Exercise Price Per Share"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.00</span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dxL_uUSDPShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z4RBCWFFrOF1" style="vertical-align: bottom; width: 10%; text-align: right" title="Weighted Average Remaining Contractual Life (Years)::XDX::P2Y10M25D"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0833">2.90</span></span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="vertical-align: bottom; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom; width: 1%"> </td></tr> <tr> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; padding-left: 12pt; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.00</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"> </td> <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pid_uShares_c20211231_zy8ImluiiIT6" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">272,000</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20211231_zPUcCHRNKwEh" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.00</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"> </td> <td id="xdx_986_ecustom--SharotebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_pid_dxL_c20210101__20211231_zIepqxYvkvbk" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="::XDX::P2Y10M25D"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0836">2.90</span></span></td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"> </td> <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_pid_uShares_c20211231_ziQFqKnn79m2" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">272,000</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20211231_zeLjsglmYGy2" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.00</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"> </td> <td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dxL_c20210101__20211231_zeBOxJZhOEdg" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="::XDX::P2Y10M25D"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0839">2.90</span></span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td></tr> </table> <p id="xdx_8AB_z0xccFDAWpW2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 272,000 warrants are held by an affiliate. The warrant agreement includes provisions for dilutive issuance and cash-less exercise and are held by an affiliate (beneficially owned by Michael Sheikh, Ola Soderquist and David Platt).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_894_ecustom--ScheduleOfNonvestedWarrantsTableTextBlock_zu7ApE0Srekk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth the status of the Company’s non-vested warrants as at December 31, 2021 and December 31, 2020:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8BC_zxmy5jQkJvo5" style="display: none; visibility: hidden">Schedule of non-vested warrants</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of Warrants</b></span></td> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted- Average Grant-Date Fair Value</b></span></td> <td style="text-align: center"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; width: 69%; padding-left: 12pt; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-vested as at December 31, 2019</span></td> <td style="width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_uShares_c20200101__20201231_zYf06UFKGyIj" style="vertical-align: bottom; width: 10%; text-align: right" title="Number of Options, Non-vested as beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0843">—</span></span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="vertical-align: bottom; width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom; width: 1%"> </td></tr> <tr> <td style="vertical-align: bottom; padding-left: 24pt; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td> <td> </td> <td style="vertical-align: bottom"> </td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_uShares_c20200101__20201231_zpFQ1ktm4i9j" style="vertical-align: bottom; text-align: right" title="Number of Options, Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">405,334</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.13</span></td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; padding-left: 24pt; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td> <td> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: bottom; padding-left: 24pt; text-indent: -12pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vested</span></td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; vertical-align: bottom; padding-bottom: 1pt"> </td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_uShares_c20200101__20201231_zohhhUEL4DTj" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: right" title="Number of Options, Vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(405,334</span></td> <td style="vertical-align: bottom; padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; vertical-align: bottom"> </td> <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.13</span></td> <td style="vertical-align: bottom; padding-bottom: 1pt"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; padding-left: 12pt; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-vested as at December 31, 2020</span></td> <td> </td> <td style="vertical-align: bottom"> </td> <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_d0_uShares_c20210101__20211231_z2mZMXtrHx41" style="vertical-align: bottom; text-align: right" title="Number of Options, Non-vested as beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: bottom; padding-left: 12pt; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">     Granted</span></td> <td> </td> <td style="vertical-align: bottom"> </td> <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_uShares_c20210101__20211231_za2drYNGQo98" style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0850">—</span></span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; padding-left: 12pt; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">     Forfeited</span></td> <td> </td> <td style="vertical-align: bottom"> </td> <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pid_uShares_c20210101__20211231_zcHTQKYIVQr8" style="vertical-align: top; text-align: right" title="Number of Options, Forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0852">—</span></span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: bottom; padding-left: 12pt; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">     Vested</span></td> <td> </td> <td style="vertical-align: bottom"> </td> <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_pid_uShares_c20210101__20211231_zMfXbfEbev0j" style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0853">—</span></span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; padding-left: 12pt; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-vested as at December 31, 2021</span></td> <td> </td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"> </td> <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_d0_uShares_c20210101__20211231_z87iRekJw9J3" style="border-bottom: black 2.25pt double; vertical-align: top; text-align: right" title="Number of Options, Non-vested as Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td></tr> </table> <p id="xdx_8A5_zs7hrUK5gael" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The weighted-average remaining contractual life for warrants exercisable at December 31, 2021 is <span id="xdx_904_ecustom--WarrantsExercisableWeightedAverageRemainingContractualTerm_dxL_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMZApWIQ0kN8" title="Warrants exercisable, weighted average remaining contractual term::XDX::P2Y10M25D"><span style="-sec-ix-hidden: xdx2ixbrl0857">2.90</span></span> years.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate intrinsic value for fully vested, exercisable warrants was $<span id="xdx_90F_ecustom--AggregateIntrinsicValueForFullyVestedExercisableWarrants_iI_dxL_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPVzU14yV74f" title="Aggregate intrinsic value for fully vested, exercisable warrants"><span style="-sec-ix-hidden: xdx2ixbrl0859">0</span></span> at December 31, 2021 and 2020 was $<span id="xdx_900_ecustom--AggregateIntrinsicValueForFullyVestedExercisableWarrants_iI_dxL_c20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztBm4bvkzmXi"><span style="-sec-ix-hidden: xdx2ixbrl0860">0</span></span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Common Stock Options</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended December 31, 2021 there were <span id="xdx_905_ecustom--AwardedOption_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2021Member_znYlZDf80Ee1" title="Awarded options">135,000</span> options awarded under the 2021 Stock Option Plan. The options total fair value at the time of award was $<span id="xdx_904_eus-gaap--FairValueAdjustmentOfWarrants_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2021Member_zYnhCnEvf5Mc" title="Fair market value of warrant">14,490</span>. For the year ended December 31, 2020 there were <span id="xdx_903_ecustom--AwardedOption_c20200101__20201231__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_zI1TLuYleGN6">192,000</span> options awarded under the 2010 Stock Option Plan. The options total fair value at the time of award was $<span id="xdx_903_eus-gaap--FairValueAdjustmentOfWarrants_c20200101__20201231__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_zzjnPX8EsmE">18,460</span>. For details, see Stock options granted and vested under note 9.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Sales of Shares in Subsidiary</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended December 31, 2021 and 2020, the Company sold <span id="xdx_90D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20211231__srt--ConsolidatedEntitiesAxis__srt--SubsidiariesMember_z9WBDZCUJrLk" title="Ownership percentage">9</span>% and <span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20201231__srt--ConsolidatedEntitiesAxis__srt--SubsidiariesMember_z0orAV1MaQ6b">15</span>%, respectively, of its subsidiary Pharmalectin for a total amount of $<span id="xdx_902_ecustom--EquityMethodInvestmentAmount_c20210101__20211231__srt--ConsolidatedEntitiesAxis__srt--SubsidiariesMember_zAqpmLSWvED3" title="Equity method investment amount">600,000</span> and $<span id="xdx_909_ecustom--EquityMethodInvestmentAmount_c20200101__20201231__srt--ConsolidatedEntitiesAxis__srt--SubsidiariesMember_zsJQfKiItcZ">950,000</span>, respectively. The external ownership interest is <span id="xdx_90C_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MichaelSheikhOlaSoderquistAndDavidPlattMember_zvYATfCis7Ch">24</span>% and are currently held by an affiliate (beneficially owned by Michael Sheikh, Ola Soderquist and David Platt).</p>
</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
<us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="From2019-12-262020-01-03_custom_AuctusNoteOneMember" decimals="INF" unitRef="Shares"> 100000 </us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
<us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2019-12-262020-01-03_custom_AuctusNoteTwoMember" decimals="0" unitRef="USD"> 12000 </us-gaap:DebtConversionConvertedInstrumentAmount1>
<us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="From2020-02-152020-02-18_custom_AuctusNoteOneMember" decimals="INF" unitRef="Shares"> 250000 </us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
<us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2020-02-152020-02-18_custom_AuctusNoteOneMember" decimals="0" unitRef="USD"> 22132 </us-gaap:DebtConversionConvertedInstrumentAmount1>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2020-03-12_custom_AuctusNoteOneAndTwoMember" decimals="INF" unitRef="Shares"> 750000 </us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1 contextRef="From2020-03-102020-03-12_custom_AuctusNoteOneAndTwoMember" decimals="INF" unitRef="Shares"> 416666 </us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1>
<us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="From2021-06-022021-06-04_custom_TwoConvertibleNotesMember" decimals="INF" unitRef="Shares"> 930864 </us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
<us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2021-06-022021-06-04_custom_TwoConvertibleNotesMember" decimals="0" unitRef="USD"> 121042 </us-gaap:DebtConversionConvertedInstrumentAmount1>
<us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="From2021-06-012021-06-04_custom_ThreeConvertibleNotesMember" decimals="INF" unitRef="Shares"> 7591261 </us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
<us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2021-06-022021-06-04_custom_ThreeConvertibleNotesMember" decimals="0" unitRef="USD"> 986864 </us-gaap:DebtConversionConvertedInstrumentAmount1>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2021-01-012021-12-31_custom_JointVentureAgreementMember" decimals="INF" unitRef="Shares"> 4754552 </us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-12-31_custom_StockPlan2010Member" decimals="INF" unitRef="Shares"> 7704909 </us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2021-12-31_custom_StockPlan2010Member" decimals="INF" unitRef="USDPShares"> 0.07 </us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized contextRef="AsOf2020-12-31_custom_StockPlan2010Member" decimals="INF" unitRef="Shares"> 9875000 </us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2020-12-31_custom_StockPlan2010Member" decimals="INF" unitRef="USDPShares"> 0.01 </us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesIssued contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares"> 110840998 </us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares"> 110840998 </us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesOutstanding contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares"> 97450673 </us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesIssued contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares"> 97450673 </us-gaap:CommonStockSharesIssued>
<bixt:ScheduleOfStockWarrantsGrantedTableTextBlock contextRef="From2021-01-01to2021-12-31">
<p id="xdx_89E_ecustom--ScheduleOfStockWarrantsGrantedTableTextBlock_zah1x98Tgd34" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of stock warrants granted for the year ended December 31, 2021 was calculated with the following assumptions:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8B7_zWVgMjvCa0r9" style="display: none; visibility: hidden">Schedule of stock warrants granted</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></td> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020</b></span></td> <td style="text-align: center"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; width: 74%; padding-left: 12pt; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rate</span></td> <td style="width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MinimumMember_zvLFLpnZSn9l" title="Risk-free interest rate, Minimum">0.16</span> - <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MaximumMember_zc6NJNbbltAd" title="Risk-free interest rate, Maximum">1.00</span></span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td style="width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MinimumMember_zi634hm9znYj" title="Risk-free interest rate, Minimum">0.46</span> - <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MaximumMember_z3NUXil9zXW6">1.67</span></span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr> <td style="vertical-align: bottom; padding-left: 12pt; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected dividend yield</span></td> <td> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zwsmUSDb4rXf" title="Expected dividend yield">0</span></span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zPqRGkJRzZ69">0</span></span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; padding-left: 12pt; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Volatility factor (monthly)</span></td> <td> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zouViYmkGbJj" title="Volatility factor (monthly)">175.34</span></span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zsAjukJiVkU3" title="Volatility factor (monthly)">158.22</span></span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr> <td style="vertical-align: bottom; padding-left: 12pt; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected life of warrant</span></td> <td> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zhXEHvDCufR4" title="Expected life of warrant::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0786">5</span></span> years</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zQuq3tM10sCi" title="::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0787">5</span></span> years</span></td> <td style="vertical-align: bottom"> </td></tr> </table>
</bixt:ScheduleOfStockWarrantsGrantedTableTextBlock>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2021-01-012021-12-31_custom_CommonStockWarrantsMember_srt_MinimumMember" decimals="INF" unitRef="Pure"> 0.0016 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2021-01-012021-12-31_custom_CommonStockWarrantsMember_srt_MaximumMember" decimals="INF" unitRef="Pure"> 0.0100 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2020-01-012020-12-31_custom_CommonStockWarrantsMember_srt_MinimumMember" decimals="INF" unitRef="Pure"> 0.0046 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2020-01-012020-12-31_custom_CommonStockWarrantsMember_srt_MaximumMember" decimals="INF" unitRef="Pure"> 0.0167 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2021-01-012021-12-31_custom_CommonStockWarrantsMember" decimals="INF" unitRef="Pure"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2020-01-012020-12-31_custom_CommonStockWarrantsMember" decimals="INF" unitRef="Pure"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2021-01-012021-12-31_custom_CommonStockWarrantsMember" decimals="INF" unitRef="Pure"> 1.7534 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2020-01-012020-12-31_custom_CommonStockWarrantsMember" decimals="INF" unitRef="Pure"> 1.5822 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="AsOf2021-12-31_us-gaap_WarrantMember" decimals="INF" unitRef="Shares"> 405334 </us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
<us-gaap:WarrantsAndRightsOutstanding contextRef="AsOf2021-12-31_us-gaap_WarrantMember" decimals="0" unitRef="USD"> 145438 </us-gaap:WarrantsAndRightsOutstanding>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2021-12-31_us-gaap_WarrantMember" decimals="INF" unitRef="Shares"> 750000 </us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="AsOf2020-12-31_us-gaap_WarrantMember" decimals="INF" unitRef="Shares"> 408333 </us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
<us-gaap:WarrantsAndRightsOutstanding contextRef="AsOf2021-12-31_us-gaap_WarrantMember_custom_ConvertibleNoteAgreementsMember" decimals="0" unitRef="USD"> 129929 </us-gaap:WarrantsAndRightsOutstanding>
<us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2021-01-01to2021-12-31">
<p id="xdx_894_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z4IOVrZOUre7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table summarizes the Company’s Common Stock warrant activity for the year ended December 31, 2021 and 2020:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8B3_zhQfgAW2guR5" style="display: none; visibility: hidden">Schedule of company's common stock warrants activity</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 95%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of Warrants</b></span></td> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average Exercise Price</b></span></td> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted- Average Remaining Expected Term</b></span></td> <td style="text-align: center"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; width: 60%; padding-left: 12pt; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding as at January 1, 2020</span></td> <td style="width: 2%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_uShares_c20200101__20201231_zrEZ7b37BCk4" style="vertical-align: bottom; width: 9%; text-align: right" title="Number of shares, Outstanding, Beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">616,666</span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="width: 2%"> </td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20200101__20201231_z3syUzJ0y2Ob" style="vertical-align: bottom; width: 9%; text-align: right" title="Weighted Average Exercise Price, Outstanding as of beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.60</span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="width: 2%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td id="xdx_982_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm_dxL_c20190101__20191231_zBrc6wLSYiLb" style="vertical-align: bottom; width: 10%; text-align: right" title="::XDX::P4Y9M18D"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0803">4.8</span></span></td> <td style="vertical-align: bottom; width: 1%"> </td></tr> <tr> <td style="vertical-align: bottom; padding-left: 12pt; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td> <td> </td> <td style="vertical-align: bottom"> </td> <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_uShares_c20200101__20201231_zKUpuupwCwt2" style="vertical-align: bottom; text-align: right" title="Number of shares, Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">405,334</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.29</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="vertical-align: bottom"> </td> <td id="xdx_987_ecustom--SharebasedCompensationArrangementByPeriodWeightedAverageRemainingContractualTermGranted_dxL_c20200101__20201231_z5XlCB1nrzD" style="vertical-align: bottom; text-align: right" title="Weighted-Average Remaining Expected Term, Options granted::XDX::P5Y"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0807">5.0</span></span></td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; padding-left: 12pt; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td> <td> </td> <td style="vertical-align: bottom"> </td> <td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_uShares_c20200101__20201231_z8vM8oKQqApj" style="vertical-align: bottom; text-align: right" title="Number of shares, Exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(750,000</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">) </span></td> <td> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: bottom; padding-left: 12pt; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited/Canceled</span></td> <td> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; padding-left: 12pt; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding as at December 31, 2020</span></td> <td> </td> <td style="vertical-align: bottom"> </td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231_z7LhlgWcFTFb" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">272,000</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20210101__20211231_zGqrXRmFx8v7" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.00</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="vertical-align: bottom"> </td> <td id="xdx_98C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm_dxL_c20200101__20201231_zd9hAxa0sFqi" style="vertical-align: bottom; text-align: right" title="Weighted-Average Remaining Expected Term, Beginning balance::XDX::P3Y10M25D"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0813">3.9</span></span></td> <td style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: bottom; padding-left: 12pt; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td> <td> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; padding-left: 12pt; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td> <td> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: bottom; padding-left: 12pt; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited/Canceled</span></td> <td> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; padding-left: 12pt; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding as at December 31, 2021</span></td> <td> </td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"> </td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210101__20211231_znyxxX6uCIDe" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="Number of shares, Outstanding, Ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">272,000</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20210101__20211231_z4gmM4dpZpw1" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="Weighted-Average Exercise Price, Outstanding, Ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.00</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"> </td> <td id="xdx_981_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm_dxL_c20210101__20211231_zFkVKm7AiOA" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="Weighted-Average Remaining Expected Term, Ending balance::XDX::P2Y10M25D"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0819">2.9</span></span></td> <td style="vertical-align: bottom"> </td></tr> </table>
</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-12-31" decimals="INF" unitRef="Shares"> 616666 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2019-12-31" decimals="INF" unitRef="USDPShares"> 0.60 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2020-01-012020-12-31" decimals="INF" unitRef="Shares"> 405334 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2020-01-012020-12-31" decimals="INF" unitRef="Shares"> 750000 </us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares"> 272000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2020-12-31" decimals="INF" unitRef="USDPShares"> 2.00 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares"> 272000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2021-12-31" decimals="INF" unitRef="USDPShares"> 2.00 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<bixt:ScheduleOfStockWarrantsTableTextBlock contextRef="From2021-01-01to2021-12-31">
<p id="xdx_89A_ecustom--ScheduleOfStockWarrantsTableTextBlock_z0NSgl7TjXhk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes information about stock warrants that are vested or expected to vest at December 31, 2021:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8BF_ztoOeGoqs151" style="display: none; visibility: hidden">Schedule of stock warrants</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 98%; margin-right: auto"> <tr style="vertical-align: bottom"> <td colspan="4" style="text-align: center"> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td style="text-align: center"> </td> <td> </td> <td colspan="5" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants Outstanding</b></span></td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td style="text-align: center"> </td> <td style="border-bottom: black 1pt solid"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercisable Warrants</b></span></td> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of Warrants</b></span></td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span><br/> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span><br/> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span><br/> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span><br/> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Per Share</b></span></td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average Remaining Contractual Life (Years)</b></span></td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate Intrinsic Value</b></span></td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of Warrants</b></span></td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average Exercise Price Per Share</b></span></td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average Remaining Contractual Life (Years)</b></span></td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate Intrinsic</b></span><br/> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></td> <td style="text-align: center"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; width: 2%; padding-left: 12pt; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="vertical-align: bottom; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.00</span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pid_uShares_c20211231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zK0pulKBznEl" style="vertical-align: bottom; width: 8%; text-align: right" title="Number of Warrants"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">272,000</span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20211231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zqljdamjmRy5" style="vertical-align: bottom; width: 7%; text-align: right" title="Weighted Average Exercise Price Per Share"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.00</span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_pid_dxL_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zMJwy3cCR8o3" style="vertical-align: bottom; width: 12%; text-align: right" title="Weighted Average Remaining Contractual Life (Years)::XDX::P2Y10M25D"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0827">2.90</span></span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="vertical-align: bottom; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_pid_uShares_c20211231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zWLMZt99kI06" style="vertical-align: bottom; width: 8%; text-align: right" title="Number of Warrants"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">272,000</span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20211231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zrge8VyrCCi9" style="vertical-align: bottom; width: 7%; text-align: right" title="Weighted Average Exercise Price Per Share"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.00</span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dxL_uUSDPShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z4RBCWFFrOF1" style="vertical-align: bottom; width: 10%; text-align: right" title="Weighted Average Remaining Contractual Life (Years)::XDX::P2Y10M25D"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0833">2.90</span></span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="vertical-align: bottom; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom; width: 1%"> </td></tr> <tr> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; padding-left: 12pt; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.00</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"> </td> <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pid_uShares_c20211231_zy8ImluiiIT6" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">272,000</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20211231_zPUcCHRNKwEh" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.00</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"> </td> <td id="xdx_986_ecustom--SharotebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_pid_dxL_c20210101__20211231_zIepqxYvkvbk" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="::XDX::P2Y10M25D"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0836">2.90</span></span></td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"> </td> <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_pid_uShares_c20211231_ziQFqKnn79m2" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">272,000</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20211231_zeLjsglmYGy2" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.00</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"> </td> <td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_pid_dxL_c20210101__20211231_zeBOxJZhOEdg" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="::XDX::P2Y10M25D"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0839">2.90</span></span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td></tr> </table>
</bixt:ScheduleOfStockWarrantsTableTextBlock>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2021-12-31_custom_CommonStockWarrantsMember" decimals="INF" unitRef="Shares"> 272000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="AsOf2021-12-31_custom_CommonStockWarrantsMember" decimals="INF" unitRef="USDPShares"> 2.00 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="AsOf2021-12-31_custom_CommonStockWarrantsMember" decimals="INF" unitRef="Shares"> 272000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice contextRef="AsOf2021-12-31_custom_CommonStockWarrantsMember" decimals="INF" unitRef="USDPShares"> 2.00 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares"> 272000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="AsOf2021-12-31" decimals="INF" unitRef="USDPShares"> 2.00 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares"> 272000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice contextRef="AsOf2021-12-31" decimals="INF" unitRef="USDPShares"> 2.00 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
<bixt:ScheduleOfNonvestedWarrantsTableTextBlock contextRef="From2021-01-01to2021-12-31">
<p id="xdx_894_ecustom--ScheduleOfNonvestedWarrantsTableTextBlock_zu7ApE0Srekk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth the status of the Company’s non-vested warrants as at December 31, 2021 and December 31, 2020:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8BC_zxmy5jQkJvo5" style="display: none; visibility: hidden">Schedule of non-vested warrants</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of Warrants</b></span></td> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted- Average Grant-Date Fair Value</b></span></td> <td style="text-align: center"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; width: 69%; padding-left: 12pt; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-vested as at December 31, 2019</span></td> <td style="width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_uShares_c20200101__20201231_zYf06UFKGyIj" style="vertical-align: bottom; width: 10%; text-align: right" title="Number of Options, Non-vested as beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0843">—</span></span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="vertical-align: bottom; width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom; width: 1%"> </td></tr> <tr> <td style="vertical-align: bottom; padding-left: 24pt; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td> <td> </td> <td style="vertical-align: bottom"> </td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_uShares_c20200101__20201231_zpFQ1ktm4i9j" style="vertical-align: bottom; text-align: right" title="Number of Options, Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">405,334</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.13</span></td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; padding-left: 24pt; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td> <td> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: bottom; padding-left: 24pt; text-indent: -12pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vested</span></td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; vertical-align: bottom; padding-bottom: 1pt"> </td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_uShares_c20200101__20201231_zohhhUEL4DTj" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: right" title="Number of Options, Vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(405,334</span></td> <td style="vertical-align: bottom; padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; vertical-align: bottom"> </td> <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.13</span></td> <td style="vertical-align: bottom; padding-bottom: 1pt"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; padding-left: 12pt; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-vested as at December 31, 2020</span></td> <td> </td> <td style="vertical-align: bottom"> </td> <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_d0_uShares_c20210101__20211231_z2mZMXtrHx41" style="vertical-align: bottom; text-align: right" title="Number of Options, Non-vested as beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: bottom; padding-left: 12pt; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">     Granted</span></td> <td> </td> <td style="vertical-align: bottom"> </td> <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_uShares_c20210101__20211231_za2drYNGQo98" style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0850">—</span></span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; padding-left: 12pt; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">     Forfeited</span></td> <td> </td> <td style="vertical-align: bottom"> </td> <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pid_uShares_c20210101__20211231_zcHTQKYIVQr8" style="vertical-align: top; text-align: right" title="Number of Options, Forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0852">—</span></span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: bottom; padding-left: 12pt; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">     Vested</span></td> <td> </td> <td style="vertical-align: bottom"> </td> <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_pid_uShares_c20210101__20211231_zMfXbfEbev0j" style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0853">—</span></span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; padding-left: 12pt; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-vested as at December 31, 2021</span></td> <td> </td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"> </td> <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_d0_uShares_c20210101__20211231_z87iRekJw9J3" style="border-bottom: black 2.25pt double; vertical-align: top; text-align: right" title="Number of Options, Non-vested as Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td></tr> </table>
</bixt:ScheduleOfNonvestedWarrantsTableTextBlock>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="From2020-01-012020-12-31" decimals="INF" unitRef="Shares"> 405334 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="From2020-01-012020-12-31" decimals="INF" unitRef="Shares"> 405334 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
<bixt:AwardedOption contextRef="From2021-01-012021-12-31_custom_StockPlan2021Member" decimals="INF" unitRef="Shares"> 135000 </bixt:AwardedOption>
<us-gaap:FairValueAdjustmentOfWarrants contextRef="From2021-01-012021-12-31_custom_StockPlan2021Member" decimals="0" unitRef="USD"> 14490 </us-gaap:FairValueAdjustmentOfWarrants>
<bixt:AwardedOption contextRef="From2020-01-012020-12-31_custom_StockPlan2010Member" decimals="INF" unitRef="Shares"> 192000 </bixt:AwardedOption>
<us-gaap:FairValueAdjustmentOfWarrants contextRef="From2020-01-012020-12-31_custom_StockPlan2010Member" decimals="0" unitRef="USD"> 18460 </us-gaap:FairValueAdjustmentOfWarrants>
<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="AsOf2021-12-31_srt_SubsidiariesMember" decimals="INF" unitRef="Pure"> 0.09 </us-gaap:EquityMethodInvestmentOwnershipPercentage>
<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="AsOf2020-12-31_srt_SubsidiariesMember" decimals="INF" unitRef="Pure"> 0.15 </us-gaap:EquityMethodInvestmentOwnershipPercentage>
<bixt:EquityMethodInvestmentAmount contextRef="From2021-01-012021-12-31_srt_SubsidiariesMember" decimals="0" unitRef="USD"> 600000 </bixt:EquityMethodInvestmentAmount>
<bixt:EquityMethodInvestmentAmount contextRef="From2020-01-012020-12-31_srt_SubsidiariesMember" decimals="0" unitRef="USD"> 950000 </bixt:EquityMethodInvestmentAmount>
<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="AsOf2021-12-31_custom_MichaelSheikhOlaSoderquistAndDavidPlattMember" decimals="INF" unitRef="Pure"> 0.24 </us-gaap:EquityMethodInvestmentOwnershipPercentage>
<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2021-01-01to2021-12-31">
<p id="xdx_80C_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_z5Ogpa6ZHkEd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 9 – <span id="xdx_82D_z8t6CVDMdmni">STOCK OPTION PLAN AND STOCK-BASED COMPENSATION</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended January 15, 2021, the Company adopted a stock option plan entitled “The 2021 Stock Plan” (2021 Plan) under which the Company may grant Options to Purchase Stock, Stock Awards or Stock Appreciation Rights up to <span id="xdx_90A_ecustom--StockAwardsStockAppreciationRightsPercentage_dp_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_zUk5Bou4wEkj" title="Percentage of stock award stock appreciation right">15</span>% of the then fully diluted number of shares of the Company’s Common Stock, automatically adjusted on January 1 each year. As at December 31, 2021, there were <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zmo79Y9k8Oq2" title="Options outstanding number of shares">668,000</span> outstanding stock options valued at historic fair market value of $<span id="xdx_909_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_c20210101__20211231_z23Yc7ldfICd" title="Options granted value">367,400</span> and <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_zJFvi9sRDTZd" title="Shares issued for services">1,669,000</span> shares issued valued at a fair historic market value of $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_zqkXL1Mu7fMl" title="Shares issued for services, value">43,919</span> at the time of award. As at December 31, 2020, there was “The 2010 Stock Plan” under this plan there were <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20201231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zhEaSFBw2xV8">533,000</span> outstanding stock options with a fair historic market value of $<span id="xdx_90C_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_z4dGN3P7ByJ">275,603</span> and <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20200101__20201231__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_zvFGLbXraYLa">11,002,000</span> shares issued with a fair historic market value of $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20200101__20201231__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_zt612NXfecvk">1,075,358</span> at the time of award.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the terms of the stock plans, the Board of Directors shall specify the exercise price and vesting period of each stock option on the grant date. Vesting of the options is typically immediate and the options typically expire in five years. Stock Awards may be directly issued under the Plan (without any intervening options). Stock Awards may be issued which are fully and immediately vested upon issuance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Shares Awarded and Issued 2010 Plan:</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 1, 2020 the Company granted <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20191230__20200102__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_zxmacOz9Rwmj" title="Number of shares, granted">250,000</span> shares with a fair market value of $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20191230__20200102__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_zTC9dEgttkL6" title="Grants in period, weighted average grant date fair value (per share)">0.285</span>/share at the time of award, to a consultant for assistance with the Companies PR work, for a total of $<span id="xdx_90D_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_c20191230__20200102__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_zPBYfnx10bLh" title="Options granted, value">71,250</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 31, 2020 the Company granted two subcontractors a total of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20200101__20200131__srt--TitleOfIndividualAxis__custom--SubcontractorsMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_zi8OpwkM3pO5">200,000</span> shares with a fair market value of $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20200101__20200131__srt--TitleOfIndividualAxis__custom--SubcontractorsMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_zM8HasmB8HH8">0.14</span>/share at the time of award, as compensation for their work with the Company’s marketing efforts, for a total of $<span id="xdx_909_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_c20200101__20200131__srt--TitleOfIndividualAxis__custom--SubcontractorsMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_ze5hcv54Hyr8" title="Options granted, value">28,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 21, 2020 the Company granted <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20200201__20200221__srt--TitleOfIndividualAxis__custom--ThreeMemberOfTheAuditCommitteeMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_z7DlC1RY8Xz3">3,000</span> shares with a fair market value of $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20200201__20200221__srt--TitleOfIndividualAxis__custom--ThreeMemberOfTheAuditCommitteeMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_zqnEfKxRv2h6">0.439</span>/share to three members of the Audit Committee as compensation for their contribution in the Audit Committee, for a total of $<span id="xdx_905_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_c20200201__20200221__srt--TitleOfIndividualAxis__custom--ThreeMemberOfTheAuditCommitteeMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_zktFcSAXhURg">1,317</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 18, 2020 the Company granted <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20200301__20200318__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_z3PNCPYoDGua">200,000</span> shares with a fair market value of $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20200301__20200318__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_zJ8EW8HE909d">0.245</span>/share at the time of award, to a consultant for assistance with the Companies PR work, for a total of $<span id="xdx_908_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_c20200301__20200318__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_zBv9hBTplsYi">49,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 25, 2020, the Company granted <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20200301__20200325__srt--TitleOfIndividualAxis__custom--ThreeMembersOfTheCompanyBoardMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_zgqqUrwaB4x9">3,000</span> shares with a fair market value of $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20200301__20200325__srt--TitleOfIndividualAxis__custom--ThreeMembersOfTheCompanyBoardMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_zwOl5bwfiM4c">0.31</span>/share to three members of the Company Board as compensation for their contribution in the Company’s Board of Directors, for a total of $<span id="xdx_90F_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_c20200301__20200325__srt--TitleOfIndividualAxis__custom--ThreeMembersOfTheCompanyBoardMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_zu3u7cMf8uBg">930</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 1, 2020 the Company appointed Mr. Mike Sheikh as EVP of Business Development. Mr. Sheikh was issued <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20200428__20200501__srt--TitleOfIndividualAxis__custom--MikeSheikhMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_zeA7MwYb48wk">8,800,000</span> shares with a fair market value of $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20200428__20200501__srt--TitleOfIndividualAxis__custom--MikeSheikhMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_zTG4yYCmj9nd">0.003</span>/share to be equally vested over a period of <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dxL_c20200428__20200501__srt--TitleOfIndividualAxis__custom--MikeSheikhMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_zbTIRO95jkZi" title="::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0911">3 years</span></span>, but fully vested upon a change of control. The shares total fair value at the time of the award was $<span id="xdx_906_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_c20200428__20200501__srt--TitleOfIndividualAxis__custom--MikeSheikhMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_zEvCND1VxnS4">26,400</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 1, 2020, the Company granted <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20200625__20200701__srt--TitleOfIndividualAxis__custom--ThreeMembersOfTheCompanyBoardMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_zhtta0Gsq2M4">3,000</span> shares with a fair market value of $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20200625__20200701__srt--TitleOfIndividualAxis__custom--ThreeMembersOfTheCompanyBoardMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_zWMT5CB6tsf9">0.19</span>/share to three members of the Company Board as compensation for their contribution in the Board and Committee contribution during the previous quarter, for a total of $<span id="xdx_908_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_c20200625__20200701__srt--TitleOfIndividualAxis__custom--ThreeMembersOfTheCompanyBoardMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_zbWtEG7aQtve">570</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 3, 2020, the Company granted a total of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20200730__20200803__srt--TitleOfIndividualAxis__custom--MedicalAdvisoryBoardMembersMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_zDgmfHk60kWd">100,000</span> shares, to two Medical Consultants for their efforts in validating the Company’s science and potential clinical pathways. The shares total fair value at the time of award was $<span id="xdx_905_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_c20200728__20200803__srt--TitleOfIndividualAxis__custom--MedicalAdvisoryBoardMembersMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2021Member_z0HP8zEUFbL8">300</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 17, 2020, the Company granted a total of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200916__20200917__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2021Member_zStf8dlnfY5h">50,000</span> shares, to a Medical Consultants for his efforts in validating the Company’s science and potential clinical pathways. The shares total fair value at the time of award was $<span id="xdx_904_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_c20200916__20200917__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2021Member_z2BXnJP5kfH7">1,500</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 1, 2020, the Company granted <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20200925__20201001__srt--TitleOfIndividualAxis__custom--ThreeMembersOfTheCompanyBoardMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_z5KMOwpy0Ejh">3,000</span> shares with a fair market value of $<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20200925__20201001__srt--TitleOfIndividualAxis__custom--ThreeMembersOfTheCompanyBoardMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_zJilMXASTaFc">0.02</span>/share to three members of the Company Board as compensation for their contribution in the Board and Committee contribution during the previous quarter, for a total of $<span id="xdx_90C_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_c20200925__20201001__srt--TitleOfIndividualAxis__custom--ThreeMembersOfTheCompanyBoardMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_zeT1MenQml5a">60</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 13, 2020, the Company granted <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20201111__20201113__srt--TitleOfIndividualAxis__custom--ThreeMembersOfTheCompanyBoardMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_z2YGyEPJFsih">63,000</span> shares with a fair market value of $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20201111__20201113__srt--TitleOfIndividualAxis__custom--ThreeMembersOfTheCompanyBoardMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_z8vv27Lmdqv3">0.18</span>/share to three members of the Company Board as compensation for their contribution in the Board and Committee contribution during the previous quarter, for a total of $<span id="xdx_909_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_c20201111__20201113__srt--TitleOfIndividualAxis__custom--ThreeMembersOfTheCompanyBoardMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_ztyfj1BEo9T3">11,580</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 13, 2020, the Company granted <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20201111__20201113__srt--TitleOfIndividualAxis__custom--TwoMedicalConsultantsMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_z8YvEAtYDE1b">200,000</span> shares with a fair market value of $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20201111__20201113__srt--TitleOfIndividualAxis__custom--TwoMedicalConsultantsMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_zDOER6wI6aaf">0.19</span>/share to two Medical Consultants for their efforts in validating the Company’s science and potential clinical pathways, for a total of $<span id="xdx_904_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_c20201111__20201113__srt--TitleOfIndividualAxis__custom--TwoMedicalConsultantsMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_zaIb9Kn6nEWb">37,500</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 1, 2021 the Company granted <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20201230__20210102__srt--TitleOfIndividualAxis__custom--MedicalAdvisoryBoardMembersMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_zad8bafw2rsj">10,000</span> shares, with a fair market value of $<span id="xdx_90C_ecustom--StockOptionsExercisePriceInDollarsPerShare_pid_c20201230__20210102__srt--TitleOfIndividualAxis__custom--MedicalAdvisoryBoardMembersMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_zYE3WV517Cmg">0.24</span>/share at the time of award, to a Medical Advisory Board Member for her contribution in the Company’s Advisory Board, for a total of $<span id="xdx_90C_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_c20201230__20210102__srt--TitleOfIndividualAxis__custom--MedicalAdvisoryBoardMembersMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_zlw5MlOIgwUj">2,400</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 15, 2021 the Company granted 3,189,200 shares of Common Stock valued at $<span id="xdx_90B_ecustom--StockOptionsExercisePriceInDollarsPerShare_c20210114__20210115__srt--TitleOfIndividualAxis__custom--ManagersBoardAndMedicalAdvisoryBoardMembersMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_zdkwZnSurPsg">0.24</span>/share, <span id="xdx_90E_ecustom--DescriptionOfDividendPay_c20210114__20210115__srt--TitleOfIndividualAxis__custom--ManagersBoardAndMedicalAdvisoryBoardMembersMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z0zPw2KSY3d7">equally divided to 227,800 shares/each</span> to fourteen of the Company’s Managers, Board- and Medical Advisory Board members, as well as to indispensable Consultants currently working on the clinical trial submissions with the FDA, for a total value of $<span id="xdx_90C_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_c20210114__20210115__srt--TitleOfIndividualAxis__custom--ManagersBoardAndMedicalAdvisoryBoardMembersMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_zcQpfgYWnlOg">765,408</span>. On November 20, 2021, the Management returned 1,083,400 of these shares to the Plan in order to avoid dilution of the Company stock, the shares were cancelled upon return. The shares market value at the time of issuance were $<span id="xdx_905_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_c20211110__20211120__srt--TitleOfIndividualAxis__custom--ManagersBoardAndMedicalAdvisoryBoardMembersMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_z6Asu2cQ9Hlb">260,016</span>, or $<span id="xdx_90D_ecustom--StockOptionsExercisePriceInDollarsPerShare_c20211110__20211120__srt--TitleOfIndividualAxis__custom--ManagersBoardAndMedicalAdvisoryBoardMembersMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_zveY2E7mxem9">0.24</span>/share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Shares Awarded and Issued 2021 Plan:</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 1, 2021 the Company granted <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210330__20210402__srt--TitleOfIndividualAxis__custom--MedicalAdvisoryBoardMembersMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2021Member_z9SQCw28W7Rg">10,000</span> shares, with a fair market value of $<span id="xdx_901_ecustom--StockOptionsExercisePriceInDollarsPerShare_pid_c20210330__20210402__srt--TitleOfIndividualAxis__custom--MedicalAdvisoryBoardMembersMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2021Member_z7fQramZAvb3">0.17</span>/share at the time of award, to a Medical Advisory Board Member for her contribution in the Company’s Advisory Board, for a total of $<span id="xdx_90F_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_c20210330__20210402__srt--TitleOfIndividualAxis__custom--MedicalAdvisoryBoardMembersMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2021Member_zFvMC59tRd2k">1,700</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 1, 2021 the Company granted <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210330__20210402__srt--TitleOfIndividualAxis__custom--AuditCommitteeMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2021Member_zpPqo5AaJ5a4">90,000</span> shares with a fair market value of $<span id="xdx_900_ecustom--StockOptionsExercisePriceInDollarsPerShare_pid_c20210330__20210402__srt--TitleOfIndividualAxis__custom--AuditCommitteeMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2021Member_zYmbcdY4y5hj">0.17</span>/share to three members of the Audit Committee as compensation for their contribution in the Audit Committee, for a total of $<span id="xdx_90A_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_c20210330__20210402__srt--TitleOfIndividualAxis__custom--AuditCommitteeMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2021Member_zRklpEq9rnA8">15,300</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 22, 2021 the Company granted <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210420__20210422__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2021Member_zcYKVna0lQ31">150,000</span> shares with a fair market value of $<span id="xdx_90F_ecustom--StockOptionsExercisePriceInDollarsPerShare_pid_c20210420__20210422__srt--TitleOfIndividualAxis__custom--ConsultantOneMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2021Member_zTj6e9PO2csi">0.17</span>/share at the time of award, to a consultant for assistance with the Companies PR work, for a total of $<span id="xdx_902_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_c20210420__20210422__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2021Member_zlPPwqx7VXW4">25,500</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 15, 2021 the Company granted <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210614__20210615__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2021Member_zQrExrT3ert2">450,000</span> shares with a fair market value of $<span id="xdx_905_ecustom--StockOptionsExercisePriceInDollarsPerShare_c20210614__20210615__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2021Member_zORozZ6Mh5Ka">0.001</span>/share at the time of award, to a consultant for assistance with the Companies PR work, for a total of $450.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 1, 2021 the Company granted <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210629__20210702__srt--TitleOfIndividualAxis__custom--ConsultantThreeMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2021Member_z2zmNnMPPwea">10,000</span> shares to a Medical Advisory Board Member for her contribution to the Company during the second quarter of 2021. The total fair market value at the time of the award was $10, or $<span id="xdx_90E_ecustom--StockOptionsExercisePriceInDollarsPerShare_c20210628__20210702__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2021Member_ztcSQLP6xRRl">0.001</span>/share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 1, 2021 the Company granted <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210629__20210702__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2021Member_zyTjoJEaeIjg">90,000</span> shares to three Board Members in reward of their attendance at Board and Committee meetings during the second quarter of 2021. The total fair market value at the time of the award was $90, or $<span id="xdx_907_ecustom--StockOptionsExercisePriceInDollarsPerShare_pid_c20210420__20210422__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2021Member_zOToItZ0KKR8">0.001</span>/share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 2, 2021 the Company granted <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210728__20210802__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2021Member_zgNfF54SuwB2">699,000</span> shares to our Investment Banker as per outlined in the PPM for a total value of $699, or $0.001/share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 1, 2021 the Company granted <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210925__20211001__srt--TitleOfIndividualAxis__custom--FourMembersOfTheCompanyBoardMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2021Member_zxDj2ouYp4re">170,000</span> shares to four Board members in reward of their attendance at Board and Committee meetings during the third quarter of 2021. The total fair market value at the time of the award was $<span id="xdx_903_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_c20210925__20211001__srt--TitleOfIndividualAxis__custom--FourMembersOfTheCompanyBoardMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_z8fhDZg4EESg">170</span>, or $<span id="xdx_904_ecustom--StockOptionsExercisePriceInDollarsPerShare_pid_c20210925__20211001__srt--TitleOfIndividualAxis__custom--FourMembersOfTheCompanyBoardMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2021Member_zJpeULfDtOo7">0.001</span>/share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 20, 2021 the Company granted <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20211110__20211120__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2021Member_zD4WI9GgDhri">3,597,529</span> shares to an affiliate for their development and regulatory work with the Company’s first indication. The total fair market value at the time of the award was $<span id="xdx_901_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_c20210925__20211001__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_zNPOksvtieH5">7,594</span>, or 0.0021/share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_89E_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zMq14qlfaMF" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 3, 2021 the Company granted <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20211201__20211203__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2021Member_z1KqiHHYkq8f">322,580</span> shares to an affiliate as compensation for Management Fee and Legal Expenses for a total value of $<span id="xdx_906_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_c20211201__20211203__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_znUyb5SxvYJg">95,000</span>, or 0.2945/share as per written agreement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of Shares</b></span></td> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair Value per Share</b></span></td> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average Market Value per Share</b></span></td> <td style="text-align: center"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; width: 59%; padding-left: 12pt; text-align: justify; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares Granted as at December 31, 2020 from the 2010 Plan</span></td> <td style="width: 1%"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 1%"> </td> <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--StockCompensationPlanMember_zw9Ew2MdPm79" style="border-bottom: black 1pt solid; vertical-align: bottom; width: 10%; text-align: right" title="Shares Granted as at December 31, 2020 from the 2010 Plan"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,002,000</span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="width: 1%"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_ecustom--FairValuePerShareBeginingBalance_iI_pid_uUSDPShares_c20201231__us-gaap--AwardTypeAxis__us-gaap--StockCompensationPlanMember__srt--RangeAxis__srt--MinimumMember_zDZSfqynz602" title="Fair value per share">0.003</span> - <span id="xdx_904_ecustom--FairValuePerShareBeginingBalance_iI_pid_uUSDPShares_c20201231__us-gaap--AwardTypeAxis__us-gaap--StockCompensationPlanMember__srt--RangeAxis__srt--MaximumMember_zn9tqwxLzLCb" title="Fair value per share">1.49</span></span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="width: 1%"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--StockCompensationPlanMember_z37BDBksemVl" style="border-bottom: black 1pt solid; vertical-align: bottom; width: 12%; text-align: right" title="Weighted Average Market Value per Share, Begining"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.10</span></td> <td style="vertical-align: bottom; width: 1%"> </td></tr> <tr> <td style="vertical-align: bottom; padding-left: 12pt; text-align: justify; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares Granted in 2021 from the 2010 Plan</span></td> <td> </td> <td style="vertical-align: bottom"> </td> <td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants_pid_uShares_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--StockCompensationPlanMember_za0ZVdwYhZLb" style="vertical-align: bottom; text-align: right" title="Shares Granted in 2021 from the 2010 Plan"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,199,200</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_ecustom--FairValuePerShareSharesGranted_pid_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockCompensationPlanMember_zPmrQLoRrsWk" title="Fair value per share">0.24</span></span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="vertical-align: bottom"> </td> <td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_pid_uUSDPShares_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--StockCompensationPlanMember_zKaQyWZcsQhh" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.24</span></td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; padding-left: 12pt; text-align: justify; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares Granted as at December 31, 2021 from the 2021 Plan</span></td> <td> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"> </td> <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockCompensationPlanMember_zuBv08jzewI1" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Shares Granted as at December 31, 2021 from the 2021 Plan"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,505,709</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_ecustom--FairValuePerShareEndingBalance_iI_pid_uUSDPShares_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockCompensationPlanMember__srt--RangeAxis__srt--MinimumMember_z0hM3H76f48f">0.001</span> – <span id="xdx_904_ecustom--FairValuePerShareEndingBalance_iI_pid_uUSDPShares_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockCompensationPlanMember__srt--RangeAxis__srt--MaximumMember_zai4o8HKOKjk">0.29</span></span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockCompensationPlanMember_zt9mhljFnM8l" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Weighted Average Market Value per Share, Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.07</span></td> <td style="vertical-align: bottom"> </td></tr> </table> <p id="xdx_8A7_zZtFw5fejd53" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended December 31, 2021, the Company recorded stock-based compensation expense of $<span id="xdx_90C_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20210101__20211231__us-gaap--AwardTypeAxis__custom--ShareBasedPaymentAwardsMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2021Member_zdFLewjch124">557,422</span> in connection with share-based payment awards. For the year ended December 31, 2020, the Company recorded stock-based compensation expense of $<span id="xdx_90A_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20200101__20201231__us-gaap--AwardTypeAxis__custom--ShareBasedPaymentAwardsMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2021Member_zEaOdOSHddKf">228,407</span> in connection with share-based payment awards.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Stock options granted and vested 2010 Plan:</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 1, 2020 the Company granted <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20191230__20200102__srt--TitleOfIndividualAxis__custom--MedicalAdvisoryBoardMembersMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_zkyCcrRPGn2g">3,000</span> three-year vested options at an exercise price of $<span id="xdx_909_ecustom--StockOptionsExercisePriceInDollarsPerShare_c20191230__20200102__srt--TitleOfIndividualAxis__custom--MedicalAdvisoryBoardMembersMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_zgdBu069W0x8">0.31</span> to a Medical Advisory Board Member for his contribution in the Company’s Advisory Board. The options total fair value at the time of award was $<span id="xdx_903_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_c20191230__20200102__srt--TitleOfIndividualAxis__custom--MedicalAdvisoryBoardMembersMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_z4ptLCfhnmM5">603</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 1, 2020 the Company granted 45,000 three-year vested options at an exercise price of $<span id="xdx_90B_ecustom--StockOptionsExercisePriceInDollarsPerShare_c20200129__20200202__srt--TitleOfIndividualAxis__custom--MedicalAdvisoryBoardMembersMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_zvsq42cVGQCe">0.15</span> to a Medical Advisory Board Member for his contribution in the Company’s Advisory Board. The options total fair value at the time of award was $<span id="xdx_90D_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_c20200129__20200202__srt--TitleOfIndividualAxis__custom--MedicalAdvisoryBoardMembersMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_zgKnSXJoxCU5">4,401</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 1, 2020 the Company granted <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20191230__20200102__srt--TitleOfIndividualAxis__custom--MedicalAdvisoryBoardMembersMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_z4bifNUXHOzf">3,000</span> three-year vested options at an exercise price of $<span id="xdx_903_ecustom--StockOptionsExercisePriceInDollarsPerShare_c20210129__20210201__srt--TitleOfIndividualAxis__custom--MedicalAdvisoryBoardMembersMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2021Member_zD4Qid14aRl7">0.32</span> to a Medical Advisory Board Member for his contribution in the Company’s Advisory Board. The options total fair value at the time of the award was $646.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 1, 2020 the Company granted <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210429__20210501__srt--TitleOfIndividualAxis__custom--MedicalAdvisoryBoardMembersMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2021Member_zvdahyWEIbv3">45,000</span> three-year vested options at an exercise price of $<span id="xdx_903_ecustom--StockOptionsExercisePriceInDollarsPerShare_c20210429__20210501__srt--TitleOfIndividualAxis__custom--MedicalAdvisoryBoardMembersMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2021Member_zrYPkB9TSKdi">0.001</span> to a Medical Advisory Board Member for his contribution in the Company’s Advisory Board. The options total fair value at the time of the award was $<span id="xdx_903_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_c20210429__20210501__srt--TitleOfIndividualAxis__custom--MedicalAdvisoryBoardMembersMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2021Member_zWepbUs614F3">45</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 1, 2020 the Company granted <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210629__20210701__srt--TitleOfIndividualAxis__custom--MedicalAdvisoryBoardMembersMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2021Member_zefnncnN2Fvk">3,000</span> three-year vested options at an exercise price of $<span id="xdx_907_ecustom--StockOptionsExercisePriceInDollarsPerShare_c20200628__20200701__srt--TitleOfIndividualAxis__custom--MedicalAdvisoryBoardMembersMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_zTAOhhVr42th">0.18</span>/share to a Medical Advisory Board Member for his contribution in the Company’s Advisory Board. The options total fair value at the time of the award was $<span id="xdx_902_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_c20200629__20200701__srt--TitleOfIndividualAxis__custom--MedicalAdvisoryBoardMembersMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_zuWc25ExvTZ2">538</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 1, 2020 the Company granted <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210729__20210801__srt--TitleOfIndividualAxis__custom--MedicalAdvisoryBoardMembersMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2021Member_ziNueyalDBh3">45,000</span> three-year vested options at an exercise price of $<span id="xdx_900_ecustom--StockOptionsExercisePriceInDollarsPerShare_c20200729__20200801__srt--TitleOfIndividualAxis__custom--MedicalAdvisoryBoardMembersMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_zaHmj68IdZM3">0.14</span>/share to a Medical Advisory Board Member for his contribution in the Company’s Advisory Board. The options total fair value at the time of the award was $<span id="xdx_903_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_c20210728__20210801__srt--TitleOfIndividualAxis__custom--MedicalAdvisoryBoardMembersMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_zTzn2vdd6y96">6,300</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 1, 2020 the Company granted <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210929__20211001__srt--TitleOfIndividualAxis__custom--MedicalAdvisoryBoardMembersMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2021Member_za6XRkonxXbf">3,000</span> three-year vested options at an exercise price of $<span id="xdx_907_ecustom--StockOptionsExercisePriceInDollarsPerShare_c20200929__20201001__srt--TitleOfIndividualAxis__custom--MedicalAdvisoryBoardMembersMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_z2d7X9DajZi8">0.05</span>/share to a Medical Advisory Board Member for his contribution in the Company’s Advisory Board. The options total fair value at the time of the award was $<span id="xdx_90B_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_c20210928__20211001__srt--TitleOfIndividualAxis__custom--MedicalAdvisoryBoardMembersMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_z2EI9eTHSZDe">135</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 1, 2020 the Company granted <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20211029__20211101__srt--TitleOfIndividualAxis__custom--MedicalAdvisoryBoardMembersMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2021Member_zVS5BwCOIloa">45,000</span> three-year vested options at an exercise price of $<span id="xdx_906_ecustom--StockOptionsExercisePriceInDollarsPerShare_c20201029__20201101__srt--TitleOfIndividualAxis__custom--MedicalAdvisoryBoardMembersMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_zCltu8gsMpy">0.18</span>/share to a Medical Advisory Board Member for his contribution in the Company’s Advisory Board. The options total fair value at the time of the award was $<span id="xdx_90A_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_c20211028__20211101__srt--TitleOfIndividualAxis__custom--MedicalAdvisoryBoardMembersMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_zQzIDTlbmc5j">5,792</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Stock options granted and vested 2021 Plan:</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 1, 2021 the Company granted <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210429__20210501__srt--TitleOfIndividualAxis__custom--MedicalAdvisoryBoardMembersMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2021Member_zkSE4EuhZyt2">45,000</span> three-year options immediately vested at an exercise price of $<span id="xdx_909_ecustom--StockOptionsExercisePriceInDollarsPerShare_c20210128__20210201__srt--TitleOfIndividualAxis__custom--MedicalAdvisoryBoardMembersMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_zn0vrn6MLUf5">0.20</span> to an Advisory Board Member for his contribution in the Company’s Advisory Board. The options total fair value at the time of award was $6,750.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 1, 2021 the Company granted <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210429__20210501__srt--TitleOfIndividualAxis__custom--MedicalAdvisoryBoardMembersMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2021Member_zn0diaQRjlh5">45,000</span> three-year options immediately vested at an exercise price of $<span id="xdx_90A_ecustom--StockOptionsExercisePriceInDollarsPerShare_c20210428__20210501__srt--TitleOfIndividualAxis__custom--MedicalAdvisoryBoardMembersMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_zvjpt1QNxdhk">0.19</span> to a Medical Advisory Board Member for his contribution in the Company’s Advisory Board. The options total fair value at the time of award was $7,650.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 1, 2021 the Company granted <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210429__20210501__srt--TitleOfIndividualAxis__custom--MedicalAdvisoryBoardMembersMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2021Member_zMM9ficCL8P5">45,000</span> 3-year options immediately vested at an exercise price of $<span id="xdx_904_ecustom--StockOptionsExercisePriceInDollarsPerShare_c20210728__20210801__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2021Member_zgNcNazHTBWk">0.001</span> to a Medical Advisory Board Member for his contribution in the Company’s Advisory Board. The options total fair value at the time of award was $<span id="xdx_909_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_c20210729__20210801__srt--TitleOfIndividualAxis__custom--MedicalAdvisoryBoardMembersMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_zwWHEOKUSmBa">45</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_89F_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zGeVLSdiAYYh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BB_zRsSFASFUgX">The fair value of stock options granted and revaluation of non-employee consultant options for the year ended December 31, 2021 and 2020 was calculated with the following assumptions:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></td> <td style="text-align: center"> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020</b></span></td> <td style="text-align: center"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; padding-left: 12pt; text-indent: -12pt; width: 74%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rate</span></td> <td style="width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_dp_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_zfyHmhtF3VJ1" title="Risk-free interest rate">0.16</span> - <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_dp_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_z05vBNSfIzx7">1.00</span></span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td style="width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_dp_c20200101__20201231__srt--RangeAxis__srt--MinimumMember_zWFujTUPiTAj">0.10</span> - <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_dp_c20200101__20201231__srt--RangeAxis__srt--MaximumMember_zN8CA9x0D5U7">1.61</span></span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr> <td style="vertical-align: bottom; padding-left: 12pt; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected dividend yield</span></td> <td> </td> <td style="vertical-align: bottom"> </td> <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20210101__20211231_zNt76S6GEo87" style="vertical-align: bottom; text-align: right" title="Expected dividend yield"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td> </td> <td style="vertical-align: bottom"> </td> <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20200101__20201231_zrXqctwaBow3" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; padding-left: 12pt; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Volatility factor (monthly)</span></td> <td> </td> <td style="vertical-align: bottom"> </td> <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20210101__20211231_ztVeegKwo1W9" style="vertical-align: bottom; text-align: right" title="Volatility factor (monthly)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">175.34</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td> </td> <td style="vertical-align: bottom"> </td> <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20200101__20201231_zkrc2uNAy41j" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">158.22</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr> <td style="vertical-align: bottom; padding-left: 12pt; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected life of option</span></td> <td> </td> <td style="vertical-align: bottom"> </td> <td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20210101__20211231_zSFHqSL6Jhxd" style="vertical-align: bottom; text-align: right" title="Expected life of option::XDX::P3Y"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1024">3 years</span></span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="vertical-align: bottom"> </td> <td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20200101__20201231_zEeBuWrFOMg8" style="vertical-align: bottom; text-align: right" title="::XDX::P3Y"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1025">3 years</span></span></td> <td style="vertical-align: bottom"> </td></tr> </table> <p id="xdx_8A1_zGK02Z5Da3t" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended December 31, 2021, the Company recorded compensation expense of $18,460 in connection with awarded stock options. The Company recorded $257,143 in awarded option valuation as compensation expense during 2020. As at December 31, 2021, there was no unrecognized compensation expense related to non-vested stock option awards.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zXLnMB6f5Iyk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BD_zKNH10yn5ppf">The following table summarizes the Company’s stock option activity during the year ended at December 31, 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of Shares</b></span></td> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price per Share</b></span></td> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average Exercise Price per Share</b></span></td> <td style="text-align: center"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; width: 59%; padding-left: 12pt; text-align: justify; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding as at December 31, 2020</span></td> <td style="width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zON5Y0VUV2lg" style="vertical-align: bottom; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">533,000</span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="vertical-align: bottom; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePricePerShare_iS_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zVJfYrG0SRqh" title="Begnning">0.001</span> - <span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePricePerShare_iS_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zIx54AV37W63">1.21</span></span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEXhFNfJ00O2" style="vertical-align: bottom; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.73</span></td> <td style="vertical-align: bottom; width: 1%"> </td></tr> <tr> <td style="vertical-align: bottom; padding-left: 12pt; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td> <td> </td> <td style="vertical-align: bottom"> </td> <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zuDbtU7fAQkb" style="vertical-align: bottom; text-align: right" title="Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">135,000</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedExercisePricePerShare_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zLR3UlgTzAu4">0.001</span> - <span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedExercisePricePerShare_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zLfrva1FQzOb">0.32</span></span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="vertical-align: bottom"> </td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zGHbN1liotA2" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.13</span></td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; padding-left: 12pt; text-align: justify; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td> <td> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: bottom; padding-left: 12pt; text-align: justify; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options forfeited/cancelled</span></td> <td> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; padding-left: 12pt; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding as at December 31, 2021</span></td> <td> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"> </td> <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1IS4wMC6Yua" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">668,000</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePricePerShare_iE_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_z7R6qUmrcJRk" title="Ending">0.001</span> - <span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePricePerShare_iE_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zFqivYHIh5p">1.21</span></span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zU2PXn642JS9" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.55</span></td> <td style="vertical-align: bottom"> </td></tr> </table> <p id="xdx_8A3_zwJGIKukZ3Rb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_zJWcaHAHh7Pa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BC_zrEghw2kzUo6">The following table summarizes information about stock options that are vested or expected to vest at December 31, 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 98%; margin-right: auto"> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercisable Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price Per Share</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (Years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price Per Share</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (Years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">0.001</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenOneMember_zXtutIjZ9lX1" style="width: 8%; text-align: right">90,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenOneMember_zH7mdmplazPc" style="width: 8%; text-align: right">0.001</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenOneMember_zBwmKuGBRbDl" style="width: 9%; text-align: right" title="::XDX::P1Y11M12D"><span style="-sec-ix-hidden: xdx2ixbrl1047">1.95</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenOneMember_zCOa7Td2jpNb" style="width: 7%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenOneMember_zh0GyYlNdQgg" style="width: 7%; text-align: right">90,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenOneMember_z0rQbMMqRFDg" style="width: 9%; text-align: right">0.001</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenOneMember_zuB6zuXcEQN2" style="width: 9%; text-align: right" title="::XDX::P1Y11M12D"><span style="-sec-ix-hidden: xdx2ixbrl1051">1.95</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenOneMember_zFq7aAtHywq3" style="width: 7%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: right">0.05</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenTwoMember_z7whezK3qWF2" style="text-align: right">3,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenTwoMember_zD3D5F6AiXgk" style="text-align: right">0.05</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenTwoMember_zqOd3OffJ8e3" style="text-align: right" title="::XDX::P1Y9M"><span style="-sec-ix-hidden: xdx2ixbrl1055">1.75</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenTwoMember_zRzFfXa41104" style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenTwoMember_zfo75dxJfD37" style="text-align: right">3,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenTwoMember_zfi241PAjeHj" style="text-align: right">0.05</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenTwoMember_z0lA8T42pplc" style="text-align: right" title="::XDX::P1Y9M"><span style="-sec-ix-hidden: xdx2ixbrl1059">1.75</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenOneMember_zvVqNZtbbVNj" style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td style="text-align: right">0.15</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenThreeMember_z9AUJZ4NqKRi" style="text-align: right">90,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenThreeMember_zsVakN8bD0w9" style="text-align: right">0.15</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenThreeMember_zVIyK8BTqL4d" style="text-align: right" title="::XDX::P1Y3M29D"><span style="-sec-ix-hidden: xdx2ixbrl1063">1.33</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenFourMember_zCK9N8evgJbc" style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenThreeMember_zfekLd5OtKV1" style="text-align: right">90,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenThreeMember_z2Rc5Rld3NKd" style="text-align: right">0.15</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenThreeMember_zN2VZL33iY2d" style="text-align: right" title="::XDX::P1Y3M29D"><span style="-sec-ix-hidden: xdx2ixbrl1067">1.33</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenOneMember_zyfBg3tZv2gk" style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: right">0.18</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenFourMember_zynScg8Im8Xf" style="text-align: right">45,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenFourMember_zqxgoTuo0Euj" style="text-align: right">0.18</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenFourMember_z7lTLdzUcGzc" style="text-align: right" title="::XDX::P1Y9M29D"><span style="-sec-ix-hidden: xdx2ixbrl1071">1.83</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenFourMember_zPFUhUlaCg5d" style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenFourMember_zTJDm2ZpOjj8" style="text-align: right">45,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenFourMember_zCQ30Ac27Hqi" style="text-align: right">0.18</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenFourMember_zlRwv3hkt6Qi" style="text-align: right" title="::XDX::P1Y9M29D"><span style="-sec-ix-hidden: xdx2ixbrl1075">1.83</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenOneMember_zshojhRLh3ab" style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td style="text-align: right">0.19</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zjUUD7Ba6RMi" style="text-align: right">45,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zC6o1a40mFEk" style="text-align: right">0.19</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zSFa9aiGlVSi" style="text-align: right" title="::XDX::P2Y3M29D"><span style="-sec-ix-hidden: xdx2ixbrl1079">2.33</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zIBlMNtZTJR6" style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenFiveMember_zGEM3ACuiU" style="text-align: right">45,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenFiveMember_zsnq1xRJawTl" style="text-align: right">0.19</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenFiveMember_zsBRmjNca0w5" style="text-align: right" title="::XDX::P2Y3M29D"><span style="-sec-ix-hidden: xdx2ixbrl1083">2.33</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenOneMember_zOxsPirjFhh" style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: right">0.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_z84czKFnzh5b" style="text-align: right">48,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zZAOxy2Qbh1a" style="text-align: right">0.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zx0r2zS43y41" style="text-align: right" title="::XDX::P2Y0M15D"><span style="-sec-ix-hidden: xdx2ixbrl1087">2.04</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zQgd08E4XWv5" style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenSixMember_z8XJIqeBKno3" style="text-align: right">48,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenSixMember_zuN7ZSHbAPpe" style="text-align: right">0.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenSixMember_zKdpMNwU0Ezh" style="text-align: right" title="::XDX::P2Y0M15D"><span style="-sec-ix-hidden: xdx2ixbrl1091">2.04</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenOneMember_zLGbwdx31GA7" style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td style="text-align: right">0.31</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zxcVvBbHgwul" style="text-align: right">3,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_z66omJrqXp4f" style="text-align: right">0.31</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zVTr6kZWoWjj" style="text-align: right" title="::XDX::P1Y"><span style="-sec-ix-hidden: xdx2ixbrl1095">1.00</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zhBknOEVXtsk" style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenSevenMember_zi1yWUkkBFi9" style="text-align: right">3,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenSevenMember_zkK26jQTtvJ4" style="text-align: right">0.31</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenSevenMember_z31GuwffEW6f" style="text-align: right" title="::XDX::P1Y"><span style="-sec-ix-hidden: xdx2ixbrl1099">1.00</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenOneMember_zoDWWFrT0hv" style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: right">0.32</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightOneMember_zEQKZpx7kipg" style="text-align: right">3,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightOneMember_z9w5m5eYf06c" style="text-align: right">0.32</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightOneMember_zU94H5ihBK84" style="text-align: right" title="::XDX::P1Y2M30D"><span style="-sec-ix-hidden: xdx2ixbrl1103">1.25</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zwpuRPUQzfia" style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenEightMember_zuq9IxNh3adh" style="text-align: right">3,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenEightMember_zOtmegXXiadk" style="text-align: right">0.32</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenEightMember_zJOizdmW8ma4" style="text-align: right" title="::XDX::P1Y2M30D"><span style="-sec-ix-hidden: xdx2ixbrl1107">1.25</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenOneMember_za7fxLkuciv1" style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td style="text-align: right">0.73</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zXajyWMYrX05" style="text-align: right">3,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_z9NA9KH6gCJ7" style="text-align: right">0.73</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zBDVypngeNYe" style="text-align: right" title="::XDX::P9M29D"><span style="-sec-ix-hidden: xdx2ixbrl1111">0.83</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zmZFe9JTeTu3" style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenNineMember_zmbAGBxix807" style="text-align: right">3,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenNineMember_z2NQsIoD8Vk2" style="text-align: right">0.73</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenNineMember_zdZstXLxfs0i" style="text-align: right" title="::XDX::P9M29D"><span style="-sec-ix-hidden: xdx2ixbrl1115">0.83</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenOneMember_z7weSfRDRIik" style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: right">0.61</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zrrHzJCvx0i6" style="text-align: right">45,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_z8lK5wW5Tube" style="text-align: right">0.61</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zNK9VvepBaGl" style="text-align: right" title="::XDX::P9M"><span style="-sec-ix-hidden: xdx2ixbrl1119">0.75</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zJUXN5a9WObg" style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenTenMember_zdrTJ71zOgae" style="text-align: right">45,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenTenMember_zxU25jNm7jX7" style="text-align: right">0.61</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenTenMember_z2WhDPx7Yx3e" style="text-align: right" title="::XDX::P9M"><span style="-sec-ix-hidden: xdx2ixbrl1123">0.75</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenOneMember_zJZYrhbFZa9j" style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td style="text-align: right">0.95</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_z9kSIREFOT4c" style="text-align: right">200,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zewchUCYZwU6" style="text-align: right">0.95</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zXjQnSJNAORd" style="text-align: right" title="::XDX::P8M12D"><span style="-sec-ix-hidden: xdx2ixbrl1127">0.70</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_ze9Weza9q1jf" style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenElevenMember_znw5ZvGslOre" style="text-align: right">200,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenElevenMember_zy7p8LIHqfv5" style="text-align: right">0.95</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenElevenMember_zByHVBxgwkAg" style="text-align: right" title="::XDX::P8M12D"><span style="-sec-ix-hidden: xdx2ixbrl1131">0.70</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenOneMember_z1BPrmebkvs" style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: right">1.09</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_z3l5dGwGk5z8" style="text-align: right">3,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_z6YqH3WlRX1j" style="text-align: right">1.09</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_z7O3eX7u6aDd" style="text-align: right" title="::XDX::P6M"><span style="-sec-ix-hidden: xdx2ixbrl1135">0.50</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_z9SxVcfPMXDe" style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenTwelveMember_zMIoLyePK7O4" style="text-align: right">3,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenTwelveMember_zn96gHTmreq7" style="text-align: right">1.09</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenTwelveMember_z3FA3plurbih" style="text-align: right" title="::XDX::P6M"><span style="-sec-ix-hidden: xdx2ixbrl1139">0.50</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenOneMember_zvfcK5zrEfHl" style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td style="text-align: right">1.10</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zwZ4VnomSWMi" style="text-align: right">45,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zEgn8WmuNVPd" style="text-align: right">1.10</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zzFfTef3lFr1" style="text-align: right" title="::XDX::P6M29D"><span style="-sec-ix-hidden: xdx2ixbrl1143">0.58</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_z9Eva31tn479" style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenThirteenMember_zxzt49upgGk5" style="text-align: right">45,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenThirteenMember_zJxYatHU08re" style="text-align: right">1.10</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenThirteenMember_zUK2tz5YR0rf" style="text-align: right" title="::XDX::P6M29D"><span style="-sec-ix-hidden: xdx2ixbrl1147">0.58</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenOneMember_zTyWjDEKTeTa" style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1.21</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zgcecsjNg8Yc" style="border-bottom: Black 1pt solid; text-align: right">45,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_ze4w6QVmXcYk" style="border-bottom: Black 1pt solid; text-align: right">1.21</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zzQGK9GfkSwh" style="border-bottom: Black 1pt solid; text-align: right" title="::XDX::P3M29D"><span style="-sec-ix-hidden: xdx2ixbrl1151">0.33</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zubayqhwsDvj" style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenFourteenMember_zpbpGX1XMtff" style="border-bottom: Black 1pt solid; text-align: right">45,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenFourteenMember_zhZvAUNIanN6" style="border-bottom: Black 1pt solid; text-align: right">1.21</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenFourteenMember_z3mpxinhu7m2" style="border-bottom: Black 1pt solid; text-align: right" title="::XDX::P3M29D"><span style="-sec-ix-hidden: xdx2ixbrl1155">0.33</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenOneMember_zhrEfsBZnm6d" style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_z70hVH8gtL0k">0.001</span>-<span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_z9EClhtnfWL5">1.21</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231_zpp7p8EX8Eo6" style="border-bottom: Black 2.5pt double; text-align: right">668,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20211231_z3glMcQs2Hm3" style="border-bottom: Black 2.5pt double; text-align: right">0.55</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dxL_c20210101__20211231_zzNeA1Cpcew8" style="border-bottom: Black 2.5pt double; text-align: right" title="::XDX::P1Y2M19D"><span style="-sec-ix-hidden: xdx2ixbrl1161">1.22</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zuPOSsnnKcK9" style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20211231_zlKdwCkBgsf5" style="border-bottom: Black 2.5pt double; text-align: right">668,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20211231_z0q7KkClOne8" style="border-bottom: Black 2.5pt double; text-align: right">0.55</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20211231_zFizMEoyVTh4" style="border-bottom: Black 2.5pt double; text-align: right" title="::XDX::P1Y2M19D"><span style="-sec-ix-hidden: xdx2ixbrl1165">1.22</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenOneMember_z2kGwBRPAGw4" style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A4_z8b0xrMWeWyd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_892_eus-gaap--ScheduleOfNonvestedShareActivityTableTextBlock_z3eBdlBwl3l8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BE_zqla8aFYf6L6">The following table sets forth the status of the Company’s non-vested stock options as at December 31, 2021 and December 31, 2020:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 98%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted- Average Grant-Date Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-vested as at December 31, 2020</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_d0_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrbDu0A3UJeg" style="text-align: right" title="Balance at beginning,Number of Options">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_d0_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zr03xC3Vmg32" style="text-align: right" title="Balance at beginning,Weighted- Average Grant-Date Fair Value">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 69%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNkONWGJPTp" style="width: 12%; text-align: right" title="Granted">135,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zsDIxhTexqu" style="width: 12%; text-align: right" title="Granted">0.13</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_pid_d0_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zy4Vdyy6nH1e" style="text-align: right" title="Forfeited">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zJ1DLipYB7H7" style="text-align: right" title="Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1180">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vested</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrKd820imSx3" style="border-bottom: Black 1pt solid; text-align: right" title="Vested">(135,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1cyzZfpvsr2" style="border-bottom: Black 1pt solid; text-align: right" title="Vested">0.13</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-vested as at December 31, 2021</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_d0_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zv3Xp9UiPIj9" style="border-bottom: Black 1pt solid; text-align: right" title="Balance at ending,Number of Options">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_d0_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zXjWkbez3eT9" style="border-bottom: Black 1pt solid; text-align: right" title="Balance at ending,Weighted- Average Grant-Date Fair Value">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> <p id="xdx_8A2_zsYbORDOfH0d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The weighted-average remaining contractual life for options exercisable at December 31, 2021 is 1.22 years.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate intrinsic value for fully vested, exercisable options was $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_c20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_zfGA3L8mTJce">0</span> at December 31, 2021. The aggregate intrinsic value of options exercised for the year ended at December 31, 2020 was $<span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_zuVdi6NH11Od">0</span>. The actual tax benefit realized from stock option exercises for the year ended at December 31, 2021 and 2020 was $0 as no options were exercised.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At December 31, 2021 the Company has <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_zJsmQRkJySnb">34,181,909 </span>options or stock awards available for grant under the 2021 Plan.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Issuance of Options in Subsidiary</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended December 31, 2021 the Subsidiary also issued <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210101__20211231__srt--TitleOfIndividualAxis__custom--ThreeMembersOfTheCompanyBoardMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2017Member_zj8reNkTEYn7">4,500,000</span> stock options to an affiliate (beneficially owned by Michael Sheikh, Ola Soderquist and David Platt) under its 2017 Stock Plan. There was <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_do_c20200101__20201231__srt--TitleOfIndividualAxis__custom--ThreeMembersOfTheCompanyBoardMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2017Member_zW0L8l2Kla9h">no</span> such issuance at the year ended December 31, 2020. The option agreement includes provisions for dilutive issuance and cash-less exercise.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At December 31, 2021 the Company has no additional options or stock awards available for grant under the subsidiary’s 2017 Plan.</p>
</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
<bixt:StockAwardsStockAppreciationRightsPercentage contextRef="From2021-01-012021-12-31_custom_StockPlan2010Member" decimals="INF" unitRef="Pure"> 0.15 </bixt:StockAwardsStockAppreciationRightsPercentage>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2021-12-31_us-gaap_StockOptionMember" decimals="INF" unitRef="Shares"> 668000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2021-01-01to2021-12-31" decimals="0" unitRef="USD"> 367400 </us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
<us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2021-01-012021-12-31_custom_StockPlan2010Member" decimals="INF" unitRef="Shares"> 1669000 </us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2021-01-012021-12-31_custom_StockPlan2010Member" decimals="0" unitRef="USD"> 43919 </us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2020-12-31_us-gaap_StockOptionMember" decimals="INF" unitRef="Shares"> 533000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2021-01-012021-12-31_custom_StockPlan2010Member" decimals="0" unitRef="USD"> 275603 </us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
<us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2020-01-012020-12-31_custom_StockPlan2010Member" decimals="INF" unitRef="Shares"> 11002000 </us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2020-01-012020-12-31_custom_StockPlan2010Member" decimals="0" unitRef="USD"> 1075358 </us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2019-12-302020-01-02_custom_ConsultantMember_custom_StockPlan2010Member" decimals="INF" unitRef="Shares"> 250000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2019-12-302020-01-02_custom_ConsultantMember_custom_StockPlan2010Member" decimals="INF" unitRef="USDPShares"> 0.285 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2019-12-302020-01-02_custom_ConsultantMember_custom_StockPlan2010Member" decimals="0" unitRef="USD"> 71250 </us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2020-01-012020-01-31_custom_SubcontractorsMember_custom_StockPlan2010Member" decimals="INF" unitRef="Shares"> 200000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2020-01-012020-01-31_custom_SubcontractorsMember_custom_StockPlan2010Member" decimals="INF" unitRef="USDPShares"> 0.14 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2020-01-012020-01-31_custom_SubcontractorsMember_custom_StockPlan2010Member" decimals="0" unitRef="USD"> 28000 </us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2020-02-012020-02-21_custom_ThreeMemberOfTheAuditCommitteeMember_custom_StockPlan2010Member" decimals="INF" unitRef="Shares"> 3000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2020-02-012020-02-21_custom_ThreeMemberOfTheAuditCommitteeMember_custom_StockPlan2010Member" decimals="INF" unitRef="USDPShares"> 0.439 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2020-02-012020-02-21_custom_ThreeMemberOfTheAuditCommitteeMember_custom_StockPlan2010Member" decimals="0" unitRef="USD"> 1317 </us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2020-03-012020-03-18_custom_ConsultantMember_custom_StockPlan2010Member" decimals="INF" unitRef="Shares"> 200000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2020-03-012020-03-18_custom_ConsultantMember_custom_StockPlan2010Member" decimals="INF" unitRef="USDPShares"> 0.245 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2020-03-012020-03-18_custom_ConsultantMember_custom_StockPlan2010Member" decimals="0" unitRef="USD"> 49000 </us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2020-03-012020-03-25_custom_ThreeMembersOfTheCompanyBoardMember_custom_StockPlan2010Member" decimals="INF" unitRef="Shares"> 3000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2020-03-012020-03-25_custom_ThreeMembersOfTheCompanyBoardMember_custom_StockPlan2010Member" decimals="INF" unitRef="USDPShares"> 0.31 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2020-03-012020-03-25_custom_ThreeMembersOfTheCompanyBoardMember_custom_StockPlan2010Member" decimals="0" unitRef="USD"> 930 </us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2020-04-282020-05-01_custom_MikeSheikhMember_custom_StockPlan2010Member" decimals="INF" unitRef="Shares"> 8800000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2020-04-282020-05-01_custom_MikeSheikhMember_custom_StockPlan2010Member" decimals="INF" unitRef="USDPShares"> 0.003 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2020-04-282020-05-01_custom_MikeSheikhMember_custom_StockPlan2010Member" decimals="0" unitRef="USD"> 26400 </us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2020-06-252020-07-01_custom_ThreeMembersOfTheCompanyBoardMember_custom_StockPlan2010Member" decimals="INF" unitRef="Shares"> 3000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2020-06-252020-07-01_custom_ThreeMembersOfTheCompanyBoardMember_custom_StockPlan2010Member" decimals="INF" unitRef="USDPShares"> 0.19 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2020-06-252020-07-01_custom_ThreeMembersOfTheCompanyBoardMember_custom_StockPlan2010Member" decimals="0" unitRef="USD"> 570 </us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2020-07-302020-08-03_custom_MedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember_custom_StockPlan2010Member" decimals="INF" unitRef="Shares"> 100000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2020-07-282020-08-03_custom_MedicalAdvisoryBoardMembersMember_custom_StockPlan2021Member" decimals="0" unitRef="USD"> 300 </us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2020-09-162020-09-17_custom_ConsultantMember_custom_StockPlan2021Member" decimals="INF" unitRef="Shares"> 50000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2020-09-162020-09-17_custom_ConsultantMember_custom_StockPlan2021Member" decimals="0" unitRef="USD"> 1500 </us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2020-09-252020-10-01_custom_ThreeMembersOfTheCompanyBoardMember_custom_StockPlan2010Member" decimals="INF" unitRef="Shares"> 3000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2020-09-252020-10-01_custom_ThreeMembersOfTheCompanyBoardMember_custom_StockPlan2010Member" decimals="INF" unitRef="USDPShares"> 0.02 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2020-09-252020-10-01_custom_ThreeMembersOfTheCompanyBoardMember_custom_StockPlan2010Member" decimals="0" unitRef="USD"> 60 </us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2020-11-112020-11-13_custom_ThreeMembersOfTheCompanyBoardMember_custom_StockPlan2010Member" decimals="INF" unitRef="Shares"> 63000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2020-11-112020-11-13_custom_ThreeMembersOfTheCompanyBoardMember_custom_StockPlan2010Member" decimals="INF" unitRef="USDPShares"> 0.18 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2020-11-112020-11-13_custom_ThreeMembersOfTheCompanyBoardMember_custom_StockPlan2010Member" decimals="0" unitRef="USD"> 11580 </us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2020-11-112020-11-13_custom_TwoMedicalConsultantsMember_custom_StockPlan2010Member" decimals="INF" unitRef="Shares"> 200000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2020-11-112020-11-13_custom_TwoMedicalConsultantsMember_custom_StockPlan2010Member" decimals="INF" unitRef="USDPShares"> 0.19 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2020-11-112020-11-13_custom_TwoMedicalConsultantsMember_custom_StockPlan2010Member" decimals="0" unitRef="USD"> 37500 </us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2020-12-302021-01-02_custom_MedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember_custom_StockPlan2010Member" decimals="INF" unitRef="Shares"> 10000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<bixt:StockOptionsExercisePriceInDollarsPerShare contextRef="From2020-12-302021-01-02_custom_MedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember_custom_StockPlan2010Member" decimals="INF" unitRef="USDPShares"> 0.24 </bixt:StockOptionsExercisePriceInDollarsPerShare>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2020-12-302021-01-02_custom_MedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember_custom_StockPlan2010Member" decimals="0" unitRef="USD"> 2400 </us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
<bixt:StockOptionsExercisePriceInDollarsPerShare contextRef="From2021-01-142021-01-15_custom_ManagersBoardAndMedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember_custom_StockPlan2010Member" decimals="INF" unitRef="USDPShares"> 0.24 </bixt:StockOptionsExercisePriceInDollarsPerShare>
<bixt:DescriptionOfDividendPay contextRef="From2021-01-142021-01-15_custom_ManagersBoardAndMedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember"> equally divided to 227,800 shares/each </bixt:DescriptionOfDividendPay>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2021-01-142021-01-15_custom_ManagersBoardAndMedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember_custom_StockPlan2010Member" decimals="0" unitRef="USD"> 765408 </us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2021-11-102021-11-20_custom_ManagersBoardAndMedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember_custom_StockPlan2010Member" decimals="0" unitRef="USD"> 260016 </us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
<bixt:StockOptionsExercisePriceInDollarsPerShare contextRef="From2021-11-102021-11-20_custom_ManagersBoardAndMedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember_custom_StockPlan2010Member" decimals="INF" unitRef="USDPShares"> 0.24 </bixt:StockOptionsExercisePriceInDollarsPerShare>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2021-03-302021-04-02_custom_MedicalAdvisoryBoardMembersMember_custom_StockPlan2021Member" decimals="INF" unitRef="Shares"> 10000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<bixt:StockOptionsExercisePriceInDollarsPerShare contextRef="From2021-03-302021-04-02_custom_MedicalAdvisoryBoardMembersMember_custom_StockPlan2021Member" decimals="INF" unitRef="USDPShares"> 0.17 </bixt:StockOptionsExercisePriceInDollarsPerShare>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2021-03-302021-04-02_custom_MedicalAdvisoryBoardMembersMember_custom_StockPlan2021Member" decimals="0" unitRef="USD"> 1700 </us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2021-03-302021-04-02_custom_AuditCommitteeMember_custom_StockPlan2021Member" decimals="INF" unitRef="Shares"> 90000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<bixt:StockOptionsExercisePriceInDollarsPerShare contextRef="From2021-03-302021-04-02_custom_AuditCommitteeMember_custom_StockPlan2021Member" decimals="INF" unitRef="USDPShares"> 0.17 </bixt:StockOptionsExercisePriceInDollarsPerShare>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2021-03-302021-04-02_custom_AuditCommitteeMember_custom_StockPlan2021Member" decimals="0" unitRef="USD"> 15300 </us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2021-04-202021-04-22_custom_ConsultantMember_custom_StockPlan2021Member" decimals="INF" unitRef="Shares"> 150000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<bixt:StockOptionsExercisePriceInDollarsPerShare contextRef="From2021-04-202021-04-22_custom_ConsultantOneMember_custom_StockPlan2021Member" decimals="INF" unitRef="USDPShares"> 0.17 </bixt:StockOptionsExercisePriceInDollarsPerShare>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2021-04-202021-04-22_custom_ConsultantMember_custom_StockPlan2021Member" decimals="0" unitRef="USD"> 25500 </us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2021-06-142021-06-15_custom_ConsultantMember_custom_StockPlan2021Member" decimals="INF" unitRef="Shares"> 450000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<bixt:StockOptionsExercisePriceInDollarsPerShare contextRef="From2021-06-142021-06-15_custom_ConsultantMember_custom_StockPlan2021Member" decimals="INF" unitRef="USDPShares"> 0.001 </bixt:StockOptionsExercisePriceInDollarsPerShare>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2021-06-292021-07-02_custom_ConsultantThreeMember_custom_StockPlan2021Member" decimals="INF" unitRef="Shares"> 10000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<bixt:StockOptionsExercisePriceInDollarsPerShare contextRef="From2021-06-282021-07-02_custom_ConsultantMember_custom_StockPlan2021Member" decimals="INF" unitRef="USDPShares"> 0.001 </bixt:StockOptionsExercisePriceInDollarsPerShare>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2021-06-292021-07-02_custom_ConsultantMember_custom_StockPlan2021Member" decimals="INF" unitRef="Shares"> 90000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<bixt:StockOptionsExercisePriceInDollarsPerShare contextRef="From2021-04-202021-04-22_custom_ConsultantMember_custom_StockPlan2021Member" decimals="INF" unitRef="USDPShares"> 0.001 </bixt:StockOptionsExercisePriceInDollarsPerShare>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2021-07-282021-08-02_custom_ConsultantMember_custom_StockPlan2021Member" decimals="INF" unitRef="Shares"> 699000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2021-09-252021-10-01_custom_FourMembersOfTheCompanyBoardMember_custom_StockPlan2021Member" decimals="INF" unitRef="Shares"> 170000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2021-09-252021-10-01_custom_FourMembersOfTheCompanyBoardMember_custom_StockPlan2010Member" decimals="0" unitRef="USD"> 170 </us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
<bixt:StockOptionsExercisePriceInDollarsPerShare contextRef="From2021-09-252021-10-01_custom_FourMembersOfTheCompanyBoardMember_custom_StockPlan2021Member" decimals="INF" unitRef="USDPShares"> 0.001 </bixt:StockOptionsExercisePriceInDollarsPerShare>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2021-11-102021-11-20_custom_ConsultantMember_custom_StockPlan2021Member" decimals="INF" unitRef="Shares"> 3597529 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2021-09-252021-10-01_custom_ConsultantMember_custom_StockPlan2010Member" decimals="0" unitRef="USD"> 7594 </us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
<us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="From2021-01-01to2021-12-31">
<p id="xdx_89E_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zMq14qlfaMF" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 3, 2021 the Company granted <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20211201__20211203__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2021Member_z1KqiHHYkq8f">322,580</span> shares to an affiliate as compensation for Management Fee and Legal Expenses for a total value of $<span id="xdx_906_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_c20211201__20211203__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_znUyb5SxvYJg">95,000</span>, or 0.2945/share as per written agreement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of Shares</b></span></td> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair Value per Share</b></span></td> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average Market Value per Share</b></span></td> <td style="text-align: center"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; width: 59%; padding-left: 12pt; text-align: justify; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares Granted as at December 31, 2020 from the 2010 Plan</span></td> <td style="width: 1%"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 1%"> </td> <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--StockCompensationPlanMember_zw9Ew2MdPm79" style="border-bottom: black 1pt solid; vertical-align: bottom; width: 10%; text-align: right" title="Shares Granted as at December 31, 2020 from the 2010 Plan"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,002,000</span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="width: 1%"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_ecustom--FairValuePerShareBeginingBalance_iI_pid_uUSDPShares_c20201231__us-gaap--AwardTypeAxis__us-gaap--StockCompensationPlanMember__srt--RangeAxis__srt--MinimumMember_zDZSfqynz602" title="Fair value per share">0.003</span> - <span id="xdx_904_ecustom--FairValuePerShareBeginingBalance_iI_pid_uUSDPShares_c20201231__us-gaap--AwardTypeAxis__us-gaap--StockCompensationPlanMember__srt--RangeAxis__srt--MaximumMember_zn9tqwxLzLCb" title="Fair value per share">1.49</span></span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="width: 1%"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--StockCompensationPlanMember_z37BDBksemVl" style="border-bottom: black 1pt solid; vertical-align: bottom; width: 12%; text-align: right" title="Weighted Average Market Value per Share, Begining"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.10</span></td> <td style="vertical-align: bottom; width: 1%"> </td></tr> <tr> <td style="vertical-align: bottom; padding-left: 12pt; text-align: justify; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares Granted in 2021 from the 2010 Plan</span></td> <td> </td> <td style="vertical-align: bottom"> </td> <td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants_pid_uShares_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--StockCompensationPlanMember_za0ZVdwYhZLb" style="vertical-align: bottom; text-align: right" title="Shares Granted in 2021 from the 2010 Plan"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,199,200</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_ecustom--FairValuePerShareSharesGranted_pid_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockCompensationPlanMember_zPmrQLoRrsWk" title="Fair value per share">0.24</span></span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="vertical-align: bottom"> </td> <td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1_pid_uUSDPShares_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--StockCompensationPlanMember_zKaQyWZcsQhh" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.24</span></td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; padding-left: 12pt; text-align: justify; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares Granted as at December 31, 2021 from the 2021 Plan</span></td> <td> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"> </td> <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockCompensationPlanMember_zuBv08jzewI1" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Shares Granted as at December 31, 2021 from the 2021 Plan"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,505,709</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_ecustom--FairValuePerShareEndingBalance_iI_pid_uUSDPShares_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockCompensationPlanMember__srt--RangeAxis__srt--MinimumMember_z0hM3H76f48f">0.001</span> – <span id="xdx_904_ecustom--FairValuePerShareEndingBalance_iI_pid_uUSDPShares_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockCompensationPlanMember__srt--RangeAxis__srt--MaximumMember_zai4o8HKOKjk">0.29</span></span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockCompensationPlanMember_zt9mhljFnM8l" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Weighted Average Market Value per Share, Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.07</span></td> <td style="vertical-align: bottom"> </td></tr> </table>
</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2020-01-012020-12-31_us-gaap_StockCompensationPlanMember" decimals="INF" unitRef="Shares"> 11002000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<bixt:FairValuePerShareBeginingBalance contextRef="AsOf2020-12-31_us-gaap_StockCompensationPlanMember_srt_MinimumMember" decimals="INF" unitRef="USDPShares"> 0.003 </bixt:FairValuePerShareBeginingBalance>
<bixt:FairValuePerShareBeginingBalance contextRef="AsOf2020-12-31_us-gaap_StockCompensationPlanMember_srt_MaximumMember" decimals="INF" unitRef="USDPShares"> 1.49 </bixt:FairValuePerShareBeginingBalance>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2020-01-012020-12-31_us-gaap_StockCompensationPlanMember" decimals="INF" unitRef="USDPShares"> 0.10 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<bixt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants contextRef="From2020-01-012020-12-31_us-gaap_StockCompensationPlanMember" decimals="INF" unitRef="Shares"> 3199200 </bixt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants>
<bixt:FairValuePerShareSharesGranted contextRef="From2021-01-012021-12-31_us-gaap_StockCompensationPlanMember" decimals="INF" unitRef="USDPShares"> 0.24 </bixt:FairValuePerShareSharesGranted>
<bixt:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1 contextRef="From2020-01-012020-12-31_us-gaap_StockCompensationPlanMember" decimals="INF" unitRef="USDPShares"> 0.24 </bixt:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2021-01-012021-12-31_us-gaap_StockCompensationPlanMember" decimals="INF" unitRef="Shares"> 4505709 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<bixt:FairValuePerShareEndingBalance contextRef="AsOf2021-12-31_us-gaap_StockCompensationPlanMember_srt_MinimumMember" decimals="INF" unitRef="USDPShares"> 0.001 </bixt:FairValuePerShareEndingBalance>
<bixt:FairValuePerShareEndingBalance contextRef="AsOf2021-12-31_us-gaap_StockCompensationPlanMember_srt_MaximumMember" decimals="INF" unitRef="USDPShares"> 0.29 </bixt:FairValuePerShareEndingBalance>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2021-01-012021-12-31_us-gaap_StockCompensationPlanMember" decimals="INF" unitRef="USDPShares"> 0.07 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="From2021-01-012021-12-31_custom_ShareBasedPaymentAwardsMember_custom_StockPlan2021Member" decimals="0" unitRef="USD"> 557422 </us-gaap:EmployeeBenefitsAndShareBasedCompensation>
<us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="From2020-01-012020-12-31_custom_ShareBasedPaymentAwardsMember_custom_StockPlan2021Member" decimals="0" unitRef="USD"> 228407 </us-gaap:EmployeeBenefitsAndShareBasedCompensation>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2019-12-302020-01-02_custom_MedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember_custom_StockPlan2010Member" decimals="INF" unitRef="Shares"> 3000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<bixt:StockOptionsExercisePriceInDollarsPerShare contextRef="From2019-12-302020-01-02_custom_MedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember_custom_StockPlan2010Member" decimals="INF" unitRef="USDPShares"> 0.31 </bixt:StockOptionsExercisePriceInDollarsPerShare>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2019-12-302020-01-02_custom_MedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember_custom_StockPlan2010Member" decimals="0" unitRef="USD"> 603 </us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
<bixt:StockOptionsExercisePriceInDollarsPerShare contextRef="From2020-01-292020-02-02_custom_MedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember_custom_StockPlan2010Member" decimals="INF" unitRef="USDPShares"> 0.15 </bixt:StockOptionsExercisePriceInDollarsPerShare>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2020-01-292020-02-02_custom_MedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember_custom_StockPlan2010Member" decimals="0" unitRef="USD"> 4401 </us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2019-12-302020-01-02_custom_MedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember_custom_StockPlan2010Member" decimals="INF" unitRef="Shares"> 3000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<bixt:StockOptionsExercisePriceInDollarsPerShare contextRef="From2021-01-292021-02-01_custom_MedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember_custom_StockPlan2021Member" decimals="INF" unitRef="USDPShares"> 0.32 </bixt:StockOptionsExercisePriceInDollarsPerShare>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2021-04-292021-05-01_custom_MedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember_custom_StockPlan2021Member" decimals="INF" unitRef="Shares"> 45000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<bixt:StockOptionsExercisePriceInDollarsPerShare contextRef="From2021-04-292021-05-01_custom_MedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember_custom_StockPlan2021Member" decimals="INF" unitRef="USDPShares"> 0.001 </bixt:StockOptionsExercisePriceInDollarsPerShare>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2021-04-292021-05-01_custom_MedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember_custom_StockPlan2021Member" decimals="0" unitRef="USD"> 45 </us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2021-06-292021-07-01_custom_MedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember_custom_StockPlan2021Member" decimals="INF" unitRef="Shares"> 3000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<bixt:StockOptionsExercisePriceInDollarsPerShare contextRef="From2020-06-282020-07-01_custom_MedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember_custom_StockPlan2010Member" decimals="INF" unitRef="USDPShares"> 0.18 </bixt:StockOptionsExercisePriceInDollarsPerShare>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2020-06-292020-07-01_custom_MedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember_custom_StockPlan2010Member" decimals="0" unitRef="USD"> 538 </us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2021-07-292021-08-01_custom_MedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember_custom_StockPlan2021Member" decimals="INF" unitRef="Shares"> 45000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<bixt:StockOptionsExercisePriceInDollarsPerShare contextRef="From2020-07-292020-08-01_custom_MedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember_custom_StockPlan2010Member" decimals="INF" unitRef="USDPShares"> 0.14 </bixt:StockOptionsExercisePriceInDollarsPerShare>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2021-07-282021-08-01_custom_MedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember_custom_StockPlan2010Member" decimals="0" unitRef="USD"> 6300 </us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2021-09-292021-10-01_custom_MedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember_custom_StockPlan2021Member" decimals="INF" unitRef="Shares"> 3000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<bixt:StockOptionsExercisePriceInDollarsPerShare contextRef="From2020-09-292020-10-01_custom_MedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember_custom_StockPlan2010Member" decimals="INF" unitRef="USDPShares"> 0.05 </bixt:StockOptionsExercisePriceInDollarsPerShare>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2021-09-282021-10-01_custom_MedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember_custom_StockPlan2010Member" decimals="0" unitRef="USD"> 135 </us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2021-10-292021-11-01_custom_MedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember_custom_StockPlan2021Member" decimals="INF" unitRef="Shares"> 45000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<bixt:StockOptionsExercisePriceInDollarsPerShare contextRef="From2020-10-292020-11-01_custom_MedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember_custom_StockPlan2010Member" decimals="INF" unitRef="USDPShares"> 0.18 </bixt:StockOptionsExercisePriceInDollarsPerShare>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2021-10-282021-11-01_custom_MedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember_custom_StockPlan2010Member" decimals="0" unitRef="USD"> 5792 </us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2021-04-292021-05-01_custom_MedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember_custom_StockPlan2021Member" decimals="INF" unitRef="Shares"> 45000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<bixt:StockOptionsExercisePriceInDollarsPerShare contextRef="From2021-01-282021-02-01_custom_MedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember_custom_StockPlan2010Member" decimals="INF" unitRef="USDPShares"> 0.20 </bixt:StockOptionsExercisePriceInDollarsPerShare>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2021-04-292021-05-01_custom_MedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember_custom_StockPlan2021Member" decimals="INF" unitRef="Shares"> 45000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<bixt:StockOptionsExercisePriceInDollarsPerShare contextRef="From2021-04-282021-05-01_custom_MedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember_custom_StockPlan2010Member" decimals="INF" unitRef="USDPShares"> 0.19 </bixt:StockOptionsExercisePriceInDollarsPerShare>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2021-04-292021-05-01_custom_MedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember_custom_StockPlan2021Member" decimals="INF" unitRef="Shares"> 45000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<bixt:StockOptionsExercisePriceInDollarsPerShare contextRef="From2021-07-282021-08-01_custom_ConsultantMember_custom_StockPlan2021Member" decimals="INF" unitRef="USDPShares"> 0.001 </bixt:StockOptionsExercisePriceInDollarsPerShare>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2021-07-292021-08-01_custom_MedicalAdvisoryBoardMembersMember_us-gaap_EmployeeStockOptionMember_custom_StockPlan2010Member" decimals="0" unitRef="USD"> 45 </us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2021-01-01to2021-12-31">
<p id="xdx_89F_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zGeVLSdiAYYh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BB_zRsSFASFUgX">The fair value of stock options granted and revaluation of non-employee consultant options for the year ended December 31, 2021 and 2020 was calculated with the following assumptions:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></td> <td style="text-align: center"> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020</b></span></td> <td style="text-align: center"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; padding-left: 12pt; text-indent: -12pt; width: 74%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rate</span></td> <td style="width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_dp_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_zfyHmhtF3VJ1" title="Risk-free interest rate">0.16</span> - <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_dp_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_z05vBNSfIzx7">1.00</span></span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td style="width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_dp_c20200101__20201231__srt--RangeAxis__srt--MinimumMember_zWFujTUPiTAj">0.10</span> - <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_dp_c20200101__20201231__srt--RangeAxis__srt--MaximumMember_zN8CA9x0D5U7">1.61</span></span></td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr> <td style="vertical-align: bottom; padding-left: 12pt; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected dividend yield</span></td> <td> </td> <td style="vertical-align: bottom"> </td> <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20210101__20211231_zNt76S6GEo87" style="vertical-align: bottom; text-align: right" title="Expected dividend yield"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td> </td> <td style="vertical-align: bottom"> </td> <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20200101__20201231_zrXqctwaBow3" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; padding-left: 12pt; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Volatility factor (monthly)</span></td> <td> </td> <td style="vertical-align: bottom"> </td> <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20210101__20211231_ztVeegKwo1W9" style="vertical-align: bottom; text-align: right" title="Volatility factor (monthly)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">175.34</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td> <td> </td> <td style="vertical-align: bottom"> </td> <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20200101__20201231_zkrc2uNAy41j" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">158.22</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr> <td style="vertical-align: bottom; padding-left: 12pt; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected life of option</span></td> <td> </td> <td style="vertical-align: bottom"> </td> <td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20210101__20211231_zSFHqSL6Jhxd" style="vertical-align: bottom; text-align: right" title="Expected life of option::XDX::P3Y"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1024">3 years</span></span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="vertical-align: bottom"> </td> <td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxL_c20200101__20201231_zEeBuWrFOMg8" style="vertical-align: bottom; text-align: right" title="::XDX::P3Y"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1025">3 years</span></span></td> <td style="vertical-align: bottom"> </td></tr> </table>
</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="From2021-01-012021-12-31_srt_MinimumMember" decimals="INF" unitRef="Pure"> 0.0016 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="From2021-01-012021-12-31_srt_MaximumMember" decimals="INF" unitRef="Pure"> 0.0100 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="From2020-01-012020-12-31_srt_MinimumMember" decimals="INF" unitRef="Pure"> 0.0010 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="From2020-01-012020-12-31_srt_MaximumMember" decimals="INF" unitRef="Pure"> 0.0161 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2021-01-01to2021-12-31" decimals="INF" unitRef="Pure"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2020-01-012020-12-31" decimals="INF" unitRef="Pure"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2021-01-01to2021-12-31" decimals="INF" unitRef="Pure"> 1.7534 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2020-01-012020-12-31" decimals="INF" unitRef="Pure"> 1.5822 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2021-01-01to2021-12-31">
<p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zXLnMB6f5Iyk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BD_zKNH10yn5ppf">The following table summarizes the Company’s stock option activity during the year ended at December 31, 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of Shares</b></span></td> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price per Share</b></span></td> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average Exercise Price per Share</b></span></td> <td style="text-align: center"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; width: 59%; padding-left: 12pt; text-align: justify; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding as at December 31, 2020</span></td> <td style="width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zON5Y0VUV2lg" style="vertical-align: bottom; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">533,000</span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="vertical-align: bottom; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePricePerShare_iS_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zVJfYrG0SRqh" title="Begnning">0.001</span> - <span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePricePerShare_iS_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zIx54AV37W63">1.21</span></span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEXhFNfJ00O2" style="vertical-align: bottom; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.73</span></td> <td style="vertical-align: bottom; width: 1%"> </td></tr> <tr> <td style="vertical-align: bottom; padding-left: 12pt; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td> <td> </td> <td style="vertical-align: bottom"> </td> <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zuDbtU7fAQkb" style="vertical-align: bottom; text-align: right" title="Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">135,000</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedExercisePricePerShare_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zLR3UlgTzAu4">0.001</span> - <span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedExercisePricePerShare_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zLfrva1FQzOb">0.32</span></span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="vertical-align: bottom"> </td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zGHbN1liotA2" style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.13</span></td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; padding-left: 12pt; text-align: justify; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td> <td> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: bottom; padding-left: 12pt; text-align: justify; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options forfeited/cancelled</span></td> <td> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; padding-left: 12pt; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding as at December 31, 2021</span></td> <td> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"> </td> <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1IS4wMC6Yua" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">668,000</span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePricePerShare_iE_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_z7R6qUmrcJRk" title="Ending">0.001</span> - <span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePricePerShare_iE_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zFqivYHIh5p">1.21</span></span></td> <td style="vertical-align: bottom"> </td> <td> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zU2PXn642JS9" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.55</span></td> <td style="vertical-align: bottom"> </td></tr> </table>
</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2020-12-31_us-gaap_EmployeeStockOptionMember" decimals="INF" unitRef="Shares"> 533000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<bixt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePricePerShare contextRef="AsOf2020-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember" decimals="INF" unitRef="USDPShares"> 0.001 </bixt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePricePerShare>
<bixt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePricePerShare contextRef="AsOf2020-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember" decimals="INF" unitRef="USDPShares"> 1.21 </bixt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePricePerShare>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2020-12-31_us-gaap_EmployeeStockOptionMember" decimals="INF" unitRef="USDPShares"> 0.73 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember" decimals="INF" unitRef="Shares"> 135000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<bixt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedExercisePricePerShare contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember" decimals="INF" unitRef="USDPShares"> 0.001 </bixt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedExercisePricePerShare>
<bixt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedExercisePricePerShare contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember" decimals="INF" unitRef="USDPShares"> 0.32 </bixt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedExercisePricePerShare>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember" decimals="INF" unitRef="USDPShares"> 0.13 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember" decimals="INF" unitRef="Shares"> 668000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<bixt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePricePerShare contextRef="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember" decimals="INF" unitRef="USDPShares"> 0.001 </bixt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePricePerShare>
<bixt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePricePerShare contextRef="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember" decimals="INF" unitRef="USDPShares"> 1.21 </bixt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePricePerShare>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember" decimals="INF" unitRef="USDPShares"> 0.55 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock contextRef="From2021-01-01to2021-12-31">
<p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_zJWcaHAHh7Pa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BC_zrEghw2kzUo6">The following table summarizes information about stock options that are vested or expected to vest at December 31, 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 98%; margin-right: auto"> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercisable Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price Per Share</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (Years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price Per Share</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (Years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">0.001</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenOneMember_zXtutIjZ9lX1" style="width: 8%; text-align: right">90,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenOneMember_zH7mdmplazPc" style="width: 8%; text-align: right">0.001</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenOneMember_zBwmKuGBRbDl" style="width: 9%; text-align: right" title="::XDX::P1Y11M12D"><span style="-sec-ix-hidden: xdx2ixbrl1047">1.95</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenOneMember_zCOa7Td2jpNb" style="width: 7%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenOneMember_zh0GyYlNdQgg" style="width: 7%; text-align: right">90,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenOneMember_z0rQbMMqRFDg" style="width: 9%; text-align: right">0.001</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenOneMember_zuB6zuXcEQN2" style="width: 9%; text-align: right" title="::XDX::P1Y11M12D"><span style="-sec-ix-hidden: xdx2ixbrl1051">1.95</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenOneMember_zFq7aAtHywq3" style="width: 7%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: right">0.05</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenTwoMember_z7whezK3qWF2" style="text-align: right">3,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenTwoMember_zD3D5F6AiXgk" style="text-align: right">0.05</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenTwoMember_zqOd3OffJ8e3" style="text-align: right" title="::XDX::P1Y9M"><span style="-sec-ix-hidden: xdx2ixbrl1055">1.75</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenTwoMember_zRzFfXa41104" style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenTwoMember_zfo75dxJfD37" style="text-align: right">3,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenTwoMember_zfi241PAjeHj" style="text-align: right">0.05</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenTwoMember_z0lA8T42pplc" style="text-align: right" title="::XDX::P1Y9M"><span style="-sec-ix-hidden: xdx2ixbrl1059">1.75</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenOneMember_zvVqNZtbbVNj" style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td style="text-align: right">0.15</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenThreeMember_z9AUJZ4NqKRi" style="text-align: right">90,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenThreeMember_zsVakN8bD0w9" style="text-align: right">0.15</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenThreeMember_zVIyK8BTqL4d" style="text-align: right" title="::XDX::P1Y3M29D"><span style="-sec-ix-hidden: xdx2ixbrl1063">1.33</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenFourMember_zCK9N8evgJbc" style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenThreeMember_zfekLd5OtKV1" style="text-align: right">90,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenThreeMember_z2Rc5Rld3NKd" style="text-align: right">0.15</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenThreeMember_zN2VZL33iY2d" style="text-align: right" title="::XDX::P1Y3M29D"><span style="-sec-ix-hidden: xdx2ixbrl1067">1.33</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenOneMember_zyfBg3tZv2gk" style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: right">0.18</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenFourMember_zynScg8Im8Xf" style="text-align: right">45,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenFourMember_zqxgoTuo0Euj" style="text-align: right">0.18</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenFourMember_z7lTLdzUcGzc" style="text-align: right" title="::XDX::P1Y9M29D"><span style="-sec-ix-hidden: xdx2ixbrl1071">1.83</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenFourMember_zPFUhUlaCg5d" style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenFourMember_zTJDm2ZpOjj8" style="text-align: right">45,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenFourMember_zCQ30Ac27Hqi" style="text-align: right">0.18</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenFourMember_zlRwv3hkt6Qi" style="text-align: right" title="::XDX::P1Y9M29D"><span style="-sec-ix-hidden: xdx2ixbrl1075">1.83</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenOneMember_zshojhRLh3ab" style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td style="text-align: right">0.19</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zjUUD7Ba6RMi" style="text-align: right">45,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zC6o1a40mFEk" style="text-align: right">0.19</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zSFa9aiGlVSi" style="text-align: right" title="::XDX::P2Y3M29D"><span style="-sec-ix-hidden: xdx2ixbrl1079">2.33</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zIBlMNtZTJR6" style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenFiveMember_zGEM3ACuiU" style="text-align: right">45,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenFiveMember_zsnq1xRJawTl" style="text-align: right">0.19</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenFiveMember_zsBRmjNca0w5" style="text-align: right" title="::XDX::P2Y3M29D"><span style="-sec-ix-hidden: xdx2ixbrl1083">2.33</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenOneMember_zOxsPirjFhh" style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: right">0.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_z84czKFnzh5b" style="text-align: right">48,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zZAOxy2Qbh1a" style="text-align: right">0.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zx0r2zS43y41" style="text-align: right" title="::XDX::P2Y0M15D"><span style="-sec-ix-hidden: xdx2ixbrl1087">2.04</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zQgd08E4XWv5" style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenSixMember_z8XJIqeBKno3" style="text-align: right">48,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenSixMember_zuN7ZSHbAPpe" style="text-align: right">0.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenSixMember_zKdpMNwU0Ezh" style="text-align: right" title="::XDX::P2Y0M15D"><span style="-sec-ix-hidden: xdx2ixbrl1091">2.04</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenOneMember_zLGbwdx31GA7" style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td style="text-align: right">0.31</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zxcVvBbHgwul" style="text-align: right">3,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_z66omJrqXp4f" style="text-align: right">0.31</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zVTr6kZWoWjj" style="text-align: right" title="::XDX::P1Y"><span style="-sec-ix-hidden: xdx2ixbrl1095">1.00</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zhBknOEVXtsk" style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenSevenMember_zi1yWUkkBFi9" style="text-align: right">3,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenSevenMember_zkK26jQTtvJ4" style="text-align: right">0.31</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenSevenMember_z31GuwffEW6f" style="text-align: right" title="::XDX::P1Y"><span style="-sec-ix-hidden: xdx2ixbrl1099">1.00</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenOneMember_zoDWWFrT0hv" style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: right">0.32</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightOneMember_zEQKZpx7kipg" style="text-align: right">3,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightOneMember_z9w5m5eYf06c" style="text-align: right">0.32</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightOneMember_zU94H5ihBK84" style="text-align: right" title="::XDX::P1Y2M30D"><span style="-sec-ix-hidden: xdx2ixbrl1103">1.25</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zwpuRPUQzfia" style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenEightMember_zuq9IxNh3adh" style="text-align: right">3,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenEightMember_zOtmegXXiadk" style="text-align: right">0.32</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenEightMember_zJOizdmW8ma4" style="text-align: right" title="::XDX::P1Y2M30D"><span style="-sec-ix-hidden: xdx2ixbrl1107">1.25</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenOneMember_za7fxLkuciv1" style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td style="text-align: right">0.73</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zXajyWMYrX05" style="text-align: right">3,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_z9NA9KH6gCJ7" style="text-align: right">0.73</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zBDVypngeNYe" style="text-align: right" title="::XDX::P9M29D"><span style="-sec-ix-hidden: xdx2ixbrl1111">0.83</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zmZFe9JTeTu3" style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenNineMember_zmbAGBxix807" style="text-align: right">3,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenNineMember_z2NQsIoD8Vk2" style="text-align: right">0.73</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenNineMember_zdZstXLxfs0i" style="text-align: right" title="::XDX::P9M29D"><span style="-sec-ix-hidden: xdx2ixbrl1115">0.83</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenOneMember_z7weSfRDRIik" style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: right">0.61</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zrrHzJCvx0i6" style="text-align: right">45,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_z8lK5wW5Tube" style="text-align: right">0.61</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zNK9VvepBaGl" style="text-align: right" title="::XDX::P9M"><span style="-sec-ix-hidden: xdx2ixbrl1119">0.75</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zJUXN5a9WObg" style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenTenMember_zdrTJ71zOgae" style="text-align: right">45,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenTenMember_zxU25jNm7jX7" style="text-align: right">0.61</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenTenMember_z2WhDPx7Yx3e" style="text-align: right" title="::XDX::P9M"><span style="-sec-ix-hidden: xdx2ixbrl1123">0.75</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenOneMember_zJZYrhbFZa9j" style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td style="text-align: right">0.95</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_z9kSIREFOT4c" style="text-align: right">200,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zewchUCYZwU6" style="text-align: right">0.95</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zXjQnSJNAORd" style="text-align: right" title="::XDX::P8M12D"><span style="-sec-ix-hidden: xdx2ixbrl1127">0.70</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_ze9Weza9q1jf" style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenElevenMember_znw5ZvGslOre" style="text-align: right">200,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenElevenMember_zy7p8LIHqfv5" style="text-align: right">0.95</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenElevenMember_zByHVBxgwkAg" style="text-align: right" title="::XDX::P8M12D"><span style="-sec-ix-hidden: xdx2ixbrl1131">0.70</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenOneMember_z1BPrmebkvs" style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: right">1.09</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_z3l5dGwGk5z8" style="text-align: right">3,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_z6YqH3WlRX1j" style="text-align: right">1.09</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_z7O3eX7u6aDd" style="text-align: right" title="::XDX::P6M"><span style="-sec-ix-hidden: xdx2ixbrl1135">0.50</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_z9SxVcfPMXDe" style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenTwelveMember_zMIoLyePK7O4" style="text-align: right">3,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenTwelveMember_zn96gHTmreq7" style="text-align: right">1.09</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenTwelveMember_z3FA3plurbih" style="text-align: right" title="::XDX::P6M"><span style="-sec-ix-hidden: xdx2ixbrl1139">0.50</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenOneMember_zvfcK5zrEfHl" style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td style="text-align: right">1.10</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zwZ4VnomSWMi" style="text-align: right">45,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zEgn8WmuNVPd" style="text-align: right">1.10</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zzFfTef3lFr1" style="text-align: right" title="::XDX::P6M29D"><span style="-sec-ix-hidden: xdx2ixbrl1143">0.58</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_z9Eva31tn479" style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenThirteenMember_zxzt49upgGk5" style="text-align: right">45,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenThirteenMember_zJxYatHU08re" style="text-align: right">1.10</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenThirteenMember_zUK2tz5YR0rf" style="text-align: right" title="::XDX::P6M29D"><span style="-sec-ix-hidden: xdx2ixbrl1147">0.58</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenOneMember_zTyWjDEKTeTa" style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1.21</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zgcecsjNg8Yc" style="border-bottom: Black 1pt solid; text-align: right">45,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_ze4w6QVmXcYk" style="border-bottom: Black 1pt solid; text-align: right">1.21</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourteenMember_zzQGK9GfkSwh" style="border-bottom: Black 1pt solid; text-align: right" title="::XDX::P3M29D"><span style="-sec-ix-hidden: xdx2ixbrl1151">0.33</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zubayqhwsDvj" style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenFourteenMember_zpbpGX1XMtff" style="border-bottom: Black 1pt solid; text-align: right">45,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenFourteenMember_zhZvAUNIanN6" style="border-bottom: Black 1pt solid; text-align: right">1.21</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenFourteenMember_z3mpxinhu7m2" style="border-bottom: Black 1pt solid; text-align: right" title="::XDX::P3M29D"><span style="-sec-ix-hidden: xdx2ixbrl1155">0.33</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenOneMember_zhrEfsBZnm6d" style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_z70hVH8gtL0k">0.001</span>-<span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_z9EClhtnfWL5">1.21</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20211231_zpp7p8EX8Eo6" style="border-bottom: Black 2.5pt double; text-align: right">668,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20211231_z3glMcQs2Hm3" style="border-bottom: Black 2.5pt double; text-align: right">0.55</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dxL_c20210101__20211231_zzNeA1Cpcew8" style="border-bottom: Black 2.5pt double; text-align: right" title="::XDX::P1Y2M19D"><span style="-sec-ix-hidden: xdx2ixbrl1161">1.22</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zuPOSsnnKcK9" style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20211231_zlKdwCkBgsf5" style="border-bottom: Black 2.5pt double; text-align: right">668,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20211231_z0q7KkClOne8" style="border-bottom: Black 2.5pt double; text-align: right">0.55</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtYxL_c20210101__20211231_zFizMEoyVTh4" style="border-bottom: Black 2.5pt double; text-align: right" title="::XDX::P1Y2M19D"><span style="-sec-ix-hidden: xdx2ixbrl1165">1.22</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_d0_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenOneMember_z2kGwBRPAGw4" style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
</us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="AsOf2021-12-31_custom_ExercisePriceSevenOneMember" decimals="INF" unitRef="Shares"> 90000 </us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="AsOf2021-12-31_custom_ExercisePriceSevenOneMember" decimals="INF" unitRef="USDPShares"> 0.001 </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2021-12-31_custom_ExercisePriceSevenOneMember" decimals="0" unitRef="USD"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="AsOf2021-12-31_custom_ExercisePriceSevenOneMember" decimals="INF" unitRef="Shares"> 90000 </us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="AsOf2021-12-31_custom_ExercisePriceSevenOneMember" decimals="INF" unitRef="USDPShares"> 0.001 </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2021-12-31_custom_ExercisePriceSevenOneMember" decimals="0" unitRef="USD"> 0 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="AsOf2021-12-31_custom_ExercisePriceSevenTwoMember" decimals="INF" unitRef="Shares"> 3000 </us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="AsOf2021-12-31_custom_ExercisePriceSevenTwoMember" decimals="INF" unitRef="USDPShares"> 0.05 </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2021-12-31_custom_ExercisePriceSevenTwoMember" decimals="0" unitRef="USD"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="AsOf2021-12-31_custom_ExercisePriceSevenTwoMember" decimals="INF" unitRef="Shares"> 3000 </us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="AsOf2021-12-31_custom_ExercisePriceSevenTwoMember" decimals="INF" unitRef="USDPShares"> 0.05 </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2021-12-31_custom_ExercisePriceSevenOneMember" decimals="0" unitRef="USD"> 0 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="AsOf2021-12-31_custom_ExercisePriceSevenThreeMember" decimals="INF" unitRef="Shares"> 90000 </us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="AsOf2021-12-31_custom_ExercisePriceSevenThreeMember" decimals="INF" unitRef="USDPShares"> 0.15 </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2021-12-31_custom_ExercisePriceSevenFourMember" decimals="0" unitRef="USD"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="AsOf2021-12-31_custom_ExercisePriceSevenThreeMember" decimals="INF" unitRef="Shares"> 90000 </us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="AsOf2021-12-31_custom_ExercisePriceSevenThreeMember" decimals="INF" unitRef="USDPShares"> 0.15 </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2021-12-31_custom_ExercisePriceSevenOneMember" decimals="0" unitRef="USD"> 0 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="AsOf2021-12-31_custom_ExercisePriceSevenFourMember" decimals="INF" unitRef="Shares"> 45000 </us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="AsOf2021-12-31_custom_ExercisePriceSevenFourMember" decimals="INF" unitRef="USDPShares"> 0.18 </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2021-12-31_custom_ExercisePriceSevenFourMember" decimals="0" unitRef="USD"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="AsOf2021-12-31_custom_ExercisePriceSevenFourMember" decimals="INF" unitRef="Shares"> 45000 </us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="AsOf2021-12-31_custom_ExercisePriceSevenFourMember" decimals="INF" unitRef="USDPShares"> 0.18 </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2021-12-31_custom_ExercisePriceSevenOneMember" decimals="0" unitRef="USD"> 0 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="AsOf2021-12-31_custom_ExercisePriceFiveMember" decimals="INF" unitRef="Shares"> 45000 </us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="AsOf2021-12-31_custom_ExercisePriceFiveMember" decimals="INF" unitRef="USDPShares"> 0.19 </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2021-12-31_custom_ExercisePriceFiveMember" decimals="0" unitRef="USD"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="AsOf2021-12-31_custom_ExercisePriceSevenFiveMember" decimals="INF" unitRef="Shares"> 45000 </us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="AsOf2021-12-31_custom_ExercisePriceSevenFiveMember" decimals="INF" unitRef="USDPShares"> 0.19 </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2021-12-31_custom_ExercisePriceSevenOneMember" decimals="0" unitRef="USD"> 0 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="AsOf2021-12-31_custom_ExercisePriceSixMember" decimals="INF" unitRef="Shares"> 48000 </us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="AsOf2021-12-31_custom_ExercisePriceSixMember" decimals="INF" unitRef="USDPShares"> 0.20 </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2021-12-31_custom_ExercisePriceSixMember" decimals="0" unitRef="USD"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="AsOf2021-12-31_custom_ExercisePriceSevenSixMember" decimals="INF" unitRef="Shares"> 48000 </us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="AsOf2021-12-31_custom_ExercisePriceSevenSixMember" decimals="INF" unitRef="USDPShares"> 0.20 </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2021-12-31_custom_ExercisePriceSevenOneMember" decimals="0" unitRef="USD"> 0 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="AsOf2021-12-31_custom_ExercisePriceSevenMember" decimals="INF" unitRef="Shares"> 3000 </us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="AsOf2021-12-31_custom_ExercisePriceSevenMember" decimals="INF" unitRef="USDPShares"> 0.31 </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2021-12-31_custom_ExercisePriceSixMember" decimals="0" unitRef="USD"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="AsOf2021-12-31_custom_ExercisePriceSevenSevenMember" decimals="INF" unitRef="Shares"> 3000 </us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="AsOf2021-12-31_custom_ExercisePriceSevenSevenMember" decimals="INF" unitRef="USDPShares"> 0.31 </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2021-12-31_custom_ExercisePriceSevenOneMember" decimals="0" unitRef="USD"> 0 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="AsOf2021-12-31_custom_ExercisePriceEightOneMember" decimals="INF" unitRef="Shares"> 3000 </us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="AsOf2021-12-31_custom_ExercisePriceEightOneMember" decimals="INF" unitRef="USDPShares"> 0.32 </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2021-12-31_custom_ExercisePriceSixMember" decimals="0" unitRef="USD"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="AsOf2021-12-31_custom_ExercisePriceSevenEightMember" decimals="INF" unitRef="Shares"> 3000 </us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="AsOf2021-12-31_custom_ExercisePriceSevenEightMember" decimals="INF" unitRef="USDPShares"> 0.32 </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2021-12-31_custom_ExercisePriceSevenOneMember" decimals="0" unitRef="USD"> 0 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="AsOf2021-12-31_custom_ExercisePriceNineMember" decimals="INF" unitRef="Shares"> 3000 </us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="AsOf2021-12-31_custom_ExercisePriceNineMember" decimals="INF" unitRef="USDPShares"> 0.73 </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2021-12-31_custom_ExercisePriceSixMember" decimals="0" unitRef="USD"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="AsOf2021-12-31_custom_ExercisePriceSevenNineMember" decimals="INF" unitRef="Shares"> 3000 </us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="AsOf2021-12-31_custom_ExercisePriceSevenNineMember" decimals="INF" unitRef="USDPShares"> 0.73 </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2021-12-31_custom_ExercisePriceSevenOneMember" decimals="0" unitRef="USD"> 0 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="AsOf2021-12-31_custom_ExercisePriceTenMember" decimals="INF" unitRef="Shares"> 45000 </us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="AsOf2021-12-31_custom_ExercisePriceTenMember" decimals="INF" unitRef="USDPShares"> 0.61 </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2021-12-31_custom_ExercisePriceSixMember" decimals="0" unitRef="USD"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="AsOf2021-12-31_custom_ExercisePriceSevenTenMember" decimals="INF" unitRef="Shares"> 45000 </us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="AsOf2021-12-31_custom_ExercisePriceSevenTenMember" decimals="INF" unitRef="USDPShares"> 0.61 </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2021-12-31_custom_ExercisePriceSevenOneMember" decimals="0" unitRef="USD"> 0 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="AsOf2021-12-31_custom_ExercisePriceElevenMember" decimals="INF" unitRef="Shares"> 200000 </us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="AsOf2021-12-31_custom_ExercisePriceElevenMember" decimals="INF" unitRef="USDPShares"> 0.95 </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2021-12-31_custom_ExercisePriceSixMember" decimals="0" unitRef="USD"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="AsOf2021-12-31_custom_ExercisePriceSevenElevenMember" decimals="INF" unitRef="Shares"> 200000 </us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="AsOf2021-12-31_custom_ExercisePriceSevenElevenMember" decimals="INF" unitRef="USDPShares"> 0.95 </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2021-12-31_custom_ExercisePriceSevenOneMember" decimals="0" unitRef="USD"> 0 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="AsOf2021-12-31_custom_ExercisePriceTwelveMember" decimals="INF" unitRef="Shares"> 3000 </us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="AsOf2021-12-31_custom_ExercisePriceTwelveMember" decimals="INF" unitRef="USDPShares"> 1.09 </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2021-12-31_custom_ExercisePriceSixMember" decimals="0" unitRef="USD"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="AsOf2021-12-31_custom_ExercisePriceSevenTwelveMember" decimals="INF" unitRef="Shares"> 3000 </us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="AsOf2021-12-31_custom_ExercisePriceSevenTwelveMember" decimals="INF" unitRef="USDPShares"> 1.09 </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2021-12-31_custom_ExercisePriceSevenOneMember" decimals="0" unitRef="USD"> 0 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="AsOf2021-12-31_custom_ExercisePriceThirteenMember" decimals="INF" unitRef="Shares"> 45000 </us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="AsOf2021-12-31_custom_ExercisePriceThirteenMember" decimals="INF" unitRef="USDPShares"> 1.10 </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2021-12-31_custom_ExercisePriceSixMember" decimals="0" unitRef="USD"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="AsOf2021-12-31_custom_ExercisePriceSevenThirteenMember" decimals="INF" unitRef="Shares"> 45000 </us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="AsOf2021-12-31_custom_ExercisePriceSevenThirteenMember" decimals="INF" unitRef="USDPShares"> 1.10 </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2021-12-31_custom_ExercisePriceSevenOneMember" decimals="0" unitRef="USD"> 0 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="AsOf2021-12-31_custom_ExercisePriceFourteenMember" decimals="INF" unitRef="Shares"> 45000 </us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="AsOf2021-12-31_custom_ExercisePriceFourteenMember" decimals="INF" unitRef="USDPShares"> 1.21 </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2021-12-31_custom_ExercisePriceSixMember" decimals="0" unitRef="USD"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="AsOf2021-12-31_custom_ExercisePriceSevenFourteenMember" decimals="INF" unitRef="Shares"> 45000 </us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="AsOf2021-12-31_custom_ExercisePriceSevenFourteenMember" decimals="INF" unitRef="USDPShares"> 1.21 </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2021-12-31_custom_ExercisePriceSevenOneMember" decimals="0" unitRef="USD"> 0 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="From2021-01-012021-12-31_srt_MinimumMember" decimals="INF" unitRef="USDPShares"> 0.001 </us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="From2021-01-012021-12-31_srt_MaximumMember" decimals="INF" unitRef="USDPShares"> 1.21 </us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares"> 668000 </us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="AsOf2021-12-31" decimals="INF" unitRef="USDPShares"> 0.55 </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2021-12-31_custom_ExercisePriceSixMember" decimals="0" unitRef="USD"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares"> 668000 </us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="AsOf2021-12-31" decimals="INF" unitRef="USDPShares"> 0.55 </us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2021-12-31_custom_ExercisePriceSevenOneMember" decimals="0" unitRef="USD"> 0 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
<us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock contextRef="From2021-01-01to2021-12-31">
<p id="xdx_892_eus-gaap--ScheduleOfNonvestedShareActivityTableTextBlock_z3eBdlBwl3l8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BE_zqla8aFYf6L6">The following table sets forth the status of the Company’s non-vested stock options as at December 31, 2021 and December 31, 2020:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 98%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted- Average Grant-Date Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-vested as at December 31, 2020</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_d0_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrbDu0A3UJeg" style="text-align: right" title="Balance at beginning,Number of Options">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_d0_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zr03xC3Vmg32" style="text-align: right" title="Balance at beginning,Weighted- Average Grant-Date Fair Value">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 69%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNkONWGJPTp" style="width: 12%; text-align: right" title="Granted">135,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zsDIxhTexqu" style="width: 12%; text-align: right" title="Granted">0.13</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_pid_d0_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zy4Vdyy6nH1e" style="text-align: right" title="Forfeited">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zJ1DLipYB7H7" style="text-align: right" title="Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1180">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vested</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrKd820imSx3" style="border-bottom: Black 1pt solid; text-align: right" title="Vested">(135,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1cyzZfpvsr2" style="border-bottom: Black 1pt solid; text-align: right" title="Vested">0.13</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-vested as at December 31, 2021</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_d0_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zv3Xp9UiPIj9" style="border-bottom: Black 1pt solid; text-align: right" title="Balance at ending,Number of Options">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_d0_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zXjWkbez3eT9" style="border-bottom: Black 1pt solid; text-align: right" title="Balance at ending,Weighted- Average Grant-Date Fair Value">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>
</us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="AsOf2020-12-31_us-gaap_EmployeeStockOptionMember" decimals="INF" unitRef="Shares"> 0 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2020-12-31_us-gaap_EmployeeStockOptionMember" decimals="INF" unitRef="USDPShares"> 0 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember" decimals="INF" unitRef="Shares"> 135000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember" decimals="INF" unitRef="USDPShares"> 0.13 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember" decimals="INF" unitRef="Shares"> 0 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember" decimals="INF" unitRef="Shares"> 135000 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue contextRef="From2021-01-012021-12-31_us-gaap_EmployeeStockOptionMember" decimals="INF" unitRef="USDPShares"> 0.13 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember" decimals="INF" unitRef="Shares"> 0 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember" decimals="INF" unitRef="USDPShares"> 0 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="AsOf2021-12-31_custom_StockPlan2010Member" decimals="0" unitRef="USD"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2021-12-31_custom_StockPlan2010Member" decimals="0" unitRef="USD"> 0 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="AsOf2021-12-31_custom_StockPlan2010Member" decimals="INF" unitRef="Shares"> 34181909 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2021-01-012021-12-31_custom_ThreeMembersOfTheCompanyBoardMember_custom_StockPlan2017Member" decimals="INF" unitRef="Shares"> 4500000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2020-01-012020-12-31_custom_ThreeMembersOfTheCompanyBoardMember_custom_StockPlan2017Member" decimals="INF" unitRef="Shares"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2021-01-01to2021-12-31">
<p id="xdx_80E_eus-gaap--IncomeTaxDisclosureTextBlock_zroQhEkaP42f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 10 – <span id="xdx_822_zoErTMh5HSL">PROVISION FOR INCOME TAXES</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b><i>Provision for Income Taxes</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2021 and December 31, 2020, no provision for income taxes was recorded as the Company generated net operating losses.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_893_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zA29elHTPqX3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The tax effects of temporary differences that give rise to deferred tax assets are presented below:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8BA_z0oIyMJuCGp1" style="display: none; visibility: hidden">Schedule of deferred tax assets</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 98%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20211231_zCxfGp83NFs2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20201231_z6yP3tkZgnt8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsNetAbstract_iB_zMCb5wOaa6Zi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred Tax Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_z2Klfxbayzud" style="vertical-align: bottom; background-color: White"> <td style="width: 74%; text-align: justify; padding-bottom: 1pt; text-indent: -12pt; padding-left: 12pt">Net operating loss carryforward</td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 10%; text-align: right">6,670,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 10%; text-align: right">3,225,628</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; text-indent: -12pt; padding-left: 12pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsGross_iI_z5QyF963GUV5" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; text-indent: -12pt; padding-left: 12pt">Total deferred tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,400,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">677,382</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; text-indent: -12pt; padding-left: 12pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_zAb2FePezv7e" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt; text-indent: -12pt; padding-left: 12pt">Valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,400,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(677,382</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; text-indent: -12pt; padding-left: 12pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsNet_iI_zM6lQYUHPIC" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: -12pt; padding-left: 12pt">Deferred tax asset, net of valuation allowance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1211">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1212">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AB_zaEMUVnTdobc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_89E_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zOZsiA22Rhd8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A reconciliation of the statutory federal income tax rate to the Company’s effective tax rate is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8B6_zZqJqdHjkalb" style="display: none; visibility: hidden">Schedule of effective tax rate</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 98%; margin-right: auto"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: justify">Tax benefit at federal statutory rate</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">(<span id="xdx_909_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_uPure_c20210101__20211231_z6keHSZmfAIg" title="Tax benefit at federal statutory rate">21.0</span></td><td style="width: 1%; text-align: left">)%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">(<span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_uPure_c20200101__20201231_zjz3mvzAKZd8">21.0</span></td><td style="width: 1%; text-align: left">)%</td></tr> </table> <p id="xdx_8AD_z54Wj0ilsPr4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company assesses the likelihood that deferred tax assets will be realized. To the extent that realization is not likely, a valuation allowance is established. Based upon the Company’s history of losses since inception, management believes that it is more likely than not that future benefits of deferred tax assets will not be realized.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At December 31, 2021, the Company had approximately $<span id="xdx_900_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_c20211231_zfcZJCk3XhQ4" title="Federal net operating losses">6,670,000</span> of federal net operating losses that may be available to offset future taxable income, At December 31, 2020, the Company had approximately $<span id="xdx_905_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_c20201231_zdkFfvHRdM06">3,225,628 </span>of federal net operating losses that may be available to offset future taxable income. $<span id="xdx_900_eus-gaap--OperatingLossCarryforwards_iI_c20211231_zkRKRzPIJo9i" title="Future taxable income">2,870</span> of the <span id="xdx_903_eus-gaap--OperatingLossCarryforwardsLimitationsOnUse_c20210101__20211231_zeeOMLxS3lXl" title="Net operating loss carry forwards, description">net operating loss carry forwards (NOL), if not utilized, will expire in 2037 for federal purposes</span>, the remaining amount of NOL can be carried forward indefinitely. As at the fiscal year 2021, a deduction for issued warrants and stock options and restricted shares awarded from the 2010 Stock Plan for a total of $<span id="xdx_909_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_c20201231__us-gaap--AwardTypeAxis__custom--RestrictedStockOptionMember__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_z0btMbZN2TGk" title="Federal net operating losses">2,030,000</span> has not yet been made, for the fiscal year 2020 this total was $<span id="xdx_902_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_c20201231__us-gaap--DerivativeInstrumentRiskAxis__custom--StockPlan2010Member_zMyMNKvRYCf8">1,448,240</span>. The market value less exercise price for these awards will be deducted if and when the warrants and stock options are exercised, while the restricted shares will be deducted at market value at the date they were awarded, once the restriction is removed.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Internal Revenue Code Section 382 (“Section 382”), certain ownership changes may subject the net operating loss carryforwards (“carryforwards”) and research and development tax credit carryforwards to annual limitations which could reduce or defer the carryforwards. Section 382 imposes limitations on a corporation’s ability to utilize carryforwards if it experiences an ownership change. An ownership change may result from transactions increasing the ownership of certain stockholders in the stock of a corporation by more than 50 percentage points over a three-year period. In the event of an ownership change, utilization of the carryforwards would be subject to an annual limitation under Section 382 determined by multiplying the value of its stock at the time of the ownership change by the applicable long-term tax-exempt rate. Any unused annual limitation may be carried over to later years. The imposition of this limitation on its ability to use the carryforwards to offset future taxable income could cause the Company to pay U.S. federal income taxes earlier than if such limitation were not in effect and could cause such carryforwards to expire unused, reducing or eliminating the benefit of such carryforwards. The Company has not completed a Section 382 study to determine if there have been one or more ownership changes due to the costs associated with such a study. Until a study is completed and the extent of the limitations, if any, is able to be determined, no additional amounts have been written off or are being presented as an uncertain tax position.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cut and Jobs Act (the “Tax Act”). The Tax Act establishes new tax laws that affects 2019 and future years, including a reduction in the U.S. federal corporate income tax rate to <span id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20171201__20171222_zzJoikC8p2i6" title="U.S. federal corporate income tax rate">21</span>%, effective January 1, 2019.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company applies the provisions of ASC 740-10, Income Taxes. The Company has not recognized any liability for unrecognized tax benefits and does not believe there is any uncertainty with respect to its tax position. The Company’s policy with respect to unrecognized tax benefits is to recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending income tax examinations. Earlier years may be examined to the extent that tax credit or net operating loss carryforwards are used in future periods. The Company’s policy is to record interest and penalties related to income taxes as part of its income tax provision.</p>
</us-gaap:IncomeTaxDisclosureTextBlock>
<us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2021-01-01to2021-12-31">
<p id="xdx_893_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zA29elHTPqX3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The tax effects of temporary differences that give rise to deferred tax assets are presented below:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8BA_z0oIyMJuCGp1" style="display: none; visibility: hidden">Schedule of deferred tax assets</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 98%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20211231_zCxfGp83NFs2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20201231_z6yP3tkZgnt8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsNetAbstract_iB_zMCb5wOaa6Zi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred Tax Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_z2Klfxbayzud" style="vertical-align: bottom; background-color: White"> <td style="width: 74%; text-align: justify; padding-bottom: 1pt; text-indent: -12pt; padding-left: 12pt">Net operating loss carryforward</td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 10%; text-align: right">6,670,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 10%; text-align: right">3,225,628</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; text-indent: -12pt; padding-left: 12pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsGross_iI_z5QyF963GUV5" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; text-indent: -12pt; padding-left: 12pt">Total deferred tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,400,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">677,382</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; text-indent: -12pt; padding-left: 12pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_zAb2FePezv7e" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt; text-indent: -12pt; padding-left: 12pt">Valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,400,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(677,382</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; text-indent: -12pt; padding-left: 12pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsNet_iI_zM6lQYUHPIC" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: -12pt; padding-left: 12pt">Deferred tax asset, net of valuation allowance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1211">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1212">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2021-12-31" decimals="0" unitRef="USD"> 6670000 </us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2020-12-31" decimals="0" unitRef="USD"> 3225628 </us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
<us-gaap:DeferredTaxAssetsGross contextRef="AsOf2021-12-31" decimals="0" unitRef="USD"> 1400000 </us-gaap:DeferredTaxAssetsGross>
<us-gaap:DeferredTaxAssetsGross contextRef="AsOf2020-12-31" decimals="0" unitRef="USD"> 677382 </us-gaap:DeferredTaxAssetsGross>
<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2021-12-31" decimals="0" unitRef="USD"> 1400000 </us-gaap:DeferredTaxAssetsValuationAllowance>
<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2020-12-31" decimals="0" unitRef="USD"> 677382 </us-gaap:DeferredTaxAssetsValuationAllowance>
<us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2021-01-01to2021-12-31">
<p id="xdx_89E_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zOZsiA22Rhd8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A reconciliation of the statutory federal income tax rate to the Company’s effective tax rate is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8B6_zZqJqdHjkalb" style="display: none; visibility: hidden">Schedule of effective tax rate</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 98%; margin-right: auto"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: justify">Tax benefit at federal statutory rate</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">(<span id="xdx_909_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_uPure_c20210101__20211231_z6keHSZmfAIg" title="Tax benefit at federal statutory rate">21.0</span></td><td style="width: 1%; text-align: left">)%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">(<span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_uPure_c20200101__20201231_zjz3mvzAKZd8">21.0</span></td><td style="width: 1%; text-align: left">)%</td></tr> </table>
</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2021-01-01to2021-12-31" decimals="INF" unitRef="Pure"> 21.0 </us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2020-01-012020-12-31" decimals="INF" unitRef="Pure"> 21.0 </us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
<us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="AsOf2021-12-31" decimals="0" unitRef="USD"> 6670000 </us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
<us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="AsOf2020-12-31" decimals="0" unitRef="USD"> 3225628 </us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
<us-gaap:OperatingLossCarryforwards contextRef="AsOf2021-12-31" decimals="0" unitRef="USD"> 2870 </us-gaap:OperatingLossCarryforwards>
<us-gaap:OperatingLossCarryforwardsLimitationsOnUse contextRef="From2021-01-01to2021-12-31"> net operating loss carry forwards (NOL), if not utilized, will expire in 2037 for federal purposes </us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
<us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="AsOf2020-12-31_custom_RestrictedStockOptionMember_custom_StockPlan2010Member" decimals="0" unitRef="USD"> 2030000 </us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
<us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="AsOf2020-12-31_custom_StockPlan2010Member" decimals="0" unitRef="USD"> 1448240 </us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="From2017-12-012017-12-22" decimals="INF" unitRef="Pure"> 0.21 </us-gaap:EffectiveIncomeTaxRateContinuingOperations>
<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2021-01-01to2021-12-31">
<p id="xdx_802_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zAZpteZ0q3ak" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 11 – <span id="xdx_820_z0c4Vr9v2gz4">COMMITMENTS AND CONTINGENCIES</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Employment contracts</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s executive officers have entered employment contracts and confidentiality, non-disclosure and assignment of invention agreements. The employment agreements do not provide for the payment of any compensation to our executive officers but provide for the payment of $<span id="xdx_902_eus-gaap--SupplementalUnemploymentBenefitsSeveranceBenefits_iI_c20211231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementsMember_zmuVP5KnGI3g" title="Payment of severance upon termination">100,000</span> in severance upon termination of employment without cause and make no provisions for any payment upon a change of control.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Litigation</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance. Legal fees for such matters are expensed as incurred and we accrue for adverse outcomes as they become probable and estimable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 5, 2020 the Supreme Court of the State of New York, County of Nassau, issued a commencement of Action based on behalf of Power Up Lending Group, Ltd (“Power Up” or the “Claimant”). The Claimant request that due to the default of their note requesting a judgment for an amount of not less than $<span id="xdx_908_ecustom--JudgmentForAmountOfNotLess_iI_c20200605__us-gaap--RelatedPartyTransactionAxis__custom--PowerUpMember_zszpg3Imf3Wl" title="Judgment for an amount of not less">420,750</span>. On January 20, 2021 the Supreme Court of the State of New York, County of Nassau, granted Power Up a summary judgement against the Company for Breach of Contact, awarding Power Up damages in the amount of $<span id="xdx_909_ecustom--PowerUpDamagesAmount_iI_c20200605__us-gaap--RelatedPartyTransactionAxis__custom--PowerUpMember_zAb7rT0SxUg3" title="Damage amount">420,750</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The underlying convertible note was, per agreement of the parties, cancelled on June 4, 2021, with Power Up agreeing to a stipulation of discontinuance with prejudice and forfeiture of on-going lawsuit and forfeiture of the mentioned awarded damages.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At present, there is no other pending litigation or proceeding involving any of our directors, officers or employees as to which indemnification is sought, nor are we aware of any threatened litigation or proceeding that may result in claims for indemnification.</p>
</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
<us-gaap:SupplementalUnemploymentBenefitsSeveranceBenefits contextRef="AsOf2021-12-31_custom_EmploymentAgreementsMember" decimals="0" unitRef="USD"> 100000 </us-gaap:SupplementalUnemploymentBenefitsSeveranceBenefits>
<bixt:JudgmentForAmountOfNotLess contextRef="AsOf2020-06-05_custom_PowerUpMember" decimals="0" unitRef="USD"> 420750 </bixt:JudgmentForAmountOfNotLess>
<bixt:PowerUpDamagesAmount contextRef="AsOf2020-06-05_custom_PowerUpMember" decimals="0" unitRef="USD"> 420750 </bixt:PowerUpDamagesAmount>
<us-gaap:SubsequentEventsTextBlock contextRef="From2021-01-01to2021-12-31">
<p id="xdx_807_eus-gaap--SubsequentEventsTextBlock_z5BQkTh5rSae" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 12 – <span id="xdx_823_zP1DHEnKcbc1">SUBSEQUENT EVENTS</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has evaluated events from December 31, 2021 through the date the financial statements were issued. The events requiring disclosure for this period are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Note Financing</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On December 31, 2021, the Company issued a Private Placement Memorandum in form of convertible Notes, “the Notes”, offered exclusively to accredited investors for an amount of up to $<span id="xdx_900_ecustom--AdditionalInvestmentAmount_iI_pp0p0_c20211231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zaduL6lJAPpb" title="Additional investment amount">1,500,000</span>, “the PPM”, to be closed no later than January 10, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_89A_ecustom--ScheduleOfShortTermDebtTableTextBlock_zWekfNMpy6F3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B3_z4RYCDdWAnme">A summary of the Notes issued under the PPM is as follows</span>:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Convertible Loan</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Date of<br/> Issuance</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Principal<br/> Amount</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Interest</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 54%; text-align: left; padding-left: 12pt">1-year convertible notes with 6% interest convertible at $0.25/share</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <sup id="xdx_F45_zzyrxvwoh2da">(1)</sup></span></td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_ecustom--InvestmentsOptionsIssuanceDate_dxL_c20211228__20211231__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zip6xBlFp5di" title="Date of issuance::XDX::Jan.%2012%2C%202022"><span style="-sec-ix-hidden: xdx2ixbrl1245">1/12/2022</span></span></span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20211231__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zUUmfTuybTX4" title="Principal amount">1,467,000</span></td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 12%; text-align: right"><span id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_uPure_c20211231__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zLzDERfWyAo1" title="Interest rate">6</span></td><td style="width: 1%; text-align: left">%</td></tr> </table> <p style="margin: 0"/> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 12pt"><span id="xdx_F02_zYgQrHsQLky3" style="font-size: 10pt">(1)<span style="font-family: Times New Roman, Times, Serif">                 </span><span id="xdx_F14_zKSkUssZ5j5c" style="background-color: white">Net cash received for these notes were $1,380,960, after a Debt Discount of $86,040 was paid to the sole Placement Agent: WallachBeth Capital, LLC (Member FINRA / SIPC). WallachBeth also received 264,060 5-year warrants exercisable at $0.25/share</span>, valued at $0.16, based on Black and Schools Option Pricing Model, for a total value of $42,250<span style="background-color: white">.</span></span></p> <p id="xdx_8A4_zEBYtKW8C1Ed" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b><i>Terms for the Notes</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Between January 5, 2022 and January 12, 2022, we entered into thirty-four (34) Securities Purchase Agreements, or “the SPA’s”, with accredited investors, under which we agreed to sell the Notes, in an aggregate principal amount of $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_c20220112__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zI8xkQA3E3g7" title="Aggregate principal amount">1,467,000</span> with 6% interest to the Holders of the Notes, “the Holders”.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span id="xdx_905_ecustom--ConvertibleNoteDescribtion_c20220105__20220112__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zFhgMbjWArq5" title="Convertible note, description">At any time after the issue date of the Notes, “the Holders”, have the option to convert all or any part of the outstanding and unpaid principal amount and accrued and unpaid interest of the Notes into shares of our Common Stock at the Conversion Price. The “Conversion Price” is set to $0.25 per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Holders are limited to holding a total of 4.99% of our issued and outstanding Common Stock. The Common Stock underlying the Notes, when issued, bear a restrictive legend are currently eligible for resale under Rule 144.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Notes are converted prior to us paying off such note, it would lead to dilution to our shareholders as a result of the conversion discounted for the Notes. There can be no assurance that there will be any funds available to pay of the Notes, or if available, on terms that will be acceptable to us or our shareholders. If we fail to obtain such additional financing on a timely basis, the Holders may convert the Notes and sell the underlying shares, which may result in dilution to shareholders due to the conversion discount, as well as a decrease in our stock price.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Common stock</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Shares awarded, but <span style="text-decoration: underline">not</span> yet issued, under the 2021 Stock Plan:</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 10, 2022 the Company granted <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220108__20220110__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zbxr2yKDKXb1" title="Number of shares, granted">40,000</span> shares of Common Stock to four Board Members in reward of their attendance at Board and Committee meetings during the fourth quarter of 2021. The total fair market value at the time of the award was $<span id="xdx_904_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensationGross_c20220108__20220110__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zpdHTqnkgFZb" title="Fair value">6,400</span>, or $<span id="xdx_904_eus-gaap--SharePrice_iI_uUSDPShares_c20220110__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_z9jTYSOQUKY9" title="Share price">0.16</span>/share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 18, 2022 the Company granted <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220108__20220110__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--ConsultantsMember_zvK6wPnPfLW6" title="Granted shares">100,000</span> shares of Common Stock to two Consultants in reward of their assistance in the filings of the IND to the US FDA and the CT-4 to the Indian CDCSO for the ProLectin-M, an oral chewable tablet for the treatment of mild to moderate cases of Covid-19.</p>
</us-gaap:SubsequentEventsTextBlock>
<bixt:AdditionalInvestmentAmount contextRef="AsOf2021-12-31_us-gaap_PrivatePlacementMember" decimals="0" unitRef="USD"> 1500000 </bixt:AdditionalInvestmentAmount>
<bixt:ScheduleOfShortTermDebtTableTextBlock contextRef="From2021-01-01to2021-12-31">
<p id="xdx_89A_ecustom--ScheduleOfShortTermDebtTableTextBlock_zWekfNMpy6F3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B3_z4RYCDdWAnme">A summary of the Notes issued under the PPM is as follows</span>:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Convertible Loan</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Date of<br/> Issuance</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Principal<br/> Amount</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Interest</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 54%; text-align: left; padding-left: 12pt">1-year convertible notes with 6% interest convertible at $0.25/share</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <sup id="xdx_F45_zzyrxvwoh2da">(1)</sup></span></td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_ecustom--InvestmentsOptionsIssuanceDate_dxL_c20211228__20211231__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zip6xBlFp5di" title="Date of issuance::XDX::Jan.%2012%2C%202022"><span style="-sec-ix-hidden: xdx2ixbrl1245">1/12/2022</span></span></span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20211231__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zUUmfTuybTX4" title="Principal amount">1,467,000</span></td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td style="width: 12%; text-align: right"><span id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_uPure_c20211231__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zLzDERfWyAo1" title="Interest rate">6</span></td><td style="width: 1%; text-align: left">%</td></tr> </table> <p style="margin: 0"/> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 12pt"><span id="xdx_F02_zYgQrHsQLky3" style="font-size: 10pt">(1)<span style="font-family: Times New Roman, Times, Serif">                 </span><span id="xdx_F14_zKSkUssZ5j5c" style="background-color: white">Net cash received for these notes were $1,380,960, after a Debt Discount of $86,040 was paid to the sole Placement Agent: WallachBeth Capital, LLC (Member FINRA / SIPC). WallachBeth also received 264,060 5-year warrants exercisable at $0.25/share</span>, valued at $0.16, based on Black and Schools Option Pricing Model, for a total value of $42,250<span style="background-color: white">.</span></span></p>
</bixt:ScheduleOfShortTermDebtTableTextBlock>
<us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2021-12-31_us-gaap_ConvertibleDebtMember_us-gaap_PrivatePlacementMember" decimals="0" unitRef="USD"> 1467000 </us-gaap:DebtInstrumentFaceAmount>
<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="AsOf2021-12-31_us-gaap_ConvertibleDebtMember_us-gaap_PrivatePlacementMember" decimals="INF" unitRef="Pure"> 6 </us-gaap:DebtInstrumentInterestRateStatedPercentage>
<us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2022-01-12_us-gaap_ConvertibleDebtMember_us-gaap_SubsequentEventMember" decimals="0" unitRef="USD"> 1467000 </us-gaap:DebtInstrumentFaceAmount>
<bixt:ConvertibleNoteDescribtion contextRef="From2022-01-052022-01-12_us-gaap_ConvertibleDebtMember_us-gaap_SubsequentEventMember"> At any time after the issue date of the Notes, “the Holders”, have the option to convert all or any part of the outstanding and unpaid principal amount and accrued and unpaid interest of the Notes into shares of our Common Stock at the Conversion Price. The “Conversion Price” is set to $0.25 per share. </bixt:ConvertibleNoteDescribtion>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2022-01-082022-01-10_us-gaap_SubsequentEventMember_srt_BoardOfDirectorsChairmanMember" decimals="INF" unitRef="Shares"> 40000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross contextRef="From2022-01-082022-01-10_us-gaap_SubsequentEventMember_srt_BoardOfDirectorsChairmanMember" decimals="0" unitRef="USD"> 6400 </us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross>
<us-gaap:SharePrice contextRef="AsOf2022-01-10_us-gaap_SubsequentEventMember_srt_BoardOfDirectorsChairmanMember" decimals="INF" unitRef="USDPShares"> 0.16 </us-gaap:SharePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2022-01-082022-01-10_us-gaap_SubsequentEventMember_custom_ConsultantsMember" decimals="INF" unitRef="Shares"> 100000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
<link:loc xlink:href="#Fact000630" xlink:label="Fact000630" xlink:type="locator"/>
<link:footnote id="Footnote000656" xlink:label="Footnote000656" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"> $210,000 to each the CFO and the CEO for 6 months of salary for the period July through December 2021, and $111,000 to the VP for salary and expenses for the same period, while there was $120,000 to each the CFO and the CEO at and $67,176 for the VP at December 31, 2020. </link:footnote>
<link:footnoteArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact000630" xlink:to="Footnote000656" xlink:type="arc"/>
<link:loc xlink:href="#Fact000631" xlink:label="Fact000631" xlink:type="locator"/>
<link:footnoteArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact000631" xlink:to="Footnote000656" xlink:type="arc"/>
<link:loc xlink:href="#Fact000692" xlink:label="Fact000692" xlink:type="locator"/>
<link:footnote id="Footnote000698" xlink:label="Footnote000698" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">
Net cash received for these notes were $<xhtml:span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--NoteSoldInExchangeForCashMember__dei--LegalEntityAxis__custom--WallachBethCapitalLLCMember_z8R6IdTrwiBj">1,045,150</xhtml:span>, after a Debt Discount of $<xhtml:span id="xdx_90B_ecustom--DebtDiscount_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--NoteSoldInExchangeForCashMember__dei--LegalEntityAxis__custom--WallachBethCapitalLLCMember_z2dxgPvsVc07" title="Debt discount">119,850</xhtml:span> was paid to the sole Placement Agent: WallachBeth Capital, LLC (Member FINRA / SIPC).
</link:footnote>
<link:footnoteArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact000692" xlink:to="Footnote000698" xlink:type="arc"/>
<link:loc xlink:href="#Fact000693" xlink:label="Fact000693" xlink:type="locator"/>
<link:footnoteArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact000693" xlink:to="Footnote000698" xlink:type="arc"/>
<link:loc xlink:href="#Fact000694" xlink:label="Fact000694" xlink:type="locator"/>
<link:footnoteArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact000694" xlink:to="Footnote000698" xlink:type="arc"/>
<link:loc xlink:href="#Fact000695" xlink:label="Fact000695" xlink:type="locator"/>
<link:footnote id="Footnote000702" xlink:label="Footnote000702" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">
The “Old Notes” were paid off and assumed by a different entity/company. Portions of the balance was forgiven and a new note of $<xhtml:span id="xdx_90D_ecustom--ConvertibleNotesPayableNetOfPremiumAndDiscountRelatedParty_iI_c20211231_zIN3Yo5YYj88" title="Note issue amount">1,000,000</xhtml:span> was issued.
</link:footnote>
<link:footnoteArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact000695" xlink:to="Footnote000702" xlink:type="arc"/>
<link:loc xlink:href="#Fact000696" xlink:label="Fact000696" xlink:type="locator"/>
<link:footnoteArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact000696" xlink:to="Footnote000702" xlink:type="arc"/>
<link:loc xlink:href="#Fact000697" xlink:label="Fact000697" xlink:type="locator"/>
<link:footnoteArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact000697" xlink:to="Footnote000702" xlink:type="arc"/>
</link:footnoteLink>
</xbrl>

28 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

11/17/21  Bioxytran, Inc.                   10-Q        9/30/21   66:8.2M                                   Nuvo Group, Inc./FA
 6/24/21  Bioxytran, Inc.                   S-1                   66:9.1M                                   Nuvo Group, Inc./FA
 6/07/21  Bioxytran, Inc.                   8-K:1,3,9   5/02/21    2:125K                                   Nuvo Group, Inc./FA
 4/09/21  Bioxytran, Inc.                   10-K       12/31/20   68:5.6M                                   SECfly Inc./FA
 3/26/20  Bioxytran, Inc.                   8-K:1,2,3,9 3/18/20    3:199K                                   EdgarAgents LLC/FA
 3/18/20  Bioxytran, Inc.                   10-K       12/31/19   61:4M                                     EdgarAgents LLC/FA
 3/12/20  Bioxytran, Inc.                   8-K:1,2,3,910/24/18    3:41K                                    EdgarAgents LLC/FA
 2/26/20  Bioxytran, Inc.                   8-K:1,2,3,9 2/18/20    6:445K                                   EdgarAgents LLC/FA
 1/15/20  Bioxytran, Inc.                   8-K:1,3,9   1/10/20    4:331K                                   EdgarAgents LLC/FA
 1/06/20  Bioxytran, Inc.                   8-K:1,3,9  12/30/19    3:215K                                   EdgarAgents LLC/FA
11/25/19  Bioxytran, Inc.                   8-K:1,3,9  11/20/19    4:254K                                   EdgarAgents LLC/FA
11/12/19  Bioxytran, Inc.                   8-K:1,3,9  11/07/19    5:405K                                   EdgarAgents LLC/FA
10/28/19  Bioxytran, Inc.                   8-K:1,2,3,910/23/19    8:761K                                   EdgarAgents LLC/FA
 9/13/19  Bioxytran, Inc.                   8-K:1,8,9   9/13/19    4:128K                                   EdgarAgents LLC/FA
 8/01/19  Bioxytran, Inc.                   8-K:1,8,9   7/26/19    5:136K                                   EdgarAgents LLC/FA
 6/12/19  Bioxytran, Inc.                   8-K:1,8,9   6/11/19    3:73K                                    EdgarAgents LLC/FA
 4/26/19  Bioxytran, Inc.                   8-K:1,3,9   4/22/19    2:93K                                    EdgarAgents LLC/FA
 4/05/19  Bioxytran, Inc.                   8-K:1,8,9   4/04/19    3:98K                                    EdgarAgents LLC/FA
 3/01/19  Bioxytran, Inc.                   8-K:1,2,3,9 2/25/19    6:541K                                   EdgarAgents LLC/FA
 2/01/19  Bioxytran, Inc.                   S-1/A                 44:3.8M                                   EdgarAgents LLC/FA
11/30/18  Bioxytran, Inc.                   S-1        11/29/18   39:2.5M                                   EdgarAgents LLC/FA
11/07/18  Bioxytran, Inc.                   8-K:5,7,9  11/02/18    3:149K                                   EdgarAgents LLC/FA
10/30/18  Bioxytran, Inc.                   8-K:1,2,3,910/25/18    6:537K                                   EdgarAgents LLC/FA
 9/24/18  Bioxytran, Inc.                   8-K:1,2,3,5 9/21/18    7:3M                                     EdgarAgents LLC/FA
 8/13/18  Bioxytran, Inc.                   8-K:3,9     8/13/18    3:440K                                   EdgarAgents LLC/FA
 2/22/10  Bioxytran, Inc.                   S-8         2/22/10    6:254K                                   Data Elec Filing… Inc/FA
10/29/09  Bioxytran, Inc.                   8-K:1,5,8,910/23/09    4:81K                                    Burningham Leonard W/FA
10/31/08  Bioxytran, Inc.                   S-1                    7:329K                                   Data Elec Filing… Inc/FA
↑Top
Filing Submission 0001539497-22-000793   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Wed., May 15, 2:56:19.3pm ET